Characterization of the relationship between two RBM5 family members by Loiselle, Julie Jennifer
  
 
 
 
Characterization of the relationship between two RBM5 family members 
 
 
 
by 
 
 
 
Julie Jennifer Loiselle 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy (PhD) in Biomolecular Sciences 
 
 
 
 
The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
 
© Julie Loiselle, 2017 
 
  
ii 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
Laurentian Université/Université Laurentienne 
Faculty of Graduate Studies/Faculté des études supérieures 
 
Title of Thesis     
Titre de la thèse   Characterization of the relationship between two RBM5 family members 
 
Name of Candidate   
Nom du candidat    Loiselle, Julie 
       
Degree                            
Diplôme                            Doctor of Philosophy  
 
Department/Program    Date of Defence 
Département/Programme         Biomolecular Sciences  Date de la soutenance July 31,2017 
                                                       
 
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. Leslie Sutherland  
(Supervisor/Directeur(trice) de thèse) 
 
Dr. Eric Gauthier    
(Committee member/Membre du comité)    
        
Dr. Amadeo Parissenti      
(Committee member/Membre du comité)    
      Approved for the Faculty of Graduate Studies 
                                                      Approuvé pour la Faculté des études supérieures 
       Dr. David Lesbarrères 
      Monsieur David Lesbarrères 
Dr. Doug Gray       Dean, Faculty of Graduate Studies 
(External Examiner/Examinateur externe)   Doyen, Faculté des études supérieures 
 
Dr. T.C. Tai  
(Internal Examiner/Examinateur interne) 
                                                 
 
 
 
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
I, Julie Loiselle, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and 
make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the 
duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or 
project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, 
dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in 
part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their 
absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that this copy is being made available in this form by the authority of the copyright 
owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted 
by the copyright laws without written authority from the copyright owner. 
  
iii 
 
Abstract 
RNA binding proteins (RBPs) control all aspects of RNA metabolism, and a single RBP can 
have numerous downstream effects. Alterations to their expression and/or function can, 
therefore, have remarkable consequences. For instance, decreased levels of the RNA binding 
motif domain (RBM) protein RBM5 are associated with increased risk of a number of cancer 
types, and RBM10 mutations can be lethal. Although these consequences are quite severe, little is 
known regarding the range of processes and events influenced by these two homologous RBPs. 
In fact, previous RBM5 and RBM10 functional studies were largely focused only on their 
abilities to promote two processes; apoptosis and cell cycle arrest. Potentially by control of these 
processes, RBM5 and RBM10 were shown to influence one event: differentiation. The objectives 
of this study were to identify all cellular processes and events enriched by changes in RBM5 
and/or RBM10 expression in a particular cultured cell line, and to determine the extent of 
functional overlap for RBM5 and RBM10 in these cells. Towards these goals, a list of RBM5 and 
RBM10 mRNA targets and differentially expressed genes was determined using next generation 
sequencing techniques. Our data suggest that RBM5 and RBM10 do influence a wide range of 
cellular processes and events. Although there is overlap in RBM5 and RBM10 mRNA targets and 
differentially expressed genes, these RBPs can have antagonistic functions; for example our data 
suggest that RBM5 prevents the transformed state, whereas RBM10 actually promotes it in an 
RBM5-null environment. Furthermore, we present a working model by which RBM5 may 
regulate RBM10’s protransformatory function. Finally, we demonstrate a relationship between 
RBM5 and RBM10 in non-transformed cells. The results presented herein provide insight not 
only into the roles and regulation of RBM5 and RBM10, but of RBPs in general. Taken together, 
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the results presented in the four papers included in this thesis expand the knowledge base of 
RBM5 and RBM10, which provides insight into the disease states associated with their disrupted 
expression or function. Our findings are thus relevant to a wide range of scientific fields 
including molecular, developmental and cancer biology. 
Keywords 
RNA binding proteins, RBM5, RBM10, RIP-Seq, RNA-Seq, Transcriptional studies, Small cell 
lung cancer, Myoblasts, Regulation of RNA binding proteins 
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1 Introduction 
 
1.1 RNA binding proteins 
Proteins are the end result of the central dogma of molecular biology, by which DNA encodes 
RNA, and RNA in turn can encode proteins. Proteins play a key role in almost every cellular 
process, from DNA replication to cell structure, and even form the extracellular environment 
(O'Connor and Adams, 2010). RNA binding proteins (RBPs) are a large and broad class of 
proteins that regulate all aspects of RNA metabolism (Glisovic et al., 2008). Their interaction 
with RNA can be accomplished via one or more consensus RNA binding sequences that form 
domains within the RBP (Lunde et al., 2007).  
 
1.1.1 RNA binding domains 
RBPs’ are classified, in large part, by the RNA binding domains present within their primary 
sequence. While certain RBPs have unconventional RNA binding domains, most contain one or 
more conventional domains, defined by consensus sequences. Such sequences include RNA-
recognition motifs (RRM), zinc-finger domains, K-homology domains, S1 domains, arginine-
rich motifs, cold-shock domains and double-stranded RNA-binding motifs (Castello et al., 2016; 
Lunde et al., 2007). Many RBPs have more than one type of RNA binding domain, which 
combined with other structural features of the protein, determine the specificity of the RBP with 
regards to RNA targets, as well as the functional consequences of the protein-RNA interaction 
(Allain et al., 2000; Lunde et al., 2007). By far the most abundant RNA binding domain is the 
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RRM, also known as RNA binding motif or ribonucleoprotein motif, with about 0.5 to 1% of 
human genes coding this sequence (Lunde et al., 2007; Venter et al., 2001).   
 
The RRM domain is approximately 90 amino acids in length, and is characterized by two 
consensus ribonucleoprotein (RNP) sequences. RNP1 and RNP2 are eight and six amino acids 
long, respectively, with the RNP1 sequence being more conserved than that of RNP2 (Bandziulis 
et al., 1989). Structurally, the RRM domain folds to form a four stranded β-sheet with two α-
helixes in a βαββαβ arrangement (Hoffman et al., 1991; Nagai et al., 1990; Oubridge et al., 
1994). The RNP domains are found on the internal two β-sheets of the RRM structure, and form 
its main RNA binding surface (Lunde et al., 2007; Oubridge et al., 1994). Each RRM domain 
can only recognize up to eight nucleotides in the target RNA (Maris et al., 2005; Price et al., 
1998). Having one RRM domain thus does not provide a high level of specificity for an RBP 
regarding RNA targets. In fact, many RBPs have multiple RRM domains and/or other types of 
RNA binding sequences, significantly increasing their ability to interact with only specific RNA 
molecules (Auweter et al., 2006). It is important to note that the three dimensional structure of a 
whole RBP, as well as the individual RNA binding domains within it, plays a role in defining the 
protein’s RNA targets. Large-scale studies predicting RNA-binding sites must thus account for 
both primary sequence and structural influences in their design (Li et al., 2014). 
 
1.1.2 Function of RBPs 
The list of proteins classified as RBPs is still growing, and consequently so are the functions 
they’re associated with (Castello et al., 2016). It is understood that RBPs influence all aspects of 
RNA metabolism, from transcription to transport, including alternative splicing, translation, 
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stability and degradation, usually as part of ribonucleoprotein particles (RNPs) (Glisovic et al., 
2008). RBPs are, therefore, involved in regulating the nature, quantity and functionality of gene 
expression products.  
 
RBPs can interact with various types of RNA, including messenger RNA (mRNA) (or pre-
mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), short 
interfering RNA (siRNA), microRNA (miRNA), and long non-coding RNA (lncRNA) (Ferre et 
al., 2016; Han et al., 2004). These interactions result in varied downstream effects. For instance, 
DNA-damage response RBPs not only regulate gene expression but also mediate DNA repair 
(Dutertre and Vagner, 2016). RBPs can also influence cellular processes, such as cell migration 
and metastasis, via interaction with other proteins, like focal adhesion proteins (de Hoog et al., 
2004). Some RBPs, such as MRPP2, even have enzymatic activities (Castello et al., 2015). In 
large part due to next generation sequencing techniques and large screens, new roles for RBPs 
are still being elucidated and the extent of the influence of RBPs on the regulation of cellular 
processes is still being unraveled. 
 
It is important to note that one single RBP can itself affect multiple aspects of RNA metabolism. 
For instance, the RNA binding protein Hu antigen R (HuR) interacts with target mRNAs to (1) 
stabilize and protect the mRNAs from decay, (2) translationally upregulate their expression, or 
(3) translationally downregulate their expression (Srikantan and Gorospe, 2012). The effect of 
HuR on a particular target depends in part on HuR’s phosphorylation status at the time of 
protein-RNA interaction (Popovitchenko et al., 2016; Srikantan and Gorospe, 2012). A HuR 
related protein, AU-binding factor 1 (AUF1), also affects multiple aspects of RNA metabolism. 
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For instance, AUF1 can promote mRNA translation and even gene transcription (Aigner et al., 
2001; Panda et al., 2014). In this manner, AUF1 regulates myogenesis, muscle regeneration and 
telomerase activity (Panda et al., 2014; Pont et al., 2012). AUF1 can also promote mRNA 
stability; AUF1 increases the parathyroid hormone transcript stability, which is in turn 
responsible for regulating serum calcium levels (Sela-Brown et al., 2000). On the other hand, 
AUF1 can de-stabilize mRNAs and promote their degradation, such as those for inflammatory 
cytokines or mRNAs of proteins involved in cell-cycle checkpoints (Pont et al., 2012). AUF1 
and HuR thus influence many processes via a number of RNA regulatory mechanisms. 
Understanding that RBPs often have multifaceted roles is, therefore, very important when 
characterizing the functions of such proteins.  
 
1.1.3 Regulation of RBP expression 
As one single RBP can influence many processes, one would anticipate their expression and 
activity to be tightly regulated. In fact, the expression and activity of RBPs themselves can be 
modulated at any point from transcription to post-translational modifications. This regulation can 
result from auto-regulation, or interactions with other RBPs (Buratti and Baralle, 2011; Pullmann 
et al., 2007).  
 
For instance, members of the Fox family, which include RBM9 (Fox-2), can auto-regulate the 
alternative splicing of Fox mRNA (Damianov and Black, 2010). In fact, Fox proteins inhibit 
exon inclusion during Fox alternative splicing, resulting in a translated variant with reduced 
RNA binding capabilities (Nakahata and Kawamoto, 2005). This exclusion variant represses 
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Fox’s influence on the alternative splicing of other genes, thus Fox proteins not only autoregulate 
their alternative splicing, but also their own function (Damianov and Black, 2010).  
 
HuR is another RBP that has multiple levels of regulation. First, HuR is transcriptionally 
regulated by NF-κB. Second, HuR mRNA’s cytoplasmic export, stabilization and translation are 
promoted by HuR protein (Pullmann et al., 2007; Yi et al., 2010). Third, additional factors 
decrease HuR translation, such as miR-519 (Abdelmohsen et al., 2010). Finally, HuR’s function, 
stabilization and cytoplasmic localization are controlled post-transcriptionally by a number of 
factors via HuR post-translational modifications such as phosphorylation, methylation and 
ubiquitination (Srikantan and Gorospe, 2012).  
 
Interestingly, RBPs are key targets for posttranscriptional modifications, including 
phosphorylation, methylation and acetylation. These changes can impact RBP interaction with 
RNA targets or other proteins, ultimately influencing function (Blackwell and Ceman, 2012; 
Thapar, 2015). For instance, phosphorylation of the RNA-binding protein DAZL, an important 
regulator of spermatogenesis, inhibits its interaction with poly(A)-binding protein, resulting in 
decreased translation of DAZL RNA targets (Williams et al., 2016). On the other hand, 
acetylation of KHDRBS1 enhanced its RNA binding activity (Babic et al., 2004). These 
numerous levels of control highlight the importance of regulated RBP expression and function to 
normal cellular processes. 
 
1.1.4 Dysregulation of RBPs and disease 
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Due to their influence on all aspects of RNA metabolism and their strict regulation, it is not 
surprising that dysregulation of RBPs can have severe downstream consequences. Interestingly, 
disease-linked mutations can be found within various regions of RBPs, not only specific RNA-
binding regions (Castello et al., 2013). RBP mutations can thus impair not only protein-RNA 
interactions, but also protein-protein interactions, complex formation and enzymatic function – 
all resulting in impaired RNA metabolism with important downstream consequences (Castello et 
al., 2013; Lunde et al., 2007). 
  
Altered RBP expression and/or function is associated with a wide spectrum of diseases, but most 
are of neurological, muscular, sensory or neoplastic origin (Castello et al., 2013; Lukong et al., 
2008). As regulation of alternative splicing is controlled by RBPs, and this process occurs at a 
high rate in the brain and throughout development, these findings are not surprising. The 
consequences of aberrant RBPs can be as varied as the associated disease. For instance, a point 
mutation in Qk1 was embryonically lethal in mice (Justice and Bode, 1988; Shedlovsky et al., 
1988). Interestingly, the lethal mutation prevented Qk1 homodimerization, and did not interfere 
with RNA binding (Chen and Richard, 1998), suggesting that critical Qk1 functions are 
dependent on more than only its ability to bind RNA. In other cases, RBP alterations can have an 
impact on the capacities of the affected individual. This is the case for Fragile X syndrome, 
which is the most frequent form of heritable mental retardation (Crawford et al., 2001). 
Genetically, this syndrome is usually caused by a CGG expansion in the 5’ untranslated region 
(UTR) of the gene encoding the FMR1 RBP (Garber et al., 2008). The associated phenotypic 
characteristics depend on the level of methylation of the CG islands in these expansion segments 
within FMR1’s 5’ UTR, with the most severe cognitive impairments presenting in patients with 
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complete methylation of this region (Garber et al., 2008). Other diseases associated with 
irregularly expressed RBPs include spinal muscular atrophy, the main monogenic cause of death 
in infants (Crawford and Pardo, 1996), and TARP syndrome, an abnormal developmental 
condition usually resulting in death prior to or soon after birth (Johnston et al., 2010). The impact 
of these RNA binding protein-associated diseases can thus be very serious, once again 
highlighting the importance of RBPs to numerous aspects of biology at both the cell and 
organism level. 
 
RBPs also play a very important role in cancer development (Wurth, 2012). As RBPs can 
influence protein expression levels of oncogenes or tumor suppressors, deregulated RBP 
expression, as observed in certain cancers, could be key to the establishment of the transformed 
state (Wurth, 2012). For instance, the expression of the RNA binding protein KHDRBS1 is 
increased in a number of cancers and promotes the alternative splicing of many cancer-
associated genes, including CD44 and CCND1, towards their transformation-promoting variant 
(Matter et al., 2002; Paronetto et al., 2010; Rajan et al., 2008; Wurth, 2012). In addition, a tumor 
suppressor, RBM5, is downregulated in a variety of cancers (Kim et al., 2010; Miller et al., 2009; 
Peng et al., 2013; Welling et al., 2002; Zhao et al., 2012). As described below, although some 
studies have begun to elucidate RBM5’s role in the cell and contribution to diseased states, much 
remains to be determined. 
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1.2 RBM5 
RNA binding motif domain protein, RBM5, is coded for on chromosome 3 at position 3p21.3 
and was first cloned by Wei et al in 1996 (Wei et al., 1996) under the name LUCA-15. The 
RBM5 transcript is approximately 3 kb, divided into 25 exons, and codes for a protein of 815 
amino acids. 
 
 
1.2.1 RBM5 alternative splice variants 
Alternative splicing dramatically increases the variety of proteins translated from a single 
primary transcript (pre-mRNA molecule). Although the RNA sequence of these isoforms may be 
very similar, the resulting proteins can have very distinct properties, such as variations in 
stability, localization, activity, and protein and RNA partners (Kelemen et al., 2013). RBM5 is 
alternatively spliced, and its variants have been quite well characterized. Three RBM5 alternative 
splice variants retain introns and are targets for non-sense mediated decay (Sutherland et al., 
2005). The truncated proteins for which they code are thus rarely, if ever, translated (Sutherland 
et al., 2005). These variants are RBM5Δ6 in which exon 6 is deleted, RBM5+6 in which intron 6 
is retained, and RBM5+5+6 in which introns 5 and 6 are retained (Maquat and Carmichael, 
2001; Sutherland et al., 2000; Sutherland et al., 2005).  Interestingly, a truncated form of 
RBM5+5+6, termed RBM5+5+6t or Clone 26, is not degraded by non-sense mediated decay and 
encodes a protein product of approximately 21 kDa (Masilamani et al., 2012). This is likely due 
to splicing of intron 5 from the RBM5+5+6t transcript (Rintala-Maki and Sutherland, 2009). 
Finally, an antisense transcript of RBM5 is also transcribed. Originally, this transcript was 
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thought to be only 326 bp and span from introns 6 to 5 (Je2) (Sutherland et al., 2000); however, 
it was later discovered that the transcript codes all the way into intron 4 (including intron 5) of 
RBM5. This transcript was termed LUST, for LUCA-15-specific transcript (Rintala-Maki and 
Sutherland, 2009). Interestingly, one study showed opposing roles for Clone 26 and Je2 in 
regards to apoptosis sensitization; therefore, the alternative splicing of RBM5 may have 
important functional consequences (Sutherland et al., 2000). 
 
1.2.2 Primary structure 
Proteins translated from alternative splice variants will have different primary structures. Primary 
structure is important as it controls higher order structures, and is used to identify consensus 
functional motifs. Many of these consensus functional motifs encode RNA binding domains. 
RBM5 codes for two RRM domains, through which RNA binding and regulation of alternative 
splicing can occur (Figure 1) (Song et al., 2012). RBM5 also has two zinc finger motifs, one 
C2H2-type and one RanBP2-type. The former can bind both DNA and RNA, and may be 
particularly important for protein-protein interactions (Brayer et al., 2008), while the latter has 
been shown to directly interact with pre-mRNA and regulate alternative splicing (Loughlin et al., 
2009). Other RBM5 consensus functional motifs include: (1) an OCRE domain that may 
influence splicing regulation (Bonnal et al., 2008; Callebaut and Mornon, 2005), (2) two bipartite 
nuclear localization signals, (3) an arginine-rich N-terminal domain that can directly bind RNA 
and regulate/influence RNA binding capabilities, and direct proteins to specific nuclear locations 
involved in splicing (Bayer et al., 2005; Li and Bingham, 1991), and (4) a G-patch domain that 
may be involved in RNA processing, as it is commonly found in RNA binding proteins (Aravind 
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and Koonin, 1999; Banerjee et al., 2015). These motifs predict the RNA binding and alternative 
splicing modulatory capabilities of RBM5. As many of these motifs are lost upon alternative 
splicing of RBM5, this may be one means of regulating RBM5’s RNA binding capabilities. 
 
 
Figure 1.1: RBM5 and RBM10 RNA binding domains. Translated RBM5 and RBM10 exons 
are represented by boxes. Numbers indicated within a box designates the exon it represents 
within the corresponding transcript. Box size does not represent exon length. Location of RBM5 
and RBM10 RNA binding domains are indicated by the thick line under the corresponding 
exon(s) boxes, and the type of RNA binding domain is indicated underneath. Arrows point to the 
location of the alternatively spliced RNA triplet in RBM10v1 and RBM10v2, which results in 
the +/- valine variants of RBM10v1 and RBM10v2. 
 
1.2.3 Function 
As mentioned, the function of RBPs can often be multifaceted. Functional studies regarding 
RBM5, however, have focused on the full-length variant, and its effect on apoptosis and cell 
cycle arrest. For instance, RBM5 overexpression in a human leukemic cell line altered the 
expression of 35 apoptosis and proliferation-associated genes (Mourtada-Maarabouni et al., 
2006) and arrested cells in the G1 cell cycle phase (Mourtada-Maarabouni et al., 2003). Cell 
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cycle arrest was also associated with RBM5 overexpression in a prostate cancer and a 
fibrosarcoma cell line (Edamatsu et al., 2000; Zhao et al., 2012). RBM5’s role in apoptosis 
promotion has been demonstrated in a number of cell lines, including breast, lymphoblastoid and 
prostate cancer cell lines. This increase in apoptosis was also shown to occur when apoptosis was 
triggered by either Fas, TNFα or TRAIL; the ligands of all three main death receptors (Rintala-
Maki and Sutherland, 2004; Sutherland et al., 2000; Zhao et al., 2012). Furthermore, fibroblast 
xenografts showed a significant reduction in growth when RBM5 was expressed (Oh et al., 
2002). RBM5 can thus modulate the cell cycle and apoptosis in a number of different human cell 
lines, both cancerous and non-transformed, however, the potential impact of RBM5 on other 
cellular processes remains to be determined. 
 
RBM5 may play a particularly important role in cells which line the lower respiratory tract. This 
is suggested by its 70-95% downregulation in lung cancer, of which there are two main types; 
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (Travis W.D., 2004). In 
fact, RBM5 is encoded within a region called the human lung tumor suppressor locus (Wei et al., 
1996), as deletions within this region of the short arm of chromosome 3 (3p21.3) are the earliest 
and most frequent genetic alterations observed in lung cancers (Hung et al., 1995; Lerman and 
Minna, 2000; Wistuba et al., 2000). In line with this, RBM5 is deleted in various lung cancer cell 
lines (Lerman and Minna, 2000). In patient lung tumors, however, RBM5 is still expressed 
(Wistuba et al., 2000), although significantly downregulated (Liang et al., 2012; Oh et al., 2002; 
Shao et al., 2012). Taken together, these findings suggest that downregulation of RBM5 may be a 
key step in lung cancer development and/or progression. Only three studies have investigated 
RBM5’s role in lung cancer cells. In the first study, undertaken by Oh et al. in 2006, investigators 
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overexpressed RBM5 in an NSCLC cell line (A549) and found that increased RBM5 expression 
was associated with promotion of apoptosis and G1 cell cycle arrest (Oh et al., 2006). They also 
showed that RBM5 expression slowed xenograft tumor growth (Oh et al., 2006). In 2011, 
Kobayashi et al. showed that RBM5 expression in the H1299 NSCLC cell line inhibited cell 
growth by both p53-dependent and independent mechanisms (Kobayashi et al., 2011). Finally, 
Shao et al. showed that RBM5 overexpression in A549 cells promoted apoptosis, and that 
injections of bacteria carrying the RBM5 plasmid decreased xenograft tumor size (Shao et al., 
2012). These studies support a tumor suppressive role for RBM5 in NSCLC. The role of RBM5 
in SCLC, however, has yet to be determined. The majority of the work presented herein was thus 
performed in a SCLC-derived cell line. Results thus not only expand our knowledge of RBM5 
function, but also shed light on the molecular basis of SCLC. 
 
1.2.4 Mechanism of action 
The primary structure of RBM5 suggests RNA binding capabilities. Identification of all RNAs 
bound by RBM5 could thus give important insight into the scope of RBM5’s influence in the 
cell. Prior to commencing my doctoral studies, an RNA binding consensus sequence targeted by 
RBM5 had yet to be determined. A few studies, however, characterized the binding capabilities 
of individual RBM5 RNA binding domains. For instance, the RRM2 of RBM5 preferentially 
bound CU and GA rich sequences (Song et al., 2012). Furthermore, RBM5’s RanBP2-type zinc 
finger had an affinity for the GGU motif (Nguyen et al., 2011). Three direct RBM5 RNA targets 
had also been confirmed in human cell lines, and RBM5 regulated alternative splicing in all three 
instances; caspase-2 (CASP2) mRNA (Fushimi et al., 2008), activation induced cytidine 
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deaminase (AID) mRNA (Jin et al., 2012) and Fas antisense transcript 1 (FAS-AS1), a lncRNA 
(Sehgal et al., 2014). In regards to the CASP2 transcript, RBM5 promoted exon 9 exclusion, and 
thus higher levels of the proapoptotic form of caspase-2, by binding to the UC-rich region in 
intron 9 (Fushimi et al., 2008). In AID, RBM5 promoted exon 4 exclusion and consequently a 
truncated protein product, by binding to the pyrimidine tract in intron 3 (Jin et al., 2012). 
RBM5’s binding to the lncRNA FAS-AS1, however, did not influence the alternative splicing of 
FAS-AS1 itself, but rather inhibited RBM5’s ability to alternatively splice another transcript 
(Bonnal et al., 2008; Sehgal et al., 2014). Interestingly, 11 direct RBM5 mRNA targets have 
been identified in mouse spermatid differentiation (O'Bryan et al., 2013). In addition, RBM5 was 
shown to influence the alternative splicing of two other transcripts, although direct protein-RNA 
interactions have yet to be established in this regard: (1) c-FLIP, for which RBM5 promoted 
exon 7 exclusion, and thus higher levels of the apoptosis regulating form (Bonnal et al., 2008; 
Chang et al., 2002), and (2) DMD, for which RBM5 influenced exons 40 and 72 skipping 
(O'Leary et al., 2009). Taken together, these findings suggest that RBM5’s regulation of 
alternative splicing is important in both cancer and development, and that the downstream effects 
can vary depending on the system. 
 
Supporting its role as a regulator of alternative splicing, RBM5 was first shown to be a 
component of prespliceosomal complexes by Hartmuth et al. (Hartmuth et al., 2002). More 
specifically, immunoprecipitation of spliceosomal complexes A and B identified RBM5 as a 
component of only spliceosomal complex A, and not B (Behzadnia et al., 2007; Deckert et al., 
2006). These results suggest a role for RBM5 in the early steps of alternative splicing. Isolation 
of other factors involved in splicing showed that RBM5 also interacted with (a) the splicing 
14 
 
 
 
factor U2AF
65
 (Bonnal et al., 2008) and (b) the spliceosomal complex component DHX15, 
resulting in stimulation of its helicase activity (Niu et al., 2012). RBM5 thus directly participates 
in the regulation of alternative splicing, and interacts with many spliceosomal components. 
 
1.2.5 Expression and regulation 
RBM5 is ubiquitously expressed in human non-tumor tissues and cell lines (Sutherland et al., 
2000; Timmer et al., 1999b). RBM5 expression, however, is decreased in many cancers, 
including vestibular schwannomas (Welling et al., 2002), biliary tract cancers (Miller et al., 
2009), stage III serous ovarian carcinoma (Kim et al., 2010), prostate cancer (Zhao et al., 2012), 
and pancreatic cancer (Peng et al., 2013). In fact, RBM5 was one of nine genes downregulated 
within a 17 gene signature associated with metastasis in human (Ramaswamy et al., 2003) and 
murine (Qiu et al., 2004) solid tumors. These expression studies strongly suggest a tumor 
suppressor activity for RBM5 across various tumor types. 
 
Little is known about the regulation of RBM5, and thus how its expression is modulated in these 
various cancerous states. In regard to transcriptional regulation, the promoter region of RBM5 
has been shown to be mutated in melanomas (Smith et al., 2015), but not hypermethylated, at 
least in lung cancers (Oh et al., 2008). In addition, a Ras mutant, Ras(G12V), influenced RBM5 
expression, although the exact mechanism involved remains to be determined (Edamatsu et al., 
2000). Ras is a guanine exchange factor involved in signal transduction, ultimately controlling 
processes such as the cell cycle and cell death (Khosravi-Far and Der, 1994). Ras(G12V), a 
constitutively active Ras mutant, downregulated RBM5 expression, and thus Ras’ promotion of 
15 
 
 
 
cell growth and survival may, in part, be accomplished via modulation of RBM5 expression 
(Edamatsu et al., 2000). In regard to posttranscriptional modifications, RBM5 has only been 
shown to be phosphorylated (Rintala-Maki et al., 2007). This phosphorylation was dependent on 
the presence of growth factors, and was reversible, suggesting phosphorylation of RBM5 may 
regulate its apoptotic functions (Shu et al., 2007). Additional studies are required to gain a 
complete understanding of the factors that regulate RBM5 expression. 
 
RBM5 shares a high degree of homology with another RNA binding motif domain protein, 
RBM10. In fact, at the protein level this similarity is approximately 50% (Sutherland et al., 
2005). It has been suggested that the duplication of similar functioning genes to different 
genomic locations, such as 3p21.3 (RBM5) and Xp11.23 (RBM10), could be an evolutionary 
means of both expanding gene expression and providing an additional level of regulation 
(Timmer et al., 1999a). The study described herein also included an examination of RBM10, to 
determine if RBM5 and RBM10 do in fact have similar functions, and if they interact or influence 
each other’s function. 
 
1.3 RBM10 
RBM10 is coded for on the X-chromosome at position p11.23 (Coleman et al., 1996; Thiselton et 
al., 2002) and was first cloned from bone marrow in 1995 (Nagase et al., 1995). The full length 
RBM10 transcript is approximately 3.5 kb long, divided into 24 exons, and translated into a 
protein of 930 amino acids (Johnston et al., 2010). 
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1.3.1 Alternative splice variants  
Like 95% of multi-exon containing transcripts (Pan et al., 2008), RBM10 can be alternatively 
spliced. The main RBM10 alternative splice variant, RBM10v2, is produced by alternatively 
splicing the fourth exon from RBM10, resulting in a protein of 853 amino acids (Johnston et al., 
2010; Sutherland et al., 2005). As depicted in Figure 1, the alternative splicing of exon 4 of 
RBM10 does not alter the number of RNA binding domains. It would be likely, however, to 
impact RBM10’s overall protein structure and could thus alter function, as discussed above.  
 
The level of homology between RBM5 and RBM10 is approximately 50%, with RBM10v1 
sharing 49% identity with RBM5, and RBM10v2 sharing 53% (Sutherland et al., 2005). Exons 4, 
9 and 15 are particularly different between RBM5 and RBM10 and are the main cause of the 
variation between both proteins (Sutherland et al., 2005). Of note, these non-homologous exons 
are located right before consensus functional motifs, suggesting similar functionality for RBM5 
and RBM10, but potentially different specificity. 
 
1.3.2 Primary structure 
Like RBM5, RBM10 contains a number of consensus functional motifs. These include two RRM 
domains, an OCRE domain and a G-patch domain, all involved in RNA binding and/or 
regulation of alternative splicing (Inoue et al., 1996; Sutherland et al., 2005). The OCRE domain 
has also been suggested to have nuclear localization abilities, along with the two other nuclear 
localization signals present within the RBM10 sequence (Inoue et al., 2008; Xiao et al., 2013). In 
addition, RBM10 has two zing finger motifs, one C2H2-type and one RanBP2-type, similar to 
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RBM5. The presence of these motifs suggests that RBM10 may, like RBM5, bind RNA and 
affect which alternative variants are expressed. 
 
1.3.3 Function 
Functionally, RBM10 has been much less studied than RBM5, but again, most studies have 
centered on a role involving apoptosis promotion and cell cycle arrest. In fact, the first functional 
study published regarding RBM10 correlated RBM10 expression with decreased cell 
proliferation and increased apoptosis in hypertrophic primary chondrocytes (James et al., 2007). 
In 2012, our group confirmed that RBM10 promoted apoptosis in two human cancer cell lines, 
and associated increased RBM10 expression with increased TNFα transcription (Wang et al., 
2012). Notably, as knockdown of only RBM5 or RBM10 has significant effects, both proteins do 
not functionally compensate for each other. Correlational studies from human tissues support an 
apoptosis-promoting role for RBM10, as RBM10 mRNA expression in breast cancer samples 
correlated with increased mRNA expression of BAX, a proapoptotic protein, and p53, a tumor 
suppressor with transcriptional activity (Martinez-Arribas et al., 2006). Unexpectedly, however, 
this study also correlated RBM10 expression with increased mRNA expression of VEGF, a 
potent promoter of angiogenesis (Martinez-Arribas et al., 2006). These findings suggest a tumor 
suppressor role for RBM10, but that additional studies are required to more clearly understand 
how this role is achieved. 
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1.3.4 Mechanism of action 
The primary sequence of RBM10 suggests RNA binding and alternative splicing capabilities. No 
direct RBM10 RNA targets, however, had been identified prior to the start of this research 
project. In addition, RBM10 had not yet been shown to modulate the alternative splicing of any 
transcript. Interestingly, the rat equivalent of RBM10, S1-1, bound poly(G) and poly(U) RNA 
homopolymers (Inoue et al., 1996). S1-1 also bound the 3’UTR of the angiotensin receptor type 
1 (AT-1) transcript and increased the transcript’s stability, ultimately leading to downregulation 
of its transcription (Mueller et al., 2009). At the amino acid level, RBM10v1 and v2 share an 85 
and 96% identity with S1-1, respectively, suggesting similar functionality (Sutherland et al., 
2005). RBM10 may thus have an affinity for poly(G) and (U) motifs, and its binding may post-
transcriptionally influence RNA expression.  
 
Protein-protein interaction studies support a regulatory role for RBM10 in alternative splicing. 
For instance, immunoprecipitation of spliceosomal complexes identified RBM10 as a component 
of spliceosomal complexes A and B (Behzadnia et al., 2007; Deckert et al., 2006; Rappsilber et 
al., 2002). Interestingly, RBM10 also interacted with the 2A-DUB deubiquitinase protein 
complex, which influences histone modifications (Zhu et al., 2007). RBM10 may, therefore, also 
epigenetically regulate gene transcription through changes in the posttranslational modification 
of histones. Taken together, these results suggest that RBM10 may, like many RBPs, influence 
various aspects of RNA metabolism and highlights that a lot remains to be determined regarding 
how RBM10 exerts its potential tumor suppressor properties. 
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1.3.5 Expression and regulation 
RBM10 is expressed at levels marginally lower than RBM5 in most, if not all, human cells 
(GeneCards data), even though one RBM10 allele is silenced due to X chromosome inactivation 
(Coleman et al., 1996; Thiselton et al., 2002). RBM10 expression is especially important during 
development, as RBM10 mutations are the cause of TARP syndrome (Gorlin et al., 1970; 
Johnston et al., 2010). This condition is characterized by many developmental abnormalities, 
particularly craniofacial deformities such as cleft palate, glossoptosis (tongue displacement) and 
micrognathia (undersized jaw), which can cause difficulties eating and breathing (Gorlin et al., 
1970). Sadly, usually due to various heart conditions associated with the disease, the affected 
children die before, or soon after, birth (Gorlin et al., 1970; Gripp et al., 2011; Johnston et al., 
2010). If significant medical attention is provided, however, there have been reports of children 
with TARP syndrome living up to three years (Gripp et al., 2011). These cases have permitted 
doctors to observe other phenotypic consequences of embryonic RBM10 mutations, including 
chronic lung disease, visual impairment, significant intellectual disability and an inability to eat 
or sit independently (Gripp et al., 2011). The severe impact of RBM10 mutations in these 
children strongly suggests a critical role for RBM10 in fetal development. This is supported by 
my recent findings showing RBM10 expression to be regulated during rat skeletal and cardiac 
muscle cell differentiation (Loiselle and Sutherland, 2014). Interestingly, the only post-
transcriptional modification identified regarding RBM10 was its phosphorylation by c-Src 
tyrosine kinase (Amanchy et al., 2008). Furthermore, this phosphorylation event was shown to 
be part of the platelet derived growth factor (PDGF) signaling pathway, an important regulator of 
cell differentiation and disease, further suggesting the importance of RBM10 to normal 
development (Amanchy et al., 2008; Heldin et al., 1998).  
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Unlike RBM5, RBM10 expression is not significantly altered in cancer. Likely for this reason, the 
regulation of RBM10 expression has yet to be studied. RBM10, however, is mutated in select 
cancer types. For instance, RBM10 was found to be truncated in 7% of lung adenocarcinomas 
(Imielinski et al., 2012), and had a frameshift mutation in pancreatic intraductal papillary 
mucinous neoplasms (Furukawa et al., 2011). Despite this, in a mutational screen of 441 tumors 
of various cancer types including breast, pancreatic and lung, only one breast and one prostate 
cancer sample, respectively, had an RBM10 mutation (Kan et al., 2010). The importance of 
functional RBM10 in regards to the transformed state, therefore, remains to be determined.       
 
1.4 Study objectives 
 
1.4.1 Overview 
RNA binding proteins regulate all aspects of RNA metabolism, and their dysregulation can have 
fatal consequences. Elucidating the broad and often multifaceted roles of specific RNA binding 
proteins will help us to better understand their influence on cellular processes, and thus how the 
associated pathways are regulated. Together with a better comprehension of the regulation of 
RBPs, studies in this area may contribute to the development of therapeutic options aimed at 
restoring or modifying RBP expression in diseases associated with their aberrant expression.  
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1.4.2 Hypothesis 
RBPs often have multifaceted functions. Functional data relating to RBM5 and RBM10, however, 
have been largely limited to their abilities to promote cell cycle arrest and apoptosis. Through the 
regulation of these processes, RBM5 and RBM10 can modulate cancer cell division and death. 
RBM5 and RBM10 expression is key for proper development, since (1) mutations in RBM10 are 
the causative agent of TARP syndrome (Johnston et al., 2010), (2) RBM5 is an important splicing 
factor in spermatid differentiation (O'Bryan et al., 2013), and (3) my master’s thesis work 
determined that RBM5 and RBM10 expression is regulated during rat myoblast differentiation 
(Loiselle and Sutherland, 2014). Of note, cell cycle arrest and apoptosis are essential processes 
involved in differentiation (Andres and Walsh, 1996; Sandri and Carraro, 1999; Walsh and 
Perlman, 1997; Wang and Walsh, 1996; Yahi et al., 2006), therefore, it may be via the control of 
these processes that RBM5 and RBM10 influence differentiation. In fact, cell cycle arrest and 
apoptosis are crucial processes involved in a number of complex events, such as epithelial to 
mesenchymal transition (EMT) and angiogenesis. Consistent with this view, apoptotic resistance 
is important to EMT initiation (Franco et al., 2010; Savagner, 2010; Valdes et al., 2002), and 
endothelial cell proliferation and apoptosis are essential for proper angiogenesis (Savagner, 
2010). To summarise, RBM5 and RBM10 have been shown to influence the processes of 
apoptosis and cell cycle, and the event of differentiation. Entering into this study, I hypothesized 
that processes influenced by changes in RBM5 and RBM10 expression are not limited to 
apoptosis and cell cycle regulation. I also hypothesized that RBM5 and RBM10 influence many 
events in addition to differentiation. Finally, based on their structural similarities, I hypothesized 
some overlap in functional roles for RBM5 and RBM10. 
 
22 
 
 
 
1.4.3 Objectives  
Based on these hypotheses, my objectives were to (1) identify all cellular processes and events 
enriched by changes in RBM5 and/or RBM10 expression in a particular cultured cell line, and 
(2) to determine the extent of functional overlap for RBM5 and RBM10 in these cells. 
 
To accomplish the first objective, I had three specific aims: (1) to identify RBM5 and RBM10 
direct mRNA targets using RNA immunoprecipitation followed by next generation sequencing 
(RIP-Seq), (2) to identify genes whose expression and/or alternative splicing was altered by 
changes in RBM5 or RBM10 expression using RNA-Seq, and (3) to determine processes and 
events influenced by RBM5 and RBM10, by carrying out functional analyses on the above RIP-
Seq and RNA-Seq data from Aims 1 and 2.  
 
To accomplish the second objective, I aimed to compare RBM5 and RBM10 targets and 
downstream effects. To do this, I compared RBM5 and RBM10 RIP-Seq and RNA-Seq results, 
at both the gene expression and process/event level. 
 
1.4.4 Rationalization for models and techniques 
Many factors come into play when choosing an in vitro model. One of the most important 
features is the suitability of the system for the project at hand. As we aimed to perform target 
identification studies, a system with null levels of RBM5 or RBM10 would be optimal since it 
would provide a wild-type (endogenously unaltered) negative control. Another factor to consider 
is clinical relevance. As mentioned, RBM5 is downregulated in 95% of SCLCs, and RBM10 is 
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mutated in approximately 7% of lung cancers (Imielinski et al., 2012; Network, 2014). The 
impact of this downregulation and mutation, respectively, however, remains to be determined. 
With a survival rate of only about 5%, it is clear that a better understanding of the molecular 
mechanisms underlying SCLC is required (Lee et al., 2006; Lekic et al., 2012; Micke et al., 
2002). Examining RBM5 and RBM10 function in a SCLC system would thus provide 
meaningful insight into how altered expression of RBM5 or RBM10 might impact SCLC 
development and progression. The GLC20 cell line filled both of these criteria; it is a SCLC cell 
line with a homozygous deletion of RBM5. This system presented, therefore, an appropriate 
model for aggressive SCLC and provided optimal experimental conditions for RBM5 target 
identification studies. The parental GLC20 cell line was established from the tumor of a male 
SCLC patient that showed no clinical response to a treatment regimen of cyclophosphamide, 
doxorubicin and vincristine (Smit et al., 1992). Five stable GLC20 sublines were established by 
various members of the Sutherland lab, each with particular levels of RBM5 and RBM10 
expression, respectively. Table 1.1 summarizes the GLC20 sublines used in this study. 
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Table 1.1: GLC20 sublines used throughout this body of work. 
GLC20 
subline 
Stably transfected 
plasmid or shRNA 
RBM5 
expression 
(FPKM) 
RBM10 expression 
(FPKM) 
Origin 
pcDNA3 pcDNA3 
0 
(endogenous) 
47 
(endogenous) 
Pooled 
population 
T2 pcDNA3.RBM5 
58 
(overexpressed) 
49 
(endogenous) 
Pooled 
population 
C4 pcDNA3.RBM5 
388 
(overexpressed) 
52 
(endogenous) 
Clonal 
population 
G300.3 
Hush 300 (control 
shRNA) 
0 
(endogenous) 
55 
(endogenous) 
Clonal 
population 
G29/30.4 
Hush 29 and Hush 
30 (target RBM10 
exon 6) 
0 
(endogenous) 
43 
(knockdown) 
Clonal 
population 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values represent RNA 
expression levels, as determined by RNA-Seq. 
 
Using this SCLC model, we set out to assemble a comprehensive list of RBM5 and RBM10 
mRNA targets. To this end, I used RIP-Seq. This technique provides the nucleotide sequence of 
all mRNA molecules within a cell that are associated with the protein of interest. This level of 
resolution allows researchers to identify the exact splice variant of a gene with which their 
protein of interest interacts. The first step of RIP-Seq involves identification of an antibody 
specific for the protein of interest. With this antibody, the protein of interest is 
immunoprecipitated, then all associated mRNAs are sequenced using next generation sequencing 
techniques. It is important to note that existing protein-protein interactions within the cell, of the 
protein of interest and any potentially complexed proteins, are not broken during this procedure. 
All mRNAs associated directly with the protein of interest, or associated with it via another 
protein, would therefore be detected. As RBM5 and RBM10 are both components of 
spliceosomal complexes (Behzadnia et al., 2007; Deckert et al., 2006; Rappsilber et al., 2002), 
this technique was anticipated to minimally identify all transcripts whose alternative splicing 
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may be influenced by RNP complexes containing RBM5 and RBM10. For these reasons, RIP-
Seq was anticipated to provide the most comprehensive list of RBM5 and RBM10 mRNA 
targets, and thus the best ability to distinguish direct mRNA targets for RBM5 and RBM10, from 
indirect effects of their modulated expression. 
 
Following mRNA target identification, we set out to determine all processes/events affected by 
changes in RBM5 and RBM10 expression levels. Many techniques available are biased in that 
they are directed towards particular cellular processes, such as apoptosis, proliferation, 
mitochondrial activity or cell cycle arrest. In order to capture all processes influenced by RBM5 
and RBM10, I performed RNA-Seq on our GLC20 sublines. RNA-Seq provides a single 
nucleotide resolution snapshot of all transcripts present within a cell. I was, therefore, able to 
identify the differences in gene expression and alternative splicing amongst the isogenic 
sublines, and consequently gained a comprehensive view of influenced processes and events, 
through an analysis of altered signaling pathways. 
 
Extending findings from a transformed system to a non-transformed system broadens the 
importance of an observed phenomenon. We, therefore, decided to extend our research past our 
SCLC-model, to determine if any potential RBM5/RBM10 relationship was restricted to 
transformed state. The non-transformed model chosen involved H9c2 rat myoblasts. This 
particular model was selected since both RBM5 and RBM10 had been previously suggested to 
be important to H9c2 differentiation (Loiselle and Sutherland, 2014). In addition, apoptosis, cell 
cycle arrest and alternative splicing, all processes previously associated with RBM5 and/or 
RBM10, are key to muscle cell differentiation (Andres and Walsh, 1996; Revil et al., 2010; 
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Sandri and Carraro, 1999; Walsh and Perlman, 1997; Wang and Walsh, 1996; Yahi et al., 2006). 
Finally, RBM5 and RBM10 are expressed in a number of tissues types, including muscle, further 
suggesting they may be important to muscle cells as well as non-transformed cells in general 
(Coleman et al., 1996; Loiselle and Sutherland, 2014; Timmer et al., 1999b). 
 
1.4.5 Chapter 2 
Although alternative splice variants are transcribed from the same gene, their effects in cells can 
be completely opposite. It is, therefore, important to know which splice variants of a gene are 
expressed within a system prior to undertaking functional studies. To this end, our first step was 
to clearly define which RBM5 and RBM10 alternative splice variants were present in our SCLC 
GLC20 model. As GLC20 cells are endogenously RBM5-null, all RBM5 transcripts expressed 
would necessarily derive from the exogenous, intron-less RBM5 wildtype cDNA sequence 
introduced. In regards to RBM10, both main RBM10 splice variants, RBM10v1 and RBM10v2, 
had been previously well characterised (Sutherland et al., 2005). It remained unclear, however, if 
both RBM10v1 and RBM10v2 had an additional variant differing by only one amino acid. 
Furthermore, if these variants did exist, it remained to be determined whether or not it was the 
result of an RBM10 allele mutation or alternative splicing. To this end, in Chapter 2, we 
performed a comprehensive analysis regarding the alternative splicing of RBM10. Using GLC20 
cells, we demonstrated that there were two full-length RBM10v1 and RBM10v2 splice variants, 
respectively, differing by the presence or absence of only one valine residue ((+/-) valine) 
(Figure 1). In addition, we showed that these variants were the result of alternative splicing, not 
mutations in RBM10 alleles. In this chapter, we also explored the functional implications of these 
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(+/-) valine RBM10 isoforms, using protein modeling and gene expression data. Taken together, 
this work was the first to demonstrate that both RBM10v1 and RBM10v2 have (+/-) valine 
variants, and that these variants are the result of alternative splicing. Our data suggest that the 
presence of the valine residue can impact the helical structure of RBM10’s RRM2 domain, 
possibly affection its RNA binding ability. 
 
1.4.6 Chapters 3 & 4 
Having characterized RBM10 splice variants in the GLC20 cell line, I went on to the main 
objectives of my doctoral studies: (1) identify all cellular processes and events enriched by 
changes in RBM5 and/or RBM10 expression in a particular cultured cell line, and (2) to 
determine the extent of functional overlap for RBM5 and RBM10 in these cells. To capture 
potential new roles for RBM5 and RBM10, next generation sequencing techniques were used; 
mRNA targets were identified using RIP-Seq, and potential processes and events altered by these 
proteins were discovered using RNA-Seq (some of which were confirmed using selected targeted 
functional assays). Results for RBM5 and RBM10, respectively, were then compared to evaluate 
the degree, and potential significance, of any overlapping roles. An important relationship 
between RBM5 and RBM10 was also evaluated, as described in Chapter 4. In addition, in 
Chapter 3, the clinical significance of RBM5 downregulation to SCLC was evaluated in terms of 
chemotherapy, sensitivity and the similarity between RBM5-altered pathways and those 
modified in tumors from SCLC patients. As GLC20 cells show some drug resistance, but are still 
able to undergo death upon exposure to cisplatin (Figure 3.2), they were deemed to be an 
appropriate model for specific drug-sensitization studies. In all, this work is the first 
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comprehensive analysis of processes altered by RBM5 and RBM10 expression, and provides a 
comprehensive list of their mRNA targets in a SCLC cell line. These manuscripts also show 
RBM5 directly regulates RBM10 function, and a working model is presented that describes this 
relationship and its functional consequences. 
 
1.4.7 Chapter 5 
Having discovered a significant relationship between RBM5 and RBM10 in the GLC20 SCLC 
cells, we extended our research past cancer cell lines to determine if any potential 
RBM5/RBM10 relationship was restricted to the transformed state, or if it was a more general 
phenomenon across cell types, species, and transformation-status. Non-transformed H9c2 rat 
myoblasts were used for the reasons described above. We determined that RBM5 expression was 
post-transcriptionally regulated in rat myoblasts and that RBM10 expression was influenced by 
the expression levels of RBM5. A model describing this regulation was proposed. This work is 
the first to describe the post-transcriptional regulation of RBM5 in a non-transformed system, as 
well as show a relationship between RBM5 and RBM10 outside of tumor cells. 
 
1.4.8 Impact statement 
A single RBP can influence RNA metabolism in a variety of ways, and consequently have 
multiple downstream effects. It is, therefore, critical to elucidate the wide range of processes 
each RBP can potentially influence when determining an RBP’s role(s) and function(s). 
Together, this knowledge would help to better understand pathway regulation and potential 
pathway-linkages. The body of work presented in this dissertation is the first comprehensive 
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analysis of the roles and relationship of two related RBPs, RBM5 and RBM10. I show not only 
potential pathways they influence, both directly and as a downstream consequence of their 
expression, but also the complex functional associations between these two proteins in 
transformed and non-transformed cells. The particularly significant regulation of RBM10 by 
RBM5, discovered and described in this work, truly highlights the complexity of RNA 
metabolism, and pathway regulation. Understanding the scope of function of RBM5 and RBM10 
not only helps to continue to evolve our knowledge of RNA binding proteins in general, but also 
to gain comprehensive insight into the impact of their downregulation and mutation in various 
disease states such as SCLC.   
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2 Insights into the role of alternative splicing within the RBM10v1 
exon 10 tandem donor site 
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 Abstract 
 
Background: RBM10 is an RNA binding protein involved in the regulation of transcription, alternative splicing 
and message stabilization. Mutations in RBM10, which maps to the X chromosome, are associated with TARP 
syndrome, lung and pancreatic cancers. Two predominant isoforms of RBM10 exist, RBM10v1 and RBM10v2. 
Both variants have alternate isoforms that differ by one valine residue, at amino acid 354 (RBM10v1) or 277 
(RBM10v2). It was recently observed that a novel point mutation at amino acid 354 of RBM10v1, replacing 
valine with glutamic acid, correlated with preferential expression of an exon 11 inclusion variant of the 
proliferation regulatory protein NUMB, which is upregulated in lung cancer.  
Findings: We demonstrate, using the GLC20 male-derived small cell lung cancer cell line - confirmed to have only 
one X chromosome - that the two (+/−) valine isoforms of RBM10v1 and RBM10v2 result from alternative splicing. 
Protein modeling of the RNA Recognition Motif (RRM) within which the alteration occurs, shows that the presence of 
valine inhibits the formation of one of the two α-helices associated with RRM tertiary structure, whereas the absence 
of valine supports the α-helical configuration. We then show 2-fold elevated expression of the transcripts encoding 
the minus valine RBM10v1 isoform in GLC20 cells, compared to those encoding the plus valine isoform. This 
expression correlates with preferential expression of the lung cancer-associated NUMB exon 11 inclusion variant. 
 
Conclusions: Our observations suggest that the ability of RBM10v1 to regulate alternative splicing 
depends, at least in part, on a structural alteration within the second RRM domain, which influences 
whether RBM10v1 functions to support or repress splicing. A model is presented. 
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2.1 Introduction 
The RNA binding protein RBM10 is capable of regulating the expression of a number of genes 
including some involved in apoptosis (e.g., FASR) [1] and cell proliferation (e.g., NUMB) [2]. In 
all of the reported cases but one, this expression regulation takes the form of alternative splicing 
regulation [1-4]. The one gene whose expression is not regulated by RBM10-mediated 
alternative splicing is the angiotensin receptor 1 (AT1), where RBM10 influences AT1 
expression by binding within the transcript’s 3′-untranslated region (UTR), stabilising the 
message and subsequently contributing to a decreased rate of transcription [4]. How RBM10 
accomplishes these disparate functions remains to be determined. 
The region(s) within the RBM10 protein that is involved in any of the RNA-protein interactions 
identified to date has not been defined although it likely involves at least one of two RNA 
Recognition Motifs (RRM) and two zinc fingers (ZnF) [5]. On the other hand, two consensus 
motifs within the target RNA with which the RBM10 protein binds have been defined as 
CUCUGAA CUC and CGAUCCCU [2]. Using HeLa cells, Bechara et al. [2] reported that 
RBM10 interactions occurred predominantly within the upstream intron of an excluded alternate 
exon but predominantly downstream of an included alternate exon. On the other hand, using 
HEK293 cells, Wang et al. [3] reported that RBM10 interactions occurred in the vicinity of the 
5′- and 3′-splice sites within both the upstream and downstream introns of alternate exons, 
though predominant binding in the vicinity of the upstream 3′-splice site was associated with less 
exon skipping. Obviously, much remains to be elucidated concerning the regulation of these 
interactions. 
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Mutations in RBM10 have been noted in cells associated with lung and pancreatic cancers and 
the neuromuscular disorder TARP syndrome [3,6-10] (summarized in Table 2.1). In one lung 
study, 12/183 (7%) adenocarcinoma specimens had RBM10 mutations, each patient having a 
different mutation (5/12 being missense, 5/12 truncating and 2/12 splice-site) [10]. In another 
lung study, a mutation - caused by a T to A substitution and consequent valine (V) to glutamic 
acid (E) substitution within the second RRM (RRM2) of RBM10 - was reported in A549 lung 
adenocarcinoma cells, with consequences for NUMB alternative splicing [2]. In the blood cells 
of patients with TARP syndrome, six different mutations were identified [6-8], and a six exon-
spanning deletion (aa 651–889) that codes for a truncated RBM10 isoform with an inability to 
regulate alternative splicing [3]. 
Table 2.1: RBM10 mutations. 
Phenotype Mutation effect Mutation Exon Protein Reference 
NSCLC Missense  2 E4K Imielinski et al. [10] 
NSCLC Missense  2 R6H Imielinski et al. [10] 
TARP syndrome Frameshift c.159delC 3 p.Lys54SerfsX80 Gripp et al. [7] 
NSCLC Nonsense  3 E67 Imielinski et al. [10] 
TARP syndrome  c.448C>T 4 p.Gln150X Johnston et al. [8] 
NSCLC Nonsense  5 R157fs Imielinski et al. [10] 
NSCLC Nonsense  7 Y206 Imielinski et al. [10] 
NSCLC Nonsense  8 R230 Imielinski et al. [10] 
TARP syndrome  c.724+2T>C 8  Johnston et al. [8] 
NSCLC Missense  10 1316F Imielinski et al. [10] 
TARP syndrome Nonsense c.1235G>A 12 p.Trp412X Johnston et al. [6] 
NSCLC Missense  16 Y580F Imielinski et al. [10] 
NSCLC Splice site  17 Y596 Imielinski et al. [10] 
Pancreatic neoplasm Frameshift c.1817-1818insA 17 p.E606EfsX37 Furukawa et al. [9] 
TARP syndrome Frameshift c.1893-1894insA 17 p.Pro632ThrfsX41 Johnston et al. [6] 
TARP syndrome Deletion aa651-889 18-23  Wang et al. [3] 
NSCLC Missense  18 R685L Imielnski et al. [10] 
TARP syndrome  c.2176C>T 20 p.Arg726X Johnston et al. [8] 
NSCLC Nonsense  21 E810 Imielinski et al. [10] 
NSCLC Splice site  22 V846 Imielinski et al. [10] 
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The pre-mRNA for RBM10 is alternatively spliced to yield two predominant protein isoforms: a 
930 amino acid (aa) (~103.5 kDa) isoform that includes exon 4, referred to as RBM10 variant 1 
(RBM10v1), and an 853 aa (~94.5 kDa) isoform that lacks exon 4, referred to as RBM10v2. In 
addition to the two major RBM10 variants, the Ensembl Database lists a variant of RBM10v2 
that is one amino acid shorter (852 aa). The 7 April 2003 Gen-Bank deposition version 1 for this 
RBM10v2(V277del) isoform (NM_152856.1) describes it as having an “alternate donor splice 
site” compared to RBM10v1. Indeed, a tandem donor splice site of the configuration GYNGYN 
was identified in RBM10 exon 10 (as GTGGTG) from a screen of expressed sequence tags 
(ESTs) for variants generated from upstream and downstream tandem repeat triplets [11]. 
Utilization of the downstream triplet (the “e” site referred to in [11]) would result in the inclusion 
of a valine at amino acid 277 for RBM10v2 and 354 for RBM10v1. For clarity throughout this 
manuscript, we will refer to the longer RBM10v2 isoform as RBM10v2 (V277), the shorter 
RBM10v2 isoform as RBM10v2 (V277del), the longer RBM10v1 isoform as RBM10v1 (V354) 
and the shorter RBM10v1 isoform as RBM10v1 (V354del). 
 
Our comprehensive review of the literature and various protein databases suggested that the 
presence of RBM10v1(V354del) is by no means generally recognized and that there appears to 
be some confusion as to its legitimacy and the mechanism by which it is generated. For instance, 
RBM10v1(V354del) has been identified as RBM10 “missing” valine 354 (UniProt – P98175-2), 
and as a mismatch of I353 with valine (on the Protein Data Bank website). For an overview of 
RBM10v1 isoforms described in various databases and references, see Table 2.2. In the study 
presented herein using a small cell lung cancer cell line, we confirm the existence of two full-
length RBM10v2 transcripts, RBM10v2(V277) and RBM10v2(V277del), and prove the 
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existence of two full-length RBM10v1 transcripts, RBM10v1(V354) and RBM10v1(V354del). 
We then demonstrate that the presence or absence of valine alters the tertiary structure of the 
second RNA Recognition Motif (RRM2) within the RBM10 protein. Finally, we show that 2-
fold higher levels of the transcripts encoding the minus- compared to the plus- valine isoforms of 
both RBM10v1 and RBM10v2 correlates with higher levels of the lung cancer associated 
NUMB exon 11 inclusion variant, compared to the exon 11 exclusion variant. 
 
Table 2.2: RBM10v1 isoforms reported in various database and references. 
Origin Sequence Reference 
   
Databases   
Ensembl STIVEAA ENST00000377604 
NIH GenBank STIVEAA NM_005676 
 STIEAA NM_001204467 
NIH GenBank STIVEAA NP_005667 
 STIEAA NP_001191396 
EMBL-EBI InterPro STIVEAA P98175 
UniProtKB STIVEAA P98175-1 
 STI-EAA P98175-2 
neXtprot beta STIVEAA iso1 
 STI-EAA iso2 
USCSC STIVEAA uc004dhf.3 
 STI-EAA uc004dhh.3 
HUGE STI-EAA KIAA0122/GenBank D50912 
References   
Bechara et al. [2] 
Minus valine 
isoform;  
 STI(E)EAA  
Inoue et al. [1] STI-EAA KIAA0122 
 
2.2 Materials and methods 
2.2.1 Cell culture and differentiation 
GLC20 cells were kindly provided by Charles Buys (University of Groningen, The Netherlands). 
Cells were cultured in RPMI supplemented with 10% fetal bovine serum (FBS). JKM1 [24], 
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Jurkat Clone E6 [25], MCF-7 [26], MDA-MB-231 [27] and TF-1 cells [25] were grown as 
previously described. A549 (from ATCC) and HeLa cells (provided by Hoyun Lee, AMRIC) 
were grown in DMEM/ F-12 medium supplemented with 10% FBS. TK6 cells (provided by 
Elliot Drobetsky, University of Montreal) were grown in DMEM/F-12 medium supplemented 
with 10% fetal horse serum. BEAS-2B cells (purchased from ATCC) were grown in LHC-9 
medium, on plates pre-coated with 0.01 mg/ml fibronectin, 0.03 mg/ml collagen and 0.01 mg/ ml 
bovine serum albumin. Media and sera were purchased from Life Technologies (Burlington, 
Canada). 
 
2.2.2 Fluorescent in situ hybridization (FISH) 
Slides were prepared from a cell suspension using standard cytogenetic techniques. Slides were 
denatured at 75°C for 2 mins and hybridized overnight at 37°C with Spectrum Green (X 
chromosome) and Spectrum Red (Y chromosome) (Vysis, Abbott Molecular, Mississauga, 
Canada). Following hybridization the slides were washed in 0.4×SSC/0.3% NP40 at 73°C for 2 
mins, then 2.0×SSC/ 0.1% NP40 at 23°C for 1 min. Slides were dried in the dark then stained 
with Vysis DAPI II and the coverslips applied. Images were captured using an Olympus BX60 
microscope equipped with a mercury bulb and camera. Images were processed with Cytovision 
software from Genetix. 
 
2.2.3 RNA extraction, reverse-transcription and PCR 
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RNA was isolated from cell pellets using Tri-Reagent (Molecular Research Center, Inc., 
Cedarlane, Burlington, Canada). Reverse transcription was carried out using 1 μg of RNA, and 
MMLV (for expression level reactions) or SuperScript II (for sequencing) reverse transcriptase 
(Life Technologies). Amplification of cDNA by polymerase chain reaction (PCR) was 
performed using gene-specific primers RBM10F and RBM10RS (exon 4 spanning) [27] (Figure 
2.1Bi) or RBM10v1/v2R (also exon 4 spanning) [20] (Figure 2.1Bii), NUMBF(exon10): 5′-
TAGAAGGGGAGG CAGAGAGC-3′ and NUMBR(exon12): 5′-CTCAGAGG 
GAGTACGTCTAT-3′ and GAPDH [28] (all primers purchased from AlphaDNA, Montreal, 
Canada). End-point PCR reaction conditions: (1) 95°C for 5 minutes, (2) gene-specific cycle 
number (40 cycles for RBM10, 28 and 40 cycles for NUMB, and 19 (Figure 2.3Bi) or 25 
(Figures 2.1Bii and 2.3Bii) cycles for GAPDH) of 95°C for 30 seconds, 62°C (RBM10F + RS), 
55°C (RBM10F + v1/v2R), 61°C (NUMB), 59°C (GAPDH) for 30 seconds, 72°C for 45 
seconds, and (3) 72°C for 10 minutes. The samples were visualized following electrophoresis 
through a 2% (40 mM Tris-acetate, 10 mM EDTA, pH 8.0) (TAE) agarose gel containing 
SYBR®safe DNA gel stain (Life Technologies). 
 
For sequencing of full-length RBM10, nested PCR was carried out, using RBM10FNhe1: 5′-
CTA GCT AGC TAG TGG CTG GGA AGT GAA ACG GAG CCA GCG-3′ and RBM10RL: 
5′-TGG CTG GGG AGT GGG CTG G-3′ primers for Reaction 1 and RBM10FNhe1 and 
RBM10RHindIII: 5′-CCC AAG CTT GGC TGG GCC TCG TTG AAG CG-3′ primers for 
Reaction 2, Platinum Pfx Polymerase (Life Technologies) and 5 μl of Reaction 1 as template for 
Reaction 2. PCR reaction conditions: Reaction 1: (1) 95°C for 2 minutes, (2) 18 cycles of 94°C 
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for 10 seconds, 66°C for 1 minute, 68°C for 3 minutes; Reaction 2: (3) 22 cycles of 94°C for 10 
seconds, 62°C for 1 minute, 68°C for 3 minutes, (4) 72°C for 5 minutes. 
 
2.2.4 Immunoblotting 
Western blotting was carried out as previously described [20]. RBM10 antibody was used at a 
dilution of 1:500. The in vitro transcription/translation reactions were carried out using a TNT® 
T7 Quick Coupled Transcription/ Translation Kit (Promega, through Fisher Scientific, Nepean, 
Canada), and plasmid constructs pcDNA3.RBM10v1 or pcDNA3.RBM10v2 [20]. 
 
2.2.5 Sequencing 
Full-length RBM10v1 and RBM10v2 amplicons were separated by agarose gel electrophoresis 
(note, no full-length RBM10v2 amplicon was detectable in the GLC20 cells) and cDNA was 
excised using a QIAquick gel extraction kit (Qiagen, Toronto, Canada). DNA quantity 
(absorbance at 260 nanometers (nm)) and purity (ratio of the absorbance at 260 and 280 nm) 
were determined using a Nano-Drop 2000C spectrophotometer (Fisher Scientific, Ottawa, 
Canada), and the samples were sent for sequencing. 
 
Samples were sequenced, using the Sanger technique, by the MOBIX Lab - DNA Sequencing 
and Oligo Synthesis Facility (McMaster University, Hamilton, Canada). Internal primers 
(sequences available upon re-quest) were generated by MOBIX. Bi-directional, over-lapping 
sequence reads of ~600 bp were generated, as detailed in Figure 2.1D. 
 
2.3 Results 
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2.3.1 Evidence that alternative splicing occurs within exon 10 
The GLC20 cell line was established from a small cell lung cancer (SCLC) of male origin [12]. It 
is RBM5-null and was determined, by FISH, to contain only one X chromosome (Figure 2.1A). 
Alternative splicing of the X-linked RBM10 gene [13], to generate both RBM10v1 and 
RBM10v2, was confirmed in the GLC20 cells, using RT-PCR (Figure 2.1B). Most of the cancer, 
or transformed, cell lines that we have tested express more RBM10v1 than RBM10v2, at both 
the mRNA (Figure 2.1B) and protein (Figure 2.1C and data not shown) levels. This observation 
is particularly true for GLC20 cells, which express such a small amount of RBM10v2 protein 
that it is technically challenging to detect. 
 
To estimate functionality of RBM10 in the GLC20 cells, sequencing of cDNA was carried out. 
Only full-length RBM10v1 cDNA was sequenced because full-length RBM10v2 cDNA could 
not be amplified from the GLC20 cells. Mixed sequence was observed beginning at the 3′-end of 
exon 10, with either the forward or reverse primer. At that point in time (June 2014), the 
Ensembl Database listed two different RBM10v2 isoforms, we are herein designating 
RBM10v2(V277) and RBM10v2(V277del) (corresponding to GenBank Accession Numbers 
NM_ 001204466.1 and NM_152856.2). To determine if the mixed sequencing read in the 
GLC20 RBM10v1 sample was the result of a mixture of transcripts with different exon 10 3′-end 
sequences, we designed primers immediately 3′- to the anticipated modified triplet site in the 
cDNA (refer to Figure 2.1D for primer locations), thereafter expecting an unambiguous sequence 
read. Indeed, clear sequence was obtained, thereby delineating the altered region as the last three 
nucleotides of exon 10 (Figure 2.1E). 
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The presence of a mixture of two different isoforms of RBM10v1 suggested either an alternative 
splicing event or two RBM10 alleles, the later possibility being unlikely since we had confirmed 
only one X chromosome by FISH analysis (Figure 2.1A). Since there remained the possibility of 
an RBM10 gene duplication with allelic variation, we decided to sequence RBM10v1 cDNA 
from additional cell lines, theorizing that if the same mixed read was observed in other cells it 
would suggest alternative splicing. We sequenced transcripts from both male and female-derived 
cell lines, since one RBM10 allele is silenced as the result of X chromosome inactivation in 
female somatic cells [14,15], therefore whether male or female-derived, cell lines would 
theoretically have only one RBM10 gene that is transcribed. RBM10v1 and RBM10v2 cDNA 
was sequenced in A549 (a male-derived lung adenocarcinoma cell line), HeLa (a female-derived 
cervical adenocarcinoma cell line) and BEAS-2B (a male-derived non-cancerous 
SV40/adenovirus-transformed lung cell line). Sequencing data revealed the same nucleotide 
variation in exon 10 of RBM10v1 and exon 9 of RBM10v2 in all three cell lines, therefore 
suggesting that the two isoforms of RBM10v1 are, as originally surmised within GenBank 
deposition NM_152856.1 and by Hiller et al. [11], the result of an alternative splicing event. An 
example of how this might occur is presented diagrammatically in Figure 2.1F. 
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Figure 2.1 Alternativge splicing of RBM10. (A) FISH analysis of GLC20 cells, with painted X and Y chromosomes, demonstrating the presence 
of only one X chromosome. (B) RBM10v1 and RBM10v2 RNA expression in various cell lines, including GLC20. Representative raw RT-PCR 
data using RBM10 exon 4 spanning primers. Bi: RBM10F with RBM10RS primers. Bii: RBM10F with RBM10v1/v2R primers. M: 100 bp DNA 
ladder (FroggaBio Inc., Toronto, Canada). NTC: no template control. (C) Protein expression by Western blot. Ci shows RBM10 expression in whole 
cell lysates from three cell lines, including GLC20. The numbers 1, 2 and 3 after JKM1 and GLC20 delineate cells from three biological replicates. 
Cii includes control HeLa protein and in vitro translated RBM10v1 and RBM10v2 protein, to confirm the location of RBM10v2 is the cell line 
extracts. (D) Cartoon of full-length RBM10v1 mRNA, not drawn to scale. Boxes represent exons. Left and right black arrows represent primer 
placement for sequencing. Approximate positioning of consensus functional motifs is indicated by text and differential shading. (E) Alignment of 
the two GLC20 RBM10v1 isoform sequences. Circled area indicates the region that differs between the two RBM10v1 isoforms. (F) Nucleotide and 
amino acid sequences of the RBM10v1 exon10/intron 10/exon 11 donor and acceptor sites for (i) RBM10v1(V354), and (ii) RBM10v1(V354del). 
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Sequence variation that occurs as a result of alternative splicing at the 3′-ends of exons with 
tandem repeats such as GYNGYN, is regulated partly by U1snRNA binding and partly by the 
presence of CGGG and GGGT sequons in the downstream intron, particularly if the downstream 
intron is shorter than 200 nucleotides (nts) [11]. Intron 10 of RBM10 is 171 nts and contains 
three CGGG sequons, two GGGT sequons and one CGGGGT sequon, suggesting that co-
expression of the two RBM10v1 isoforms is indeed a regulated alternative splicing event. The 
stimuli that control this regulation remain to be determined, but are unlikely limited to male, lung 
or cancer cells, since both RBM10v1(V354) and RBM10v1(V354del) were present in A549, 
HeLa, BEAS-2B and GLC20 cells. 
 
2.3.2 Structural consequences of alternative splicing of RBM10v1 
RBM10v1 and RBM10v2 both contain two RRMs (refer to Figure 2.1D) defined as ~75-85 
amino acids that three dimensionally form four β-sheets flanked by two α-helices. The most 
conserved sequences within any RRM comprise the RNP2 and RNP1 domains (reviewed in [5]), 
RNP1 having the most highly conserved sequence of the two. Notably, amino acid 354 in 
RBM10v1 is located in approximately the middle of RRM2, at the beginning of the second α-
helix and near to the end of β-sheet three, which is encoded by the highly conserved RNP1 
domain [16]. 
 
Valines have a high free energy that is associated with α-helix disruption and since α-helices are 
known to contribute to the stabilization of RNA/protein interactions, disruption of the α-helix by 
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a valine insertion would be predicted to destabilize any RNA/protein interaction. In RBM10, the 
placement of the altered amino acid adjacent to the highly conserved β-sheet three structure 
suggested that any potential alteration to the second α-helical structure within RRM2 might have 
a significant effect on overall protein conformation, and consequently, the ability to interact with 
RNA. Indeed, Bechara et al. [2] recently described a G to T mutation in the terminal exon 10 
codon of RBM10, which changed the amino acid coded from valine (V) to a glutamic acid (E). 
This single mutation had dramatic functional consequences, manifesting as an altered ability to 
splice specific downstream targets, such as pre-mRNA encoding the proliferation regulatory 
protein NUMB [2]. 
 
To better understand how a change to this residue might contribute to RBM10 functional 
alterations we compared the structures of a valine-retaining, a glutamic acid-substituting and a 
valine-lacking amino acid within RRM2. We uploaded these altered RBM10v1 RRM2 sequences 
into SwissProtKB/Swiss-Prot (www.expasy.org), a program that predicts a two-dimensional 
configuration and ranks it against similar configurations of previously crystalized structures. A 
crystal structure for a minus-valine RBM10 RRM2 (designated 2m2d) [17,18] was the reference 
structure for the V354, V354E and V354del RBM10v1 RRM2 predictions. We also uploaded the 
RRM2 sequences into Phyre
2
 (the Protein Homology/analogY Recognition Engine v2.0, 
www.sbg.bio.ic.ac.uk). To visualize a rotatable three-dimensional structure, the structure pre-
dictions for V354, V354E and V354del from both Swiss ProtKB and Phyre
2
 were uploaded into 
the Yasara modeling program (Yet Another Scientific Artificial Reality Application, 
www.yasara.org). A comparison of all the predictions (Figure 2.2) revealed that the addition of 
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valine did, as anticipated, disrupt the α-helical structure and thus the classic configuration of an 
RRM domain (shown as a colour change from dark blue to cyan by the Yasara software). 
Exclusion of the valine was associated with an α-helix. Substitution of the V for an E resulted in 
two slightly different configurations, depending on the prediction program used: both programs, 
however, predicted a change to, but a retention of, an α-helical structure compared to either the 
V354del or the V354. These modelling results suggest that conformational changes to the 
RBM10v1 protein could be responsible for altering the protein’s ability to interact with RNA. 
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2.3.3 Functional consequences of alternative splicing of RBM10v1 
Using PAR-CLIP technology Bechara et al. [2] identified an RBM10 cluster in the 3′-splice site 
region preceding NUMB exon 11 (the current Ensembl exonic designation for the previously 
referred to NUMB exon 9) [2]. They then went on to demonstrate, using an A549 non-small cell 
Figure 2.2 Conformation of RBM10v1 RRM2. The RBM10 RRM2 conformation was modeled using SwissProtKB (A) or Phyre2 (B). (i) 
Isoforms V354. (ii) Isoforms V354E. (iii) Isoforms V354del. Arrow indicates the position of the +/− valine. Yasara structure colors indicate beta-
sheets (red), alpha-helixes (dark blue), turns (green) and random coils (cyan). 
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lung cancer (NSCLC) cell line with an RBM10v1 (V354E) mutation (herein referred to as A549-
JV), that expression of recombinant RBM10v1 protein, with either a valine or a glutamic acid at 
amino acid 354, altered NUMB splicing. With valine present (RBM10v1(V354)), there was 
preferential NUMB exon 11 exclusion - associated with NOTCH repression and decreased 
proliferation. On the other hand, the glutamic acid-containing isoform (RBM10v1(V354E)) 
demonstrated preferential NUMB exon 11 inclusion – associated with NOTCH activation and 
increased proliferation. Recognizing that a V354E substitution would not necessarily have a 
similar effect as a V354del, but taking into consideration our structural predictions, the fact that 
the valine to glutamic acid mutation occurred at exactly the same site as the RBM10v1 
alternative splicing of RBM10v1(V354) to RBM10v1(V354del) suggested to us that regulated 
alternative splicing of RBM10v1 has functional significance and is important to lung cancer. 
 
Considering that RBM10v1(V354) expression correlated with preferential NUMB exon 11 
exclusion and RBM10v1(V354E) expression correlated with preferential NUMB exon 11 
inclusion [2] and that expression of the exon 11 retaining NUMB transcript is frequently in-
creased in lung adenocarcinomas [19], one might predict that (a) downregulation of 
RBM10v1(V354) is one means by which lung cancer cells circumvent proliferation controls, and 
(b) more RBM10v1(V354del) than RBM10v1 (V354) is expressed in lung cancers. Interestingly, 
we have whole transcriptome-sequencing data (manuscript in preparation) demonstrating that in 
the GLC20 small cell lung cancer cells and three stable GLC20 sublines, transcripts encoding 
RBM10v1(V354del) and RBM10v2(V277del) have ~2-fold higher expression than transcripts 
encoding RBM10v1(V354) and RBM10v2(V277) (Figure 2.3A). When NUMB exon 11 
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alternative splicing was examined in the GLC20 cells, as predicted, preferential expression of the 
NUMB exon 11 inclusion variant was observed (Figure 2.3B). 
 
NUMB splicing was also examined in HeLa and BEAS-2B cells as well as our A549 cells 
(herein referred to as A549-LS) that, unlike those used by Valcárcel and colleagues [2], express 
transcripts encoding both RBM10v1 (V354) and RBM10v1(V354del), as opposed to only 
RBM10v1(V354E). If RBM10v1(V354del) functions in a similar manner to RBM10v1(V354E) 
- to generate the NUMB exon 11 inclusion transcript - then we anticipated A549-LS cells would 
express both the NUMB exon 11 inclusion and exclusion transcripts. We also anticipated more 
of the NUMB exon 11 exclusion transcript in the A549-LS cells (resulting from 
RBM10v1(V354) expression), compared to the A549-JV subline (which lacks 
RBM10v1(V354)). As shown in Figure 2.3B, and confirming the observations of Valcárcel and 
colleagues [2], the A549-LS subline expressed both NUMB variants, but significantly more of 
the NUMB exclusion variant than the inclusion variant (as opposed to the A549-JV subline that 
expressed predominantly the NUMB exon 11-inclusion transcript: see [2], Figure Six C, upper 
panel, lane 14). In the transformed but non-tumourigenic BEAS-2B bronchial epithelial cells, we 
predicted a lower NUMB exon 11 inclusion to exclusion ratio, based on the previously reported 
observations that the ratio of NUMB exon 11 inclusion to exon 11 exclusion is higher in lung 
cancer than in normal cells [19] and our hypothesis that the RBM10v1(V354del) isoform is more 
prevalent in cancer cells. As shown in Figure 2.3B, the BEAS-2B cells did indeed have the 
lowest NUMB exon 11 inclusion to exclusion ratio of the four cell lines examined. Finally, as 
expected, and previously shown by Bechara et al. [2], HeLa cells had a clearly higher inclusion 
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to exclusion expression ratio. The only unexpected observation from this cell line RNA analysis 
was the high level of the NUMB exon 11 exclusion variant in the A549-LS cells, considering 
they are a lung cancer cell line. Determination of the relative expression levels of the transcripts 
encoding RBM10v1(V354) and RBM10v1(V354del) isoforms in this subline would help to 
resolve this conundrum. 
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Figure 2.3 Functional effects associated with RBM10 variant expression. (A) In GLC20 cells, comparative expression levels of RBM10v1 and 
RBM10v2 transcripts encoding the valine-retaining and valine-lacking isoforms, as determined by RNA-seq. *p < 0.05. (B) NUMB alternative 
splicing in A549, HeLa, BEAS-2B and GLC20 cells. (i) and (ii) are 2% agarose gels with SYBR®safe, showing representative amplicon 
expression levels following end-point PCR with (i) 28 cycles, or (ii) 40 cycles, using NUMB exon 11-spanning primers and (i) 19 cycles or (ii) 25 
cycles for GAPDH. (iii) Following densitometry of amplicons from six end-point PCR reactions (three at 28 cycles and three at 40 cycles) of the 
two different cDNA preparations from one RNA extraction for each cell line, the percentage of the NUMB exon 11 exclusion variant was 
calculated and plotted. Error bars represent the standard error of the mean. Significances were calculated using an unpaired Student’s t-test, with 
*p < 0.05, **p < 0.01 and ****p < 0.0001. (C) Model depicting how the +/− valine isoforms of RBM10v1 might influence NUMB exon 11 
alternative splicing. The plus and minus valine isoforms are present, at low levels, in normal cells, and contribute to the production of both the 
exon 11 inclusion and exclusion variants of NUMB. Both RBM10 isoforms are able to bind NUMB pre-mRNA, but the minus valine isoform of 
RBM10v1 does so with higher affinity, having the classical α-helix structure. The plus valine isoform does not bind as efficiently, thereby 
interfering with recognition of the intron 10 3′splice site, resulting in NUMB exon 11 exclusion. 
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2.4 Discussion 
RBM10 is an apoptosis regulatory protein [20] and its paralogue, RBM5 functions in the same 
capacity, but has the added ability to regulate the cell cycle [21,22]. Based on the findings of 
Bechara et al. [2], it appears that RBM10 is also able to regulate the cell cycle, via the NOTCH 
signaling pathway [2]. Is the regulation of RBM10v1(V354) versus RBM10v1(V354del) 
alternative splicing a means by which normal cells temporarily modulate proliferation prior to a 
repair versus apoptosis event? Have cancer cells hijacked this alternative splicing mechanism as 
one means of circumventing proliferation controls? Of the mutations identified so far in 
pancreatic cancer and NSCLCs, none occurs at this site to permanently generate the minus valine 
isoform, except the mutation described by Bechara et al. [2] in a lung adenocarcinoma cell line 
(see Table 2.1). It is therefore difficult to predict how important the regulation of this alternative 
splicing event is to cancer initiation and/or progression. We have initiated studies to more 
thoroughly characterise the expression of transcripts encoding the two RBM10v1 and RBM10v2 
isoforms in primary lung cancer specimens. Additional studies relating to protein expression are 
also warranted, as are studies concerning the regulation of this expression. 
 
In an attempt to align our observations with those of Bechara et al. [2] and Wang et al. [3] we 
propose a model to explain how changes in RBM10v1 splicing might be predicted to regulate 
NUMB splicing. The model takes into consideration the following observations. Firstly, 
overexpression of RBM10 correlates with NUMB exon 11 exclusion [2,3]. Secondly, in lung 
cancer there is preferential expression of the NUMB exon 11 inclusion variant. Thirdly, in lung 
cancer RBM10 is highly expressed [10], but while in our A549, HeLa, BEAS-2B and GLC20 
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cells transcripts encoding both RBM10v1 isoforms were observed, there was two-fold more 
RBM10v1(V354del) than RBM10v1(V354) in the GLC20 SCLC cells. Our model does not 
attempt to reconcile the somewhat conflicting binding data previously reported [2,3]. 
 
Our model, depicted in Figure 2.3C, posits that RBM10v1 (V354) and RBM10v1(V354del) are 
both expressed in normal cells, but that in cancers RBM10v1(V354del) is preferentially 
expressed. RBM10v1(V354) and RBM10v1 (V354del) are both capable of interacting with pre-
mRNA, and do so in the vicinity of the upstream intronic 3′-splice site of the alternate exon. 
RBM10v1(V354del), however, has a higher affinity interaction with pre-mRNA than 
RBM10v1(V354) (resulting from its ability to form the second α-helix within RRM2). In its 
capacity as a higher affinity binder, RBM10v1(V354del) is able to function as an auxiliary 
splicing factor. As for RBM10v1 (V354), disruption of the second α-helical structure within 
RRM2 generates an RBM10v1 isoform that interacts with the same pre-mRNA as 
RBM10v1(V354del) but in a manner that impedes splicing. As a result of either less efficient or 
lower affinity binding or an inability to optimally interact with other auxiliary/splicing factors, 
expression of RBM10v1(V354) functions to increase the splicing of the alternative transcript. In 
our model, the increase in the NUMB exon 11 inclusion transcript that is associated with 
downregulation of RBM10 results from the presence of reduced levels of the competing, less 
efficient binding, RBM10v1(V354) isoform and consequently more binding of the higher affinity 
RBM10v1(V354del) isoform, resulting in more of the NUMB exon 11 inclusion product. 
According to our model, therefore, alternative splicing regulation by RBM10 depends not only 
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on the ratio of RBM10v1(V354) to RBM10v1(V354del), but on the total levels of RBM10v1 
protein as well. 
 
Exactly how the structural change associated with a valine insertion at amino acid 354 of 
RBM10v1 results in splicing changes is unknown. Multiple binding motifs have been identified 
for RBM10 [2] as have multiple potential binding regions within pre-mRNA [2,3], suggesting 
that interaction of RBM10 with pre-mRNA targets may be a dynamic and flexible phenomenon. 
And while expression of RBM10 is more frequently associated with alternate exon exclusion [1-
3,23], it is also associated with alternate exon inclusion [2,3]. Perhaps binding and function of 
RBM10 is more influenced by tertiary structure than primary sequence of the protein, and the 
multiple sequence motifs and binding regions identified within pre-mRNAs reflect interactions 
with different RBM10 isoforms that each assume a slightly different conformation. 
 
To note just prior to submission of this manuscript, Ensembl (which had not, at least during the 
course of this investigation, listed RBM10v1(V354del) in its database) removed the 
RBM10v2(V277del) isoform, thereby eliminating all reference to the minus-valine isoforms. The 
minus valine isoforms are those which form the classic α-helical structure associated with the 
RRM domains (as shown herein), RNA transcripts encoding the minus valine isoform of 
RBM10v1 exist in multiple cell types (as shown herein), and functional studies demonstrate the 
apoptotic regulatory ability [20] and alternative splicing ability [2] of RBM10v1(V354del). We 
therefore suggest that the alternative splicing of RBM10v1, and likely RBM10v2, is a regulated 
event worthy of consideration in functional studies. 
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Chapter 3  
3 RBM5 reduces small cell lung cancer growth, increases cisplatin 
sensitivity and regulates key transformation-associated pathways 
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3.1 Abstract 
 
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer, with almost 95% of 
patients succumbing to the disease. Although RBM5, a tumor suppressor gene, is downregulated 
in the majority of lung cancers, its role in SCLC is unknown. Using the GLC20 SCLC cell line, 
which has a homozygous deletion encompassing the RBM5 gene locus, we established stable 
RBM5 expressing sublines and investigated the effects of RBM5 re-expression. Transcriptome 
and target identification studies determined that RBM5 directly regulates the cell cycle and 
apoptosis in SCLC cells, as well as significantly downregulates other important transformation-
associated pathways such as angiogenesis and cell adhesion. RNA sequencing of paired non-
tumor and tumor SCLC patient specimens showed decreased RBM5 expression in the tumors, 
and expression alterations in the majority of the same pathways that were altered in the GLC20 
cells and sublines. Functional studies confirmed RBM5 expression slows SCLC cell line growth, 
and increases sensitivity to the chemotherapy drug cisplatin. 
 
Overall, our work demonstrates the importance of RBM5 expression to the non-transformed state 
of lung cells and the consequences of its deletion to SCLC development and progression. 
 
 
 
3.2 Introduction 
 
According to the American Cancer Society, more people die from primary cancers of the lung 
than from any other type of cancer. The most aggressive type of lung cancer occurs in the “small 
cells”, found in the main bronchi (Travis et al., 2004). Small cell lung cancer (SCLC) almost 
61 
 
 
 
exclusively occurs in people with a history of tobacco smoking (Jackman and Johnson, 2005; 
Travis et al., 2004). 
 
Lung cancer initiation and progression are attributed at the molecular level to many factors, but 
arguably the most interesting is the loss of heterozygosity in a few regions throughout the short 
arm of chromosome three. Notably, allelic loss within the 3p21.3 region is evidenced even in 
pre-neoplastic tissue from smokers (Wistuba et al., 2000). An overlapping homozygous deletion 
within 3p21.3, noted in lung and breast tumors, harbors a number of tumor suppressor genes 
(Lerman and Minna, 2000). RNA Binding Motif 5 (RBM5), a putative lung cancer tumor 
suppressor gene (Sutherland et al., 2010), resides near the end of the telomeric deletion 
breakpoint that was noted in three SCLC cell lines (Lerman and Minna, 2000). In the majority of 
lung cancers (including SCLC and non-small cell lung cancer (NSCLC)), expression of RBM5 is 
downregulated but present (Oh et al., 2002). The cause of this downregulation is unknown, but 
does not appear to result from gene mutation or promoter hypermethylation (Oh et al., 2008; Oh 
et al., 2007), suggesting allelic loss may be responsible. The almost universal downregulation of 
RBM5 in all types of lung cancer does suggest it plays an important role in lung cancer initiation 
and/or progression. RBM5 was, in fact, identified as one of nine downregulated genes within a 17 
gene signature associated with metastasis in various human solid tumors, including lung 
(Ramaswamy et al., 2003). 
 
Previous functional work relating to RBM5 in a variety of cancer cell lines identified it as a 
modulator of the cell cycle and apoptosis, partially via its influence on alternative splicing 
(Bechara et al., 2013; Oh et al., 2002). In regards to lung cancer specifically, some functional 
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work regarding RBM5 has been performed using a lung adenocarcinoma cell line (A549), which 
showed that increased RBM5 expression correlated with (a) G1 cell cycle arrest (Network, 2014; 
Shao et al., 2012), and (b) increased apoptosis (Oh et al., 2006; Shao et al., 2012). No functional 
work, however, has been undertaken for RBM5 in SCLC. This project set out to determine the 
importance of RBM5 in SCLC, in order to better understand the consequences of its 
downregulation to the development and progression of this disease. Furthermore, since SCLC is 
the most aggressive type of lung cancer, with 95% of patients eventually succumbing to the 
disease (Govindan et al., 2006), it is clear that a better understanding of this disease, as well as 
more effective treatment options, are required. 
 
GLC20 is a SCLC cell line derived from small cells within a lung tumor biopsy (Smit et al., 
1992). The cells have two 3p21 homozygous deletions, one of which includes RBM5, making the 
cells an attractive model in which to study the functional consequences of RBM5 re-expression 
(Angeloni, 2007; Kok et al., 1994). We established two RBM5 expressing populations, with 
different levels of RBM5, and conducted transcriptome analyses to identify the pathways affected 
by altering the levels of RBM5. Target identification experiments were carried out to determine 
which of these pathways were directly affected by RBM5. To validate our findings, we (a) 
compared our in vitro transcriptomic results to transcriptomic data from two paired non-
tumor/tumor patient specimens with a 50% downregulation of RBM5 expression, and (b) 
experimentally examined the effects of no versus low versus high RBM5 expression on cell 
proliferation and apoptosis. Our results suggest that RBM5 is a key SCLC suppressor and 
guardian of the non-transformed phenotype. 
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3.3 Materials & methods 
 
3.3.1 Cell culture 
 
SCLC GLC20 cells were a kind gift from the late Dr. Charles Buys from the University of 
Groningen (Groningen, Netherlands). GLC20 cells and sublines pcDNA3, T2 and C4 were 
maintained in RPMI 1640 (Gibco, Life Technologies) supplemented with 10% fetal bovine 
serum (FBS, Gibco) (termed complete media), with the addition of 0.1 mg/mL G418/Geneticin 
(Gibco) for pcDNA3, T2 and C4 sublines. Cells were maintained at 37 °C with 5% CO2 in a 
humidified chamber. 
 
3.3.2 Southern blotting 
 
Genomic DNA was isolated by spooling, following overnight incubation in Tail Buffer (1% 
SDS, 0.1 M NaCl, 0.1 M EDTA, 0.05 M Tris, pH8), treated with 50 μg/ ml of RNase A 
(Amersham Biosciences) and cleaned using Qiagen Genomic-tip 100/G columns, following the 
manufacturer’s instructions. The Southern blot was prepared and probed as previously described 
(Rintala-Maki and Sutherland, 2009). The RBM5 probe was prepared using the PROSTAR HF 
single tube RT-PCR System (Stratagene), labelling with radioactive phosphate, and cleaning 
with a G25 sepharose column, following manufacturer’s instructions. 
 
3.3.3 GLC20 apoptosis profiles 
 
GLC20 cells were diluted 1:2 in a 24 well plate 24 h before treatment. The following day, cells 
were treated with cisplatin (Sigma-Aldrich) dissolved in dimethyl sulfoxide (DMSO) and/or 
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etoposide (Sigma-Aldrich) dissolved in DMSO. Cells were then incubated for varying amounts 
of time, as shown in Fig. 3.2, at 37 °C in a 5% CO2 humidified incubator. 
 
3.3.4 Western blotting 
 
Primary antibodies used were rabbit anti-RBM5 LUCA-15-UK (non-commercially available) 
(1:2,500 or 1:5,000) (Sutherland et al., 2000), rabbit anti-human PARP (1:1,500–1:2,000, C2-10: 
BD Pharmingen) and mouse anti-α-tubulin primary antibody (1:10,000, sc-8035, Santa Cruz 
Biotechnology, Inc.). Secondary antibodies used were goat anti-mouse HRP-conjugated 
secondary antibody (1:10,000, sc-2005; Santa Cruz Biotechnologies Inc.) or goat anti-rabbit 
HRP-conjugated secondary antibody (1:10,000, sc-2004; Santa Cruz Biotechnologies Inc.). 
Protein was exposed using Amersham ECL Western blotting detection reagents (GE-Healthcare) 
to Amersham Hyperfilm (GE-Healthcare). Film was then developed using a SRX-101A medical 
film processor (Konica Minolta Medical and Graphic Inc.). 
 
3.3.5 Establishment of stable RBM5-expressing GLC20 sublines 
 
GLC20 sublines were established following DMRIE-C transfection with pcDNA3 or 
pcDNA3.RBM5, and stable selection with G418 at 1.0 mg/ml in soft agar for 120 days. Detailed 
protocol is as follows; Cells were passaged 1:2, 24–48 h prior to transfection. 10 ml of cell 
culture (∼ 2 × 106 cells) were used in each transfection, with 24 μl DMRIE-C (Life 
Technologies) and 8 μg total DNA (pcDNA3 or pcDNA3.RBM5). DMREI-C and DNA were 
incubated for ∼30 min prior to cell addition. The cell/DMREI-C/DNA mix was then incubated at 
37 °C and 5% CO2 for 4 h, and the transfection terminated by adding serum. Transfected cells 
were selected using G418, at a concentration of 1.0 mg/ml, a concentration previously 
65 
 
 
 
determined to kill all untransfected cells by seven days. Following transfection, a clonal 
population of cells was established following plating in soft agar, as previously described 
(Longthorne and Williams, 1997). Four empty vector transfected clones and five RBM5 
transfected clones were picked following 36 days of G418 selection in soft agar. After 120 days 
of continuous growth in G418 (following the first dilution of 10 ml of stably transfected cells, 
the selection reagent concentration was reduced from 1.0 to 0.1 mg/ml), only two of the five 
RBM5-transfected clones survived. One of these, designated C4, as well as one empty vector 
control clone, were used in subsequent studies. A second transfection was carried out in order to 
generate a pooled population of RBM5-transfected cells (eventually designated T2). 
 
 
3.3.6 RNA extraction 
 
GLC20 RNA samples were isolated using Tri-Reagent (BioCan Scientific). For RNA templates 
used in PCR, reverse transcription was performed as previously described (Loiselle and 
Sutherland, 2014). In regards to the Ontario Tumour Bank (OTB) tissue samples, 20 mg of tissue 
was cut with a sterile blade from fresh frozen tissue specimens that had been stored at −80 °C. 
The 20 mg tissue piece was transferred to a Bessman Tissue Pulverizer (VWR) that had been 
placed in liquid nitrogen for 10 min. Once the pulverizer was secured, a hammer was used to 
smash the tissue until it obtained a powder-like consistency. Powdered tissue was transferred to a 
solution containing Buffer RLT (Qiagen) and 0.14 mM β-mercaptoethanol, and homogenized 
using a Polytron PT 1300 D Homogenizer (Kinematica). The lysate was centrifuged for 3 min at 
17000 x g to pellet tissue matter that did not homogenize. Supernatant was transferred to an 
Allprep DNA/RNA/Protein Mini Kit spin column (Qiagen) and RNA was extracted according to 
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manufacturer’s instructions. It is important to note that RNA was extracted from two 20 mg 
pieces of tissue, and combined. 
 
3.3.7 PCR 
 
RBM5 genomic DNA PCR was performed using Gen1E2Fc (exon 2: 5′-
CTTCAGTGGGACAATGGGTTCAGA-3′) and Gen2E3I2R (exon 3/intron 2: 5′-
CCACTACGCTCTGTTCTACTCACTCTGCCA-3′) primers, with the follow-ing PCR 
amplification program 95 °C 5 min, [95 °C 30 s/65 °C 30 s/68 °C 2 min] (40 cycles), 68 °C 10 
min. RBM5 RT-PCR was performed using LU15(2) (exon 4) and LU15(3) (exon 8) primers, as 
previously described (Sutherland et al., 2000).GAPDH was amplified using GAPDH-F (exon 6: 
5′ AACACAGTCCATGC-CATCAC 3′) and GAPDH-R (exon 7: 5′ 
TCCACCACCCTGTTGCTGTA), with an annealing temperature of 58−59 °C and 25–35 
amplification cycles. PCR and product visualization were carried out as previously described 
(Loiselle and Sutherland, 2014). Approximate primer locations shown in Fig. 3.1G. 
 
3.3.8 RNA-Sequencing and analyses 
 
Extracted RNA was sent to the Donnelly Sequencing Centre (Toronto, Canada) for Illumina 
TruSeq stranded mRNA library preparation with Ribozero depletion, followed by paired-end 
high throughput sequencing using the Illumina HiSeq 2500 platform. 
 
All four untreated GLC20 subline samples were multiplexed together during sequencing, as were 
the four cisplatin-treated samples. It is important to note that there were some differences 
between sample preparation and sequencing for cisplatin treated and untreated RNA-Seq 
67 
 
 
 
samples; (1) untreated samples were DNase treated prior to sequencing, (2) reads were 100 bp 
for untreated samples and 125 bp for cisplatin treated samples, and (3) untreated samples were 
sequenced in duplicate (multiplexed on each of two paired-end lanes), while treated samples 
were not sequenced in duplicate. Due to the longer read length for the cisplatin treated samples 
and overall higher output, however, similar depth was achieved for treated and untreated 
samples. Nonetheless, we only ran analysis within the treated and untreated groups, and 
compared the outputs, so as to not potentially introduce sequencing biases into our analyses. All 
four OTB specimens (two paired tumor and non-tumor specimens) were also multiplexed and 
sequenced in duplicate. 
 
Transcriptome sequencing data quality was verified by FastQC (Babraham Bioinformatics, 
http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). All specimens had quality score 
distributions over all sequences above 37 (on a phred 33 quality scale). Primers and adapters 
used for sequencing were then removed using cutadapt version 1.4.2 (Martin, 2011) using a 
quality cut-off of 26, as recommended (Del Fabbro et al., 2013). Following trimming, data 
quality was verified using FastQC. Trimmed reads were analyzed using the Tuxedo suite tools as 
follows: (1) TopHat 2.0.11 (Kim et al., 2013) was used to align reads to the human reference 
genome USCS hg19, (2) Cufflinks 2.1.1 (Trapnell et al., 2010) was used to assemble the mapped 
reads and obtain FPKM values for each investigated gene and isoform, (3) Cuffdiff 2.1.1 
(Trapnell et al., 2013) was used to investigate differential expression, and (4) CummeRbund 
(Trapnell et al., 2010) was used for visualization. Samtools (Li et al., 2009) and Picard (http:// 
broadinstitute.github.io/picard/) were used to assess mapping quality. For untreated and treated 
GLC20 subline RNA-Seq samples, all samples had a very good percentage of overall mapped 
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reads and concordantly mapped paired reads, with small standard deviations, permitting 
comparison between samples; in untreated samples 94.06% ± 0.44% (SD) reads mapped, with 
89.18% ± 0.28% being concordant for both forward and reverse reads, and in the cisplatin treated 
samples 94.51% ± 0.87% reads were mapped, with 91.73 ± 1.07 of paired reads mapping 
concordantly. Values were slightly lower for OTB patient specimens, as expected, with 89.84 ± 
3.08% reads mapped and 86.06 ± 2.87% concordant. 
 
Prior to differential expression analysis, gene expression levels in both control samples (parental 
GLC20 and GLC20.pcDNA3) were compared to see if they were sufficiently similar to be 
combined into one experimental group; more replicates provides greater power and accuracy in 
RNA-Seq experiments (Liu et al., 2014). In fact, gene expression levels in both samples were 
very highly correlated (r = 0.9699 in untreated samples and r = 0.9813 in cisplatin treated 
samples), and thus both controls were combined into one experimental group. 
 
Pathway enrichment was investigated using the FIDEA (Functional Interpretation of Differential 
Expression Analysis) program (D'Andrea et al., 2013) with the KEGG database (Kanehisa and 
Goto, 2000; Kanehisa et al., 2016). Pathway analysis was also performed using GSAASeqSP 
(Gene Set Association Analysis for RNA-Seq with Sample Permutation) (Xiong et al., 2014) 
with the Molecular Signatures Database (MSigDB) Hallmark gene set collection (Liberzon et al., 
2015). Since each program uses a different algorithm in their calculations, and each gene 
set/functional interaction pathway set is curated separately, with different foci, a broad view of 
affected cellular processes affected is gained, and results can be compared between programs to 
identify the most robust changes. 
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For analysis of alternative splicing events in our RNA-Seq data, stringent parameters were used 
in order to identify alternative splicing events: (1) the expression of at least one alternative splice 
variant had to be significantly upregulated, and (2) the expression of at least one other alternative 
splice variant had to be significantly downregulated. 
 
 
3.3.9 RNA immunoprecipitation followed by next generation sequencing 
(RIP-Seq) 
 
The basic RIP technique was carried out as previously described (Jain et al., 2011). RNA 
associated with the immunoprecipitated samples was sequenced by the Donnelly Sequencing 
Centre. Illumina TruSeq Stranded Total RNA library preparation, including Ribozero Gold 
depletion, was performed along with random priming. Samples were sequenced in duplicate on 
the Illumina HiSeq 2500 platform, with each run being paired-ended, 125 bp reads. 
 
RIP-Seq results were analyzed using the Tuxedo Pipeline (Trapnell et al., 2012), with the same 
quality control steps used for RNA-Seq analysis. Using the FPKM and log2-fold change values 
generated by Cuffdiff, the following inclusion criteria were used to distinguish RBM5 targets 
from IP contaminants: the RBM5 RIP sample target had to have (1) an FPKM value greater than 
one, (2) a log2-fold change greater than one, and (3) a positive log2-fold change (meaning it was 
more highly expressed than in the control RIP). 
 
3.3.10 Cell counting, cell growth and cell death assays 
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Cells were plated at 10,000 per well in 96-well flat-bottom plates at a density of 50 cells/μL, in 
triplicate wells per treatment. Cells were left for 24 h at 37 °C with 5% CO2 in a humidified 
chamber. After 24 h, the cells were treated with the following conditions: left untreated, saline 
(0.9% NaCl in H2O) control, 1.0 μM cisplatin in saline for 0, 2, 4, 6, 8 and 10 days, or 0.1, 0.5, 
10.0 and 100.0 μM cisplatin for 4 and 8 days. Cisplatin (Sigma) was prepared, as previously 
described (Hall et al., 2014), in saline at a concentration of 1.0 mg/mL. The cells were then 
counted every other day by transferring cells to a 96-well Vee-bottom plate and subjecting them 
to centrifugation at 500 x g for 5 min at 21 °C. The supernatant was discarded and cells treated 
with 0.25% Trypsin-EDTA for 10 min at 37 °C with 5% CO2 in a humidified chamber. 
Complete media was added to cells and they were subjected to centrifugation at 500 x g for 5 
min 21 °C. Cells were resuspended in complete media and counted in a 1:1 ratio of cells in 
complete media and 0.2% nigrosin, using a hemocytometer. 
 
Live cells were counted as cells with intact membranes, characterized by a lack of blue/purple 
nigrosin within the cells, and dead cells were counted as cells without intact membranes, 
characterized by the presence of blue/purple nigrosin within the cell. Live cell counts were used 
to monitor cell growth, relative to day 0 counts, and the average of biological triplicates was 
plotted. A two-way ANOVA was performed with Bonferroni post-hoc analysis, comparing all 
subline cell growth to the pcDNA3 subline, calculated using Graphpad Prism 5. Percent intact 
membrane by nigrosin was calculated using the following equation: percent intact membrane by 
nigrosin = number of live cells divided by (number of live cells + number of dead cells) x 100. 
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Percent intact membrane by nigrosin for the 1.0 μM cisplatin values was also made relative to 
saline controls, and the average of biological triplicates was plotted. A two-way ANOVA was 
performed with Bonferroni post-hoc analysis, comparing all subline results to the pcDNA3 
subline, calculated using Graphpad Prism 5. Day eight cisplatin results were made relative to the 
saline control for the calculation of EC50 values. EC50 values were calculated using ‘log 
(inhibitor) vs. response (three parameters)’ on Graphpad Prism 5, and the average of biological 
triplicates was plotted with the saline control represented at 10
−10
 M on the graphs. A one-way 
ANOVA was performed with Tukey post-hoc analysis, comparing all sublines to the pcDNA3 
subline. 
 
3.3.11 Apoptosis assays − Fluorescent microscopy 
 
GLC20 cells and sublines were counted and 2.0 × 10
6
 cells were plated in T75 flasks at a cell 
density of 50 cells/μL. After 24 h incubation at 37 °C with 5% CO2 in a humidified chamber, 
cells were either exposed to 5.0 μM cisplatin or left untreated for 4 days. A fraction of cells was 
collected by centrifugation at 149 x g for 7 min at 21 °C and supernatant was discarded, 
followed by centrifugation at 5,900 x g for 2 min at 21 °C, with supernatant discarded, and the 
pellet stored at −80 °C for PARP cleavage analysis by Western Blot. 
 
Another fraction of cells was used for apoptosis analysis by fluorescent microscopy. These cells 
were subjected to centrifugation at 149 x g for 7 min at 21 °C, supernatant was discarded, and the 
cells were treated with 0.25% Trypsin-EDTA for 10 min at 37 °C with 5% CO2 in a humidified 
chamber, to obtain a single cell suspension. Cells were then washed two times in complete media 
and centrifuged at 500 x g for 5 min at 21 °C, with changes in media between each 
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centrifugation, then counted in a 1:1 ratio of cells in complete media and 0.2% nigrosin, using a 
hemocytometer. 0.5 × 10
6
 cells were resuspended at a 1000 cell/μL density in cold PBS for 
fluorescence analysis. If fewer than 0.5 × 10
6
 cells were counted, cells were adjusted to a smaller 
volume at a 1000 cell/μL density in cold PBS. 
 
Before staining, cells were washed three times in cold PBS at 5,900 x g for 2 min at 21 °C, with 
changes in cold PBS between centrifugations, then resuspended in Annexin V binding buffer (10 
mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2) at a density of 1000 cells/μL. Cells were triple 
stained with 7-aminoactinomycin D (7AAD) in DMSO, Annexin V-AlexaFlour
®
 488 
conjugated, and Hoescht 33342 Nucblue
®
 Live Cell Stain ReadyProbe Reagent (all Life 
Technologies) at 0.02 mg/ mL, 5 μL/100 μL, and 1 drop/500 μL concentrations, respectively, at 
21 °C for 15 min in the dark. Cells were then washed three times in cold Annexin V binding 
buffer at 5,900 x g for 10 min at 21 °C, then resuspended in 100 μL of cold PBS. 
 
Samples were loaded into Cytospin
TM
 columns (Symport, VWR International) that were pre-
loaded with a microscope slide (VistaVision, VWR International). Cells were centrifuged onto 
the microscope slides at 500 rpm for 2 min 21 °C in a Shandon Cytospin
TM
 4 cytocentrifuge 
(Thermo Scientific), rotor # 4127 0806 59930093. Samples on slides were air-dried, then fixed 
with 4% paraformaldehyde (Sigma-Aldrich) in PBS at 21 °C in the dark for 10 min. Slides were 
washed sequentially in three changes of PBS, then air-dried. 90% glycerol (Sigma-Aldrich) in 
PBS was added to the samples and a No. 1 coverslip (VWR) was placed on top of the sample. 
The cover slip was sealed with nail polish and the slides stored at 4 °C in the dark until 
visualized (∼24 h later). 
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Cells were visualized using an Olympus 1 × 73 Microscope (Olympus Life Sciences). 
Fluorphores were excited using Lumen Dynamics Xcite 120 LED (Lumen Dynamics), Olympus 
LED PS and LBM laser systems (Olympus Life Sciences). Fluorescence emission spectra were 
captured for Hoescht 33342 (Ex: 250 nm/Em: 461 nm), AlexaFlour
®
 488 (Ex: 495 nm/Em: 519 
nm), and 7-AAD (Ex: 546 nm/Em: 647 nm). In addition to fluorphores, cell morphology was 
observed using phase contrast (images not included). Images of the stained cells were captured 
using the Olympus DP80 camera (Olympus Life Sciences) and CellSens Dimensions imaging 
software (Olympus Life Sciences). Images obtained that were later counted underwent no post-
production adjustments. Images presented underwent post-production adjustments using the 
‘Adjust Display’ function in the CellSens Dimensions imaging software. In brief, background 
colour intensities were excluded from the images using the histogram tool. Colour threshold 
intensity was then increased. These changes were applied to all the images and at the same 
intensities. 
 
Exposure times and gain were made constant during the imaging of each biological replicate. 
Although exposure times varied, the Hoechst 33342 stain was exposed for roughly 250 
milliseconds (ms), the Annexin V- Alex-Fluor 488 stain was exposed for roughly 2 seconds (s) 
with a gain of 2X, and the 7-AAD stain was exposed for roughly 800 ms. All images were taken 
using a 40X objective lens. ‘Live’ events were defined as cells with visually uncondensed nuclei, 
stained with Hoechst 33342, and lacking green Annexin V stain or red 7-AAD stain. ‘Early 
Apoptosis’ events were defined as cells that had either or both green Annexin V stain (indicative 
of phosphatidylserine flipping) and condensed nuclei (condensed blue Hoechst 33342 staining). 
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Lastly, ‘Late Apoptosis/Necrosis’ was defined as the loss of membrane integrity, which was 
indicated by the presence of the red stain of 7-AAD (made purple/pink in images). Three 
biological replicates were performed. For each biological replicate, the events were totalled 
between ten fields of view counted. A minimum of 300 events was counted per biological 
replicate. Values were then transformed to a percentage of the total number of events that were 
counted, for each biological replicate. The average of the three biological replicates was 
presented and one-way ANOVA was performed between the sublines for each defined event. 
Tukey post-hoc analysis was done, comparing all the sublines to the pcDNA3 subline. 
 
3.4 Results & discussion 
 
3.4.1 Establishment of a GLC20 model for SCLC studies relating to 
RBM5 
 
GLC20 cells are RBM5-null and were established from a tumor that was multidrug resistant 
(doxorubicin, cyclophosphamide and vincristine), a common characteristic of advanced SCLC. 
As depicted in Fig. 3.1A, the breakpoint for the GLC20 deletion is upstream of RBM5, and the 
entire RBM5 gene is deleted (Lerman and Minna, 2000). We verified the absence of RBM5 
DNA, RNA and protein (Fig. 3.1B–E). 
 
To better understand the impact of RBM5 downregulation on SCLC, stable populations of 
RBM5 expressing cells were established. Two RBM5-expressing sublines were established, one 
clonal (designated GLC20.C4 or “C4”) and one from a pooled population of RBM5-expressing 
transfectants (designated GLC20.T2 or “T2”) (Fig. 3.1F). We also established an empty vector 
control subline (GLC20. pcDNA3 or “pcDNA3”).  
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Figure 3.1 Characterization of wildtype GLC20 cells and RBM5 expressing sublines. (A) Cartoon of location of deletion breakpoints in 
various lung cell lines. (B) Genomic DNA PCR results from different cell lines. (C) RBM5 Southern Blot. (D) RT-PCR results from different cell 
lines. (E) Western Blot. (F) RBM5 expression in GLC20 stable transfectants by RT-PCR and Western Blot. (G) Cartoon of 5′ end of RBM5 gene, 
not drawn to scale, showing approximate locations of various probes. Box marked “W”: Western antibody LUCA-15 UK; box marked “S”: 
Southern probe; RT-PCR primers LU15(2) and LU15(3) (black thin open arrowheads); genomic PCR primers Gen1E2Fc and Gen2E3I2R (red 
thick arrows). 
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To ensure that a GLC20 model would be useful for functional studies relating to RBM5, chiefly 
known as a modulator of apoptosis, we examined their cell death profile when exposed to 
various apoptogenic agents. The highly resistant nature of GLC20 cells to chemotherapy was 
demonstrated (Fig. 3.2), since cisplatin exposure, without etoposide, required a concentration of 
80 μg/ml (226 μM) to be somewhat effective at promoting apoptosis by 24 h post exposure (Fig. 
3.2A, lanes 1–3). GLC20 cells are, however, capable of undergoing apoptosis, since PARP 
cleavage was observed 24 h following co-administration of 10 μg/ml (33 μM) cisplatin and 10 or 
20 μg/ml (17 or 34 μM) etoposide (Fig. 3.2A, lanes 4–9), and almost complete following 40 to 
48 h incubation with these agents (Fig. 3.2B lanes 4–9). Thus, although these cells are highly 
drug resistant, they are capable of experiencing cisplatin-mediated apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 RNA-Seq shows that over 12% of the transcriptome is differentially 
expressed by RBM5 in GLC20 cells, SLC25A53 is the most 
altered gene, and pathways relating to cancer are the most likely 
impacted 
 
Figure 3.2 Apoptosis induction by various apoptogenic stimuli. GLC20 cells were treated with cisplatin with 
or without etoposide, for the various times indicated. Details in Materials & methods. See Figure S2 for full blots. 
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To investigate if and how RBM5 expression influences GLC20 cells, deep sequencing of the 
transcriptome (RNA-Seq) of the parental GLC20 cells and three sublines was carried out. See 
Materials & methods for an explanation of the “control” used in sequencing analyses. 
 
Firstly, we confirmed RBM5 expression levels within the transcriptomic data for T2 and C4 (Fig. 
3.3A). Differential expression testing (refer to Materials & methods) identified that 12.5% of the 
transcriptome examined was significantly differentially expressed between control and T2, and 
18.4% between control and C4 (Fig. 3.3B). Furthermore, over 50% of the genes that were 
differentially expressed in T2 were also differentially expressed in C4, suggesting that any effect 
in C4 is not likely the result of a clonal effect related to subclone establishment. Solute Carrier 
Family 25 Member 53 (SLC25A53) was the most significantly differentially expressed gene in 
both T2 and C4 compared to control (based on log2 (fold-change); 1112.1 FPKM (Fragments 
Per Kilobase of transcript per Million mapped reads) to 0.068 FPKM in control vs. C4, and 
1127.3 FPKM to 0.073 FPKM in control vs. T2). This gene is part of a large family of 
transporters that control various cellular functions, although a particular role for SLC25A53 has 
yet to be identified (Palmieri, 2013). Other highly downregulated genes common to both T2 and 
C4 include CD9, Discs Large Homolog Associated Protein 1 (DLGAP1), and Feline Sarcoma 
(FES). Interestingly, CD9 and FES have previously been associated with cell adhesion and tumor 
metastasis, with the effect of their expression seeming to be cell type-specific (Delfino et al., 
2006; Huan et al., 2015; Kanda et al., 2009; Rappa et al., 2015). Of the two, only CD9 has been 
investigated in regards to SCLC specifically, and low expression levels were linked to increased 
motility and invasiveness (Funakoshi et al., 2003). The fact that RBM5 expression decreased 
CD9 expression was thus unexpected, as we hypothesized that RBM5 would promote a non-
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transformed state in SCLC cells. However, CD9 gene expression levels in our control were much 
lower than those in our clinical SCLC tumor samples (described below) (average of 6.6 FPKM in 
our cell line control and 109.1 FPKM in tumor samples), suggesting that although RBM5’s 
influence on CD9 may be statistically significant, it may not be physiologically relevant in our 
system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, two genes other than RBM5 were highly upregulated in both T2 and C4 
compared to control; MKRN3 and ZNF85. Of note, the former has been previously associated 
with development, particularly the onset of puberty, which is in line with the pathway results 
presented below (Abreu et al., 2013). 
Figure 3.3 Transcriptome analysis of GLC20 sublines. (A) RBM5 expression in control, T2 and C4 samples as determined by RNA-Seq. **p 
< 0.01. (B) Venn diagram demonstrating significantly differentially expressed genes between T2 and C4 compared to control, respectively, as 
determined by RNA-Seq. Number of genes in each group indicated in parenthesis. (C and D) FIDEA pathway analysis results for altered KEGG 
pathways in control vs T2 (C) and C4 (D) samples, respectively, from RNA-Seq transcriptome data. (E) GSAASeqSP blue-pink o’gram 
representing the expression levels of core enriched genes within the MSigDB Angiogensis Hallmark gene set in control and C4 (RNA-Seq data). 
Blue indicates low expression, whereas red indicates high expression levels. Genes listed in order of Rank Metric Score. (F) KRAS and SOX2 
expression in control and C4 samples as determined by RNA-Seq. 
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Using two different pathway analysis programs, we went on to determine the functional 
implications of genes differentially expressed upon expression of RBM5. First, the Functional 
Interpretation of Differential Expression Analysis (FIDEA) (D'Andrea et al., 2013) program with 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (Kanehisa and Goto, 
2000; Kanehisa et al., 2014) was used, thus differentially expressed genes are placed in known 
signaling pathways to determine if these pathways are significantly up- or downregulated. 
Analysis results are presented in Fig. 3.3C and D. Pathways in cancer was significantly 
downregulated in both T2 and C4 compared to control. Other transformation-related pathways 
were also downregulated upon RBM5 expression in T2 such as the cell cycle, small cell lung 
cancer and pancreatic cancer. The fact that these pathways were not also significantly changed in 
C4 may be due to the larger number of differentially expressed genes in this sample, which may 
mask the effect of RBM5 on these particular cancer-related pathways. In addition, both axon 
guidance and alcoholism were significantly altered in both T2 and C4. This is very interesting 
since axon guidance, as well as alcoholism, have been shown to play a substantial role in cancer 
development and progression (Chedotal et al., 2005; Forsyth et al., 2010). 
 
To complement our KEGG pathway results, we used an additional pathway analysis program − 
the Gene Set Association Analysis for RNA-Seq with Sample Permutation (GSAASeqSP) 
program (Xiong et al., 2014) - as it takes into account inherent bias present in RNA-Seq data. In 
combination with the Broad Institute’s Molecular Signatures Database (MSigDB) Hallmark gene 
set (Liberzon et al., 2015), genes are grouped based on established biological processes, and 
enriched gene sets determined. We identified 12 and 17 gene sets with false discovery rates 
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(FDR) at or below 10% in T2 and C4, respectively, compared to control. Over half of these T2 
altered gene sets were common to C4, once again suggesting that any effect seen in C4 is not 
likely due to a clonal effect related to subclone establishment. Gene sets with FDR at or below 
10% in control vs. C4 are presented in Table 3.1, along with their FDR in control vs. T2. 
Interestingly, many differentially expressed gene sets are important to development, which 
validates our experimental findings, as RBM5 was recently shown to be involved in myogenesis, 
spermatogenesis and neuronal development (Fushimi et al., 2008; Loiselle and Sutherland, 2014; 
O'Bryan et al., 2013). Furthermore, apoptosis and TNFα signaling, both pathways RBM5 has 
been previously associated with in Jurkat T lymphoblastoid cells (Rintala-Maki and Sutherland, 
2004; Sutherland et al., 2000) and MCF-7 cells (Rintala-Maki et al., 2004) were altered in T2 
and C4. Fig. 3.4 lists the core enriched genes in these gene sets and how their expression 
changed upon RBM5 expression in C4, highlighting the importance of RBM5 to these cellular 
functions. 
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Figure 3.4 Expression changes of core enriched genes in RBM5-altered gene sets. GSAASeqSP blue-
pink o’gram representing the expression changes of core enriched genes from the MSigDB Hallmark 
Apoptosis (A) and TNFα signaling via NFκB (B) gene sets in control vs. C4 samples (RNA-Seq data). Blue 
indicates low expression, whereas red indicates high expression. Genes listed in order of Rank Metric 
Score. 
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Other gene sets identified in this GSAASeqSP analysis are important to the transformed state, 
supporting our KEGG pathway results and providing additional insight into the role of RBM5 in 
SCLC cells. These gene sets (Table 3.1) include genes involved in (a) angiogenesis, where 
RBM5 expression (in T2 and C4) correlated with significantly decreased expression of pro-
angiogenic factors, such as Vascular Endothelial Growth Factor A (VEGFA) (Fig. 3.3E), (b) 
epithelial to mesenchymal transition (EMT), and (c) the immune response. RBM5 may, 
therefore, not only promote a non-transformed state, but be important for identification and 
elimination of cells that adopt cancerous characteristics. 
 
Table 3.1: Altered gene sets Altered gene sets with FDR below 10% between control and C4 
samples, as determined by GSAASeqSP analysis with the MSigDB Hallmark gene set using the 
samples’ RNA-Seq results. Ranked based on FDR value in control vs. C4 analysis. FDR value in 
control vs. T2 samples is also indicated for the given pathways. Italics indicates FDR values 
above 10%. 
 
 Control vs. C4 Control vs. T2 
    
Gene Set FDR FDR 
   
Hedgehog signaling 0.000 0.033 
Angiogenesis 0.000 0.067 
Apoptosis 0.054 0.28 
Androgen response 0.058 0.067 
Myogenesis 0.064 0.183 
Estrogen response late 0.064 0.033 
TNFα signaling via NF-κB 0.070 0.075 
Coagulation 0.071 0.115 
IL2 STAT5 signaling 0.075 0.125 
UV response down 0.076 0.226 
Apical surface 0.078 1.000 
Cholesterol homeostasis 0.080 0.113 
IL6 JAK STAT3 signaling 0.083 0.147 
Estrogen response early 0.087 0.057 
Inflammatory response 0.094 0.432 
KRAS signaling up 0.100 0.114 
Epithelial to mesenchymal transition 0.100 0.073 
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Taken together, these RNA-Seq pathway analysis results for the GLC20 sublines indicate that in 
SCLC cells, RBM5 expression is very important to the maintenance of the non-transformed state, 
particularly via regulation of cell death, angiogenesis, cell-cell adhesion and immune response 
pathways. 
3.4.3 RBM5 regulates expression of SCLC-associated genes 
 
To investigate the influence of RBM5 expression particularly on SCLC-associated pathways, we 
examined the expression of previously identified lung cancer-associated genes in our GLC20 
sublines. In a report released by the National Cancer Institute (NCI) in June 2014, entitled 
Scientific Framework for Small Cell Lung Cancer, a list of 37 ‘Genes of Interest in SCLC’ was 
compiled. Interestingly, the expression of 43.2% of these ‘Genes of Interest in SCLC’ (16/37) 
significantly changed expression in C4, compared to control (Table 3.2), with 11 of these 
differentially expressed genes changing expression in a manner that would promote suppression 
of tumor growth upon RBM5 expression; BCL2, CCNE1, COBL, CREBBP, EPHA7, MED12L, 
MYCL1, RAB37, SLIT2, SMO and SOX2. Furthermore, 11 of the 21 non-differentially expressed 
genes had very low expression in the control and C4 (FPKM below one), and thus may not play 
an important role in GLC20 cells. The observation that RBM5 expression influences the 
expression levels of so many NCI-collated ‘Genes of Interest in SCLC’ highlights (1) the 
importance of RBM5 to SCLC, (2) the impact that RBM5 gene deletion may have on the 
development of lung cancer, and (3) the effect that re-establishment of RBM5 expression may 
have on SCLC tumors. 
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Table 3.2: Expression of NCI ‘Genes of Interest in SCLC’ in control and C4 samples, as 
determined by RNA-Seq. Expression values are expressed as FPKM. Italics identify genes with 
non-significant differential expression between control and C4 and expression below one FPKM 
in both samples. 
Gene name Control C4 p-value Significance 
     
BCL2
† 
1.8307 0.2914 0.00005 Yes 
CCNE1
† 
18.139 10.6106 0.00005 Yes 
CDK14
‡ 
17.0371 19.8042 0.0083 Yes 
CDKN2A 78.3537 89.0263 0.0378 No 
COBL
† 
0.885007 0.011419 0.004 Yes 
CREBBP
‡ 
5.47952 6.5709 0.0018 Yes 
DMBX1 0.048243 0.102193 1 No 
EP300 7.62326 7.82019 0.789641 No 
EPHA7
‡ 
20.1031 26.6501 0.0001 Yes 
FGFR1 0.171331 0.212293 1 No 
GPR113 0.475767 0.661619 0.6777 No 
GPR133 0.003737 0 1 No 
GPR55 0.001965 0 1 No 
GRID1 0.553261 0.587185 0.6624 No 
LRRK2 0.068785 0.016732 1 No 
MED12L
† 
3.18195 0.191165 0.00005 Yes 
MLL (KMT2A) 11.1758 11.5143 0.5842 No 
MYCL
† 
11.114 8.99515 0.0044 Yes 
NOTCH1
‡ 
4.87757 6.22612 0.00005 Yes 
NOTCH2
‡ 
3.44146 4.85108 0.00005 Yes 
NOTCH3 0.06277 0.11642 1 No 
PIK3CA 9.39427 8.64243 0.1883 No 
PPEF2 0.037315 0.063875 1 No 
PRKD3 26.8136 28.0848 0.4054 No 
PTEN
† 
17.1134 14.0056 0.0007 Yes 
PTPRD 0 5.72938 1 No 
RAB37
† 
0.660452 0.186656 0.00005 Yes 
RASGRF1 0.00182 0.006163 1 No 
RASGRF2 0.377979 0.006163 1 No 
RB1 6.22425 6.86606 0.1533 No 
RUNX1T1
‡ 
5.11373 8.39718 0.00005 Yes 
SLIT2
‡ 
5.19232 9.74325 0.00005 Yes 
SMO
† 
5.93771 3.35434 0.00005 Yes 
SOX2
† 
14.0653 10.8382 0.0003 Yes 
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Table 3.2. 
(Continued)      
     
Gene name Control C4 p-value Significance  
      
STK38 20.2447 18.0817 0.0533 No 
TP53 2.85615 3.40231 0.2023 No 
TRRAP 13.9452 12.2657 0.0716 No 
 
†
 Indicates genes significantly downregulated in C4.  
‡
 Indicates genes significantly upregulated in C4. 
 
 
In addition to these NCI-collated ‘Genes of Interest in SCLC’, we examined the influence of 
RBM5 expression on Sex-determining region Y-box 2 (SOX2) and Kirsten Rat Sarcoma Viral 
Oncogene Homolog (KRAS), as overexpression of the former has been observed in many types 
of lung cancers and is linked with tumor initiation (Tam and Ng, 2014), and activation of the 
latter occurs in approximately 30% of smoking-associated lung adenocarcinomas (Unni et al., 
2015). In our C4 samples, SOX2 and KRAS were significantly downregulated (Fig. 3.3F), 
suggesting once again the importance of RBM5 expression in lung tissue. 
 
3.4.4 Alternative splicing accounts for a minority of the differential gene 
expression 
 
RBM5 influences processes such as apoptosis and cell cycle arrest in a variety of cancer cell 
lines at least in part via the modulation of alternative splicing of key factors, such as NUMB and 
CASPASE 2 (CASP2) (Bechara et al., 2013; Fushimi et al., 2008). To see if RBM5 influences 
processes in SCLC via modulation of alternative splicing, we mined our RNA-Seq data for 
significant alternative splicing changes. 
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In the control vs. T2 group, 2,546 variants were significantly differentially expressed (5.12% of 
the 49,772 variants examined), with 10 genes showing a significant change from one alternative 
splice variant to another (Table 3.3). In the control vs. C4 group, 4,180 variants were 
differentially expressed, with 47 genes showing a significant change from one alternative splice 
variant to another (Table 3.4). The greater number of alternative splicing events occurring in the 
C4 subline, compared to T2, suggests an additive effect of RBM5 on alternative splicing, which 
was expected. There was no overlap, however, of splicing events between T2 and C4, potentially 
due to the stringent search parameters used, and no significant enrichment of these splicing 
events in any KEGG pathway or MSigDB Hallmark gene set. Furthermore, the number of 
significant alterations in splicing between control and T2 and C4, respectively, was much lower 
than expected, given the high number of differentially expressed genes (even considering the 
stringent search parameters). This suggests that modulation of alternative splicing is not the only 
means by which RBM5 influences important transformation-associated pathways in SCLC. 
RBM5 may, for instance, regulate gene expression levels by influencing transcription or 
stabilizing transcripts, as has been shown for other RNA-binding proteins, including the RBM5-
related protein RBM10 (Guallar and Wang, 2014; Mueller et al., 2009). We therefore proceeded 
to carry out binding studies in order to identify targets with which RBM5 interacts, either 
directly or indirectly, and thereby gain a better understanding of how RBM5 influences the 
identified pathways. 
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Table 3.3: Genes with at least one alternative splice variant significantly upregulated, and at 
least one alternative splice variant significantly downregulated between control and T2 (RNA-
Seq results). Each row indicates expression levels of a different variant for the given gene. 
Arranged alphabetically, by gene. 
  Control vs. T2  
    
Gene name Log2 (fold-change) p-value q-value 
    
BAG6 0.633915 0.0002 0.00279 
 -2.0923 0.0027 0.03018 
EML1 1.18146 0.004 0.04069 
 -0.321613 0.0019 0.02236 
FERMT2 -0.682011 0.0012 0.01589 
 0.326233 0.0039 0.04029 
INF2 -0.707866 5e-05 0.00106 
 1.40674 5e-05 0.00106 
IQCE -1.59194 0.0004 0.00645 
 0.571945 0.0045 0.04469 
KCTD15 0.509451 0.0006 0.00906 
 -0.932889 5e-05 0.00106 
KIF2A 1.13138 5e-05 0.00106 
 -1.01307 5e-05 0.00106 
LIG3 1.44254 0.0003 0.00434 
 -0.360436 0.0007 0.01032 
LIPA 0.547552 0.0005 0.0078 
 -0.676966 5e-05 0.00106 
ZBTB14 -1.18342 0.0025 0.02843 
 2.62976 0.001 0.01382 
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Table 3.4: Genes with at least one alternative splice variant significantly upregulated, and at 
least one alternative splice variant significantly downregulated between control and C4 (RNA-
Seq results). Each row indicates expression levels of a different variant for the given gene. 
Arranged alphabetically, by gene. 
  Control vs. C4  
    
Gene log2 (fold-change) p-value q-value 
    
ADAM22 0.983 8E-04 0.007 
 -0.691 0.006 0.0374 
ADAT2 -0.412 0.002 0.0155 
 0.885 1E-04 0.0011 
AR 0.444 5e-05 0.0006 
 -0.979 0.002 0.0119 
ASAP1 -0.454 0.003 0.0219 
 0.722 5e-05 0.0006 
ASPH 1.693 1E-04 0.0011 
 -0.679 0.005 0.0327 
ATG16L1 0.718 5e-05 0.0006 
 -0.648 0.003 0.0204 
BCKDHB 0.544 0.004 0.0242 
 -0.531 2E-04 0.0016 
BZW2 -1.239 0.001 0.0091 
 0.281 0.002 0.0125 
C14orf93 -1.649 8E-04 0.0066 
 1.096 0.002 0.0149 
C8orf59 -0.413 0.004 0.0267 
 0.564 0.001 0.0098 
CDK13 0.711 1E-04 0.0011 
 -0.303 0.003 0.0201 
CEP41 1.715 0.006 0.0395 
 -0.482 5e-05 0.0006 
CEP78 -1.025 5e-05 0.0006 
 1.100 5e-05 0.0006 
CTNNB1 0.498 0.004 0.0281 
 -0.689 5e-05 0.0006 
DMTF1 -0.427 0.002 0.0155 
 1.026 0.001 0.0091 
DST -0.791 5e-05 0.0006 
 0.740 4E-04 0.0034 
GGA1 1.047 8E-04 0.007 
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Table 3.4. (Continued)    
    
  Control vs. C4  
    
Gene log2 (fold-change) p-value q-value 
    
 -1.099 0.002 0.0161 
 1.028 0.001 0.0091 
HMGXB4 0.567 5e-05 0.0006 
 -0.764 5e-05 0.0006 
KIAA1958 1.630 1E-04 0.0011 
 -1.107 4E-04 0.0034 
LIMA1 1.434 0.003 0.0213 
 -0.742 5e-05 0.0006 
MAPKAP1 0.660 5e-05 0.0006 
 -0.474 0.001 0.0105 
MUM1 0.479 0.004 0.0248 
 -0.875 5e-05 0.0006 
MYO1B 0.763 5e-05 0.0006 
 0.906 0.001 0.0098 
 -1.790 0.004 0.0273 
NAP1L1 -0.41 0.001 0.0109 
 0.404 0.002 0.0167 
NUMB -1.472 0.008 0.0499 
 0.951 0.005 0.0314 
 -0.516 8E-04 0.0066 
PAXBP1 -1.167 0.005 0.0319 
 1.058 5e-05 0.0006 
PCBP2 -1.724 0.002 0.0177 
 0.652 0.006 0.0356 
PDE1C -0.722 8E-04 0.007 
 0.911 5e-05 0.0006 
PDHA1 -0.269 0.007 0.0435 
 2.175 0.003 0.0195 
PHF8 0.834 2E-04 0.0021 
 -0.396 0.006 0.0374 
PTK2 0.558 0.003 0.0231 
 -0.666 5e-05 0.0006 
RAC1 0.297 0.006 0.0389 
 -1.588 5e-05 0.0006 
RBBP5 -1.255 5e-05 0.0006 
 0.472 0.002 0.017 
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Table 3.4. (Continued)    
    
  Control vs. C4  
    
Gene log2 (fold-change) p-value q-value 
    
RBFOX2 0.971 5e-05 0.0006 
 -0.499 3E-04 0.0026 
RPAP3 -1.041 0.005 0.0309 
 0.308 0.005 0.0303 
RTN1 0.501 4E-04 0.0034 
 -2.439 3E-04 0.003 
SLC29A1 -0.849 5e-05 0.0006 
 0.395 0.005 0.0325 
SLC9A6 -1.393 5e-05 0.0006 
 0.492 0.006 0.0364 
SSBP3 0.785 5e-05 0.0006 
 -0.597 3E-04 0.003 
SYT1 1.903 5e-05 0.0006 
 -5.079 1E-04 0.0011 
TPM1 1.473 5e-05 0.0006 
 -0.922 0.004 0.0258 
UGGT1 0.626 5e-05 0.0006 
 -0.95 5e-05 0.0006 
UPF3B 0.927 5e-05 0.0006 
 -1.231 5e-05 0.0006 
ZBTB20 -1.234 0.004 0.0261 
 0.746 6E-04 0.0055 
ZNF260 0.424 2E-04 0.0021 
 -0.933 0.001 0.0098 
ZNF566 0.791 0.004 0.0273 
 -0.804 5E-04 0.0043 
ZNF655 -1.174 0.005 0.034 
 0.690 0.007 0.0425 
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3.4.5 RIP-Seq identified RBM5 RNA targets regulate RNA metabolism 
and cell cycle pathways, ZNRF3 being the most enriched gene 
 
Although some studies have investigated RBM5’s binding motif (Bechara et al., 2013; Ray et al., 
2013), the number of identified RNA targets that are directly bound by RBM5 is low. In cancer 
cell lines, only three directly bound RNA targets have been identified to date; Caspase-2 
(CASP2) (Fushimi et al., 2008), the antisense transcript of FAS (FAS-AS1) (Sehgal et al., 2014), 
and Activation-induced cytidine deaminase (AID) (Jin et al., 2012). In mouse spermatid 
differentiation, 11 RNA targets have been identified (O'Bryan et al., 2013). In its capacity as a 
component of spliceosomal complexes (Hegele et al., 2012; Niu et al., 2012), RBM5 is also 
likely capable, however, of binding many important RNA targets indirectly (e.g., via another 
protein within the complex). 
 
In order to identify direct and indirect RNA targets of the RBM5 protein in GLC20 cells, we 
used RNA Immunoprecipitation followed by next generation sequencing (RIP-Seq). RIP-Seq 
experiments were performed using our non-commercially available RBM5-specific LUCA-
15UK antibody (Sutherland et al., 2000) because, as demonstrated in Fig. 3.5, the commercially 
available antibodies that were tested were not specific for RBM5. Two different negative 
controls were used in each of two RIP-Seq replicates, to ensure the validity of identified RBM5 
targets. Firstly, a non-specific IgG IP in C4 cells (vs. LUCA-15UK IP in C4 cells), and secondly, 
LUCA-15UK IP in GLC20.pcDNA3 cells (vs. LUCA-15UK IP in C4 cells). Western blots 
showing successful IP of RBM5 for both replicates are presented in Fig. 3.6A. 
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RNA from both RIP-Seq experiments was sequenced. The distribution of gene expression values 
in our control vs. RBM5 RIP samples is presented in Fig. 3.6B, for genes with FPKMs < 5000 
(10 genes had FPKMs above 5000). This figure highlights the high level of gene expression in 
our RBM5 RIP samples, compared to the control, confirming the success of our technique. We 
identified 773 genes as RBM5 targets (see Materials & methods for exclusion details), a not 
unexpectedly large number since this technique identifies all RNA bound by a complex of which 
RBM5 is a part. 
Figure 3.5 RBM5 antibody testing. The same whole cell lysate from either GLC20 cells (wt) or GLC20.C4 RBM5 containing 
cells (C4) was loaded in alternate lanes and probed with the antibodies indicated. The LUCA-15-UK blot was probed with a 
1:1000 antibody dilution, overnight at 4 °C, and exposed for 2 min. The upper Origene blot was probed with a 1:3000 antibody 
dilution, for 3 h at RT, and exposed for 60 min. The lower Origene blot was reprobed with a 1:500 antibody dilution, overnight at 
4 °C, and exposed for 60 min. The upper Abnova blot was probed with a 1:500 antibody dilution, for 3 h at RT, and exposed for 
60 min. The lower Abnova blot was reprobed with a 1:350 antibody dilution, overnight at 4 °C, and exposed for 60 min. The 
Abcam blot was probed with a 1:2500 antibody dilution, overnight at 4 °C, and exposed for 5 min. The Sp1 and Sp2 blots were 
probed with a 1:5000 antibody dilution, for 3 h at RT, and exposed for 1 min. All commercially available antibodies (therefore 
excluding Sp1 and Sp2 – a gift from Juan Valcárcel − and LUCA-15-UK) interacted with product around the same molecular 
weight as RBM5 even in GLC20 cells, making them unsuitable for use in RIP-Seq experiments.  
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The most significant RBM5 targets included Zinc & ring finger 3 (ZNRF3), Suppressor of cancer 
cell invasion (SCAI), Growth factor receptor-bound protein 2 (GRB2), Zw10 kinetochore protein 
(ZW10), DEP domain containing (DEPDC1) and Activating transcription factor 2 (ATF2). None 
of these genes were detected in the control IP and all had FPKM values above 350 in the RBM5 
RIP (ZNRF3 had the highest count with 1.23 × 10
7
 FPKM, followed by SCAI with 2866.53 
FPKM and GRB2 with 1482.74 FPKM). Interestingly, these six genes have all been shown to 
play important roles in the control of the cell cycle and proliferation. It is important to note that 
the previously identified direct RBM5 targets - CASP2, FAS and AID - were not identified in our 
RIP-Seq experiments. Lack of detection of these potentially direct targets could be a cell type-
specific phenomenon, since neither FAS nor AID were expressed above 0.1 FPKM in our 
samples. 
Figure 3.6 RBM5 RIP-Seq optimization and quality control. (A) Raw Western Blot data demonstrating 
successful immunoprecipitation of RBM5. (B) Scatterplot representing expression of genes with FPKM < 5000 in 
control and RBM5 RIP samples, respectively. All Western Blot ladder sizes are in kilodaltons (kDa). 
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To determine the importance of these targets to cellular functions, pathway analysis was carried 
out on RIP-Seq identified RBM5 RNA targets. FIDEA analysis, using the KEGG database, 
identified only three significantly changed pathways; ‘Spliceosome’ (hsa03040) (with a 
Benjamini value of 1.37 × 10
−4
),‘RNA transport’ (hsa03013) (1.53 × 10−3) and ‘Ribosome’ 
(hsa03010) (9.07 × 10
−3
). These results support our findings that RBM5 influences important 
pathways in SCLC via regulation of alternative splicing and other pre- and/or post-transcriptional 
processes. These results also help to confirm the success of our technique, since RBM5 was 
previously shown to be a key component of spliceosomal complexes (Hegele et al., 2012; Niu et 
al., 2012). 
 
As with our RNA-Seq data, we used an additional pathway analysis program to support our 
results. For this RIP-Seq data, our second program was Cytoscape with the Reactome FI 
Network plugin, as the GSAASeq program is designed specifically for RNA-Seq data. Using 
Reactome, we found 68 pathways with an FDR < 8% (Table 3.5), many involved in gene 
expression and mRNA splicing/ metabolism. Interestingly, there was an enrichment of RBM5 
targets in the EGFR pathway (Fig. 3.7), as well as many cell cycle pathways and the ‘Apoptosis 
induced DNA fragmentation’ pathway (Fig. 3.8), supporting our RNA-Seq results and 
suggesting that RBM5 may play a direct role in regulating the cell cycle and apoptosis in SCLC 
cells. 
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Table 3.5: RBM5 RIP-Seq results, showing top enriched pathways (FDRs below 8%), identified 
by Cytoscape Reactome FI Plugin tool using the Reactome Pathway Database. 
 
Reactome Pathway FDR 
Nonsense-Mediated Decay (NMD) 5.88E-05 
NMD enhanced by the Exon Junction Complex 5.88E-05 
Influenza Infection 6.67E-05 
HATs acetylate histones 7.14E-05 
Influenza Life Cycle 7.69E-05 
Processing of Capped Intron-Containing Pre-mRNA 8.33E-05 
GTP hydrolysis and joining of the 60S ribosomal subunit 9.09E-05 
NMD independent of the Exon Junction Complex 1.00E-04 
mRNA Splicing 1.00E-04 
mRNA Splicing - Major Pathway 1.00E-04 
Influenza Viral RNA Transcription and Replication 1.05E-04 
Eukaryotic Translation Elongation 1.11E-04 
L13a-mediated translational silencing of Ceruloplasmin expression 1.25E-04 
3' -UTR-mediated translational regulation 1.25E-04 
Eukaryotic Translation Initiation 1.67E-04 
Cap-dependent Translation Initiation 1.67E-04 
Cell Cycle, Mitotic 2.27E-04 
Formation of a pool of free 40S subunits 2.38E-04 
Translation 2.50E-04 
Attenuation phase 2.61E-04 
Metabolism of proteins 3.08E-04 
Translation initiation complex formation 3.20E-04 
Ribosomal scanning and start codon recognition 3.20E-04 
Chromatin modifying enzymes 3.33E-04 
Chromatin organization 3.33E-04 
SRP-dependent cotranslational protein targeting to membrane 6.88E-04 
Cellular responses to stress 6.97E-04 
Cell Cycle 7.10E-04 
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 7.33E-04 
Mitochondrial biogenesis 7.35E-04 
Viral mRNA Translation 7.59E-04 
Peptide chain elongation 7.59E-04 
Eukaryotic Translation Termination 7.59E-04 
HSF1-dependent transactivation 9.14E-04 
Organelle biogenesis and maintenance 1.00E-03 
Gene Expression 1.00E-03 
Calnexin/calreticulin cycle 1.84E-03 
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Table 3.5. (Continued)   
Reactome Pathway FDR  
   
Deadenylation of mRNA 2.11E-03 
G2/M Transition 2.21E-03 
Transcriptional activation of mitochondrial biogenesis 2.53E-03 
Mitotic G2-G2/M phases 2.81E-03 
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 4.26E-03 
EGFR downregulation 4.67E-03 
Cellular response to heat stress 6.91E-03 
ISG15 antiviral mechanism 7.04E-03 
Antiviral mechanism by IFN-stimulated genes 7.04E-03 
M Phase 7.45E-03 
Formation of the ternary complex, and subsequently, the 43S complex 1.07E-02 
Activation of gene expression by SREBF (SREBP) 1.11E-02 
Deadenylation-dependent mRNA decay 1.11E-02 
Regulation of PLK1 Activity at G2/M Transition 1.12E-02 
Regulation of cholesterol biosynthesis by SREBP (SREBF) 1.84E-02 
Cellular Senescence 2.37E-02 
Mitotic Anaphase 2.40E-02 
Mitotic Prometaphase 2.51E-02 
Mitotic Metaphase and Anaphase 2.55E-02 
Resolution of Sister Chromatid Cohesion 3.48E-02 
Centrosome maturation 4.44E-02 
Recruitment of mitotic centrosome proteins and complexes 4.44E-02 
Loss of Nlp from mitotic centrosomes 6.15E-02 
Loss of proteins required for interphase microtubule organization from the centrosome 6.15E-02 
mRNA Splicing − Minor Pathway 7.52E-02 
MicroRNA (miRNA) biogenesis 7.79E-02 
Initiation of Nuclear Envelope Reformation 7.79E-02 
Nuclear Envelope Reassembly 7.79E-02 
Recycling of eIF2:GDP 7.79E-02 
Apoptosis induced DNA fragmentation 7.79E-02 
Activator of DNA fragmentation factor 7.79E-02 
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Figure 3.7 RBM5 targets in the EGFR signaling pathway. Network analysis results of RBM5 targets (identified by 
RIP-Seq) in a portion of the EGFR Signaling pathway. Purple indicates that the gene was identified as an RBM5 target. 
98 
 
 
 
 
 
 
 
Figure 3.8 RBM5 targets in the Apoptotic Execution Phase pathway. Pathway analysis results of RBM5 
targets (identified by RIP-Seq) in a portion of the Reactome Apoptotic Execution Phase pathway. Purple 
indicates that the gene was identified as an RBM5 target. 
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It is interesting to note that of all the genes shown in our RNA-Seq experiments to experience a 
significant change in alternative splicing upon RBM5 expression in T2 or C4 (Table 3.3 and 
Table 3.4), only one, ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain (ASAP1), 
was identified as an RBM5 target in our RIP-Seq experiments. This suggests that the effect of 
RBM5 expression on alternative splicing largely results from downstream consequences of 
changes in RBM5 expression, as opposed to a targeted RBM5 interaction with the alternatively 
spliced transcript. 
  
Taken together, our RNA-Seq and RIP-Seq pathway analyses revealed that RBM5 directly 
influences many processes involved in the maintenance of a non-transformed state, and this by 
means distinct from regulation of alternative splicing. 
 
3.4.6 Functionally, RBM5 inhibits cell growth and sensitizes cells to 
cisplatin–mediated apoptosis 
 
In other cancer cell lines, RBM5 has been shown to regulate the cell cycle and modulate 
responses to apoptogenic stimuli (Kobayashi et al., 2011; Oh et al., 2006; Rintala-Maki and 
Sutherland, 2004). Since we identified ‘Cell Cycle’ (Fig. 3.3C and D) and ‘Apoptosis’ (Table 
3.1) as pathways likely influenced by the differentially expressed genes in T2 and C4, 
respectively, we decided to validate our sequencing data by carrying out functional studies. 
 
To see if and how RBM5 affects the cell cycle in SCLC, we performed a proliferation and 
membrane integrity assay using our GLC20 cells and sublines. As shown in Fig. 3.9A, C4 had 
significantly decreased cell numbers, relative to the vector control, by day six, while membrane 
integrity was unaffected (Fig. 3.9B). This suggests that when RBM5 levels are high, such as in 
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C4, RBM5 slows cell cycle progression in untreated SCLC cells, thereby promoting a non-
transformed state, a result that supports our RNA-Seq findings. 
 
In North America, due to the usual late stage diagnosis and consequent metastasis, SCLC tumors 
are not commonly resected, but rather treated with a combination of platinum-based agents such 
as cisplatin or carboplatin, and the topoisomerase inhibitor etoposide (Gaspar et al., 2012; 
Jackman and Johnson, 2005; Johnson et al., 2014; Travis et al., 2004). Initially, the patient may 
show a complete response to the treatment, but most will relapse as the cancer develops 
resistance (Jackman and Johnson, 2005). Understanding how SCLC cells develop resistance to 
these drugs is thus of great importance. We therefore included a platinum-based treatment in our 
functional analysis, and determined the effects of RBM5 expression on SCLC cells’ response to 
the drug. Cisplatin was our drug of choice since, as demonstrated in Fig. 3.2, GLC20 cells are 
already quite resistant to cisplatin, making them a good model for a drug sensitization study. 
Interestingly, RBM5 overexpression in the cisplatin-resistant NSCLC cell line A549 reduced 
resistance to cisplatin, manifesting as increased cisplatin-induced apoptosis (Li et al., 2012), thus 
we expected that RBM5 expression in our SCLC cell line would have a similar effect. 
 
The GLC20 parental cell line and sublines were treated with 1 μM cisplatin, and cell 
proliferation and membrane integrity assessed. Both T2 and C4 cells showed significantly 
decreased cell numbers, relative to the vector control, following 10 days of cisplatin exposure 
(Fig. 3.9A), and a significant decrease in membrane integrity by day four (Fig. 3.9B). In 
addition, the IC50 for cisplatin in both of the RBM5 expressing sublines was significantly lower 
than the vector control (Fig. 3.9C). 
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Figure 3.9 Effect of RBM5 expression +/- cisplatin on cell proliferation and membrane integrity. (A and B) GLC20 sublines were 
left untreated, or exposed to either a saline control or 1.0 μM cisplatin and cell numbers (A) or membrane integrity (B) monitored every 
other day by cell counting using a hemocytometer. Average of three biological replicates carried out in technical triplicate with standard 
error is displayed. A two-way ANOVA was performed between pcDNA3 and the other sublines, with Bonferroni post-hoc analysis. (C) 
GLC20 subline membrane integrity was monitored after eight days of exposure to various concentrations of cisplatin. Results represent 
the average of three biological replicates performed in technical triplicate with standard error using the calculated average EC50 
(calculated from Graphpad Prism 5, ‘non-linear fit − log(inhibitor) vs response (3 parameters)’). Graph represents the average EC50 of 
three biological replicates. One-way ANOVA was performed with Tukey post-hoc analysis, between sublines, with *p < 0.05, **p < 0.01, 
***p < 0.001 and ****p <0.0001. 
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To determine if the decreased membrane integrity observed in T2 and C4 upon cisplatin 
treatment was due to increased apoptosis, we examined apoptotic marker expression using 
fluorescence microscopy. When cells were untreated, no significant change in the level of cell 
death was observed between sublines (Fig. 3.10A and B), consistent with our membrane integrity 
results (Fig. 3.9B). Following four days of exposure to 5 μM cisplatin, however, significantly 
more cells were observed in both early and late stage apoptosis in the C4 cells, compared to the 
vector control (Fig. 3.10C and D). Furthermore, Poly(ADP-Ribose) Polymerase (PARP) 
cleavage was significantly increased in the C4 cells, following cisplatin treatment (Fig. 3.10E 
and F). (An insignificant increase in cisplatin-mediated apoptosis was observed in the T2 
subline, by Western blot (Fig. 3.10E and F) and fluorescence microscopy (Fig. 3.10C and D)). 
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Figure 3.10 Effect of RBM5 expression +/- cisplatin on apoptosis. GLC20 sublines were left untreated (A, B) or treated with 5 μM 
cisplatin (C, D, E, F) and collected after four days for fluorescence microscopy (A, C) or PARP cleavage analysis (E, F). Average number of 
Live (only Hoechst/blue), Early Apoptosis (condensed Hoechst/blue and/or Annexin-V/green) and Late Apoptosis/Necrosis (7-AAD/Red) 
fluorescence microscopy events from three biological replicates, each with 10 different fields of view, with standard error, for the untreated 
cells (B) and 5 μM cisplatin (D). (E) A representative Western blot for PARP cleavage, in the cisplatin-treated samples, with (F) 
densitometric analysis of ‘percent 89kDa PARP cleavage product’ [(89kDa cleaved PARP/total PARP)x100], with standard error, from three 
biological replicates, using the AlphaEase FC, ‘1D-Multi’ analysis tool. One-way ANOVA was performed with Tukey post-hoc analysis, 
between sublines, with *p < 0.05 and ***p < 0.001.  
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These results suggest that RBM5 expression does in fact sensitize cells to cisplatin’s pro-
apoptotic effects, being in line with our RNA-Seq and RIP-Seq data, which suggest that RBM5 
influences the regulation of apoptotic pathways. 
 
3.4.7 In cisplatin-treated GLC20 cells, RNA-Seq shows that 7% of the 
transcriptome is differentially expressed by RBM5, and that DSG2 
and ATP11C are the most altered genes, potentially driving the 
observed downstream effects of RBM5 expression 
 
Having demonstrated that RBM5 expression can significantly influence a SCLC cell line’s 
response to cisplatin, at least in terms of cell proliferation, membrane integrity and apoptosis, we 
decided to examine this influence on a more global level, by performing RNA-Seq on the cells 
treated with 5 μM cisplatin for four days. 
 
We identified 1,797 differentially expressed genes in the control vs. T2 group (7% of genes 
examined), 1,225 in the control vs. C4 group (4.7%), with 457 genes being common to both 
groups. Fewer differentially expressed genes in C4 compared to T2 was an unexpected finding, 
based on our RNA-Seq data from the untreated samples, and was possibly due to the increased 
rate of apoptosis in the high RBM5 expressing cells, limiting the measurable effect on gene 
expression by RNA-Seq. 
 
The most highly upregulated genes common to treated T2 and C4 cells were Protein Phosphatase 
1 Regulatory Inhibitor Subunit 1A (PPP1R1A) and Makorin Ring Finger Protein 3 (MKRN3). 
MKRN3 has been shown to be important to development, particularly the onset of puberty 
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(Abreu et al., 2013), which is in line with previously identified RBM5 functions, as described 
above. 
 
The most highly downregulated genes common to treated T2 and C4 include (a) Translocase of 
Outer Mitochondrial Membrane 40 Like (TOMM40L), which is a component of the outer 
mitochondrial membrane translocase, and thus influences many mitochondrial processes 
(Humphries et al., 2005), (b) ATPase Phospholipid Transporting 11C (ATP11C), whose cleavage 
(or downregulation) is required for phosphatidylserine exposure and consequent phagocytosis 
during apoptosis (Segawa et al., 2014; Yabas et al., 2016), and (c) Desmoglein 2 (DSG2), a 
ubiquitously expressed cell adhesion protein upregulated in many epithelial-derived cancers 
(Brennan and Mahoney, 2009; Harada et al., 1996; Kurzen et al., 2003) and shown to promote 
cell cycle progression and apoptosis-resistance (Brennan et al., 2007; Gupta et al., 2015). These 
three genes thus play an important role in cell survival, and it may be via their downregulation 
that RBM5 slows SCLC growth and sensitizes them to cisplatin-mediated apoptosis. 
Interestingly, ATP11C and DSG2 are also significantly downregulated in untreated T2 and C4 
cells, suggesting that cisplatin treatment may complement/enhance the effect of RBM5’s 
expression on SCLC. 
 
FIDEA analysis using the KEGG database showed that no pathways were downregulated and 
two pathways were significantly enriched in our control vs. T2 group; ‘Axon guidance’ 
(Benjamini value of 2.02 × 10
−6
) and ‘Retrograde endocannabinoid signaling’ (Benjamini value 
of 4.22 × 10
−4
). In our control vs. C4 group, only ‘Axon guidance’ was significantly enriched 
(Benjamini value of 9.44 × 10
−3
). These results are very interesting since axon guidance is 
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involved in the establishment of a transformed state (Chedotal et al., 2005), and was also 
significantly altered in our untreated T2 and C4 samples, suggesting cisplatin treatment may 
complement this particular RBM5 function. Absence of ‘Retrograde endocannabinoid signaling’ 
in the control vs. C4 group might explain the presence of fewer differentially expressed genes in 
the C4 vs. T2 group. 
 
Using the GSAASeqSP program with the MSigDB Hallmark gene set, we identified 24 enriched 
gene sets with FDRs < 10% between cisplatin-treated control and T2, and 18 between control 
and C4, of which 16 were common between both (Table 3.6). It is important to note that only 12 
MSigDB Hallmark gene sets were identified as significantly enriched in our untreated control vs. 
T2 samples, and 17 in untreated control vs. C4. The greater number of significantly changed 
pathways in the treated samples, but with fewer genes differentially expressed overall, suggests 
once again that cisplatin directs the effect of RBM5’s expression to particular genes. Noticeably, 
10 of the 16 enriched pathways that were common to the T2 and C4 cisplatin treated sample sets 
were also enriched in the untreated C4 samples at a FDR of 10% or lower, demonstrating that 
cisplatin exposure did not totally alter the influence of RBM5 expression on the SCLC cell’s 
transcriptomes. 
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Table 3.6: Altered gene sets with FDRs below 10% between both cisplatin-treated control and 
T2, and control and C4 samples, respectively, as determined by GSAASeq analysis with the 
MSiDB Hallmark gene set using the samples’ RNA-Seq results. Ranked based on FDR value in 
control vs. C4 analysis. 
 Control vs. T2 Control vs. C4 
      
Gene set p-value FDR p-value FDR 
     
TGFβ signaling 0.0 0.05 0.0 03 
Notch signaling 0.2 0.07 0.0 0.04 
EMT 0.0 0.00 0.0 0.04 
Myogenesis 0.0 0.05 0.0 0.04 
Estrogen response early 0.0 0.04 0.0 0.05 
Coagulation 0.0 0.04 0.0 0.05 
Angiogenesis 0.0 0.00 0.1 0.07 
Androgen response 0.0 0.05 0.0 0.07 
UV response down 0.0 0.05 0.0 0.08 
Apoptosis 0.0 0.04 0.0 0.08 
Inflammatory response 0.0 0.03 0.0 0.08 
Estrogen response late 0.0 0.03 0.0 0.08 
KRAS signaling up 0.0 0.04 0.0 0.08 
TNFα signaling via NFκB 0.0 0.03 0.0 0.08 
IL2 STAT5 signaling 0.0 0.04 0.0 0.08 
Apical junctions 0.0 0.04 0.0 0.09 
      
 
 
 
 
The ‘Apoptosis’ gene set was one of the significantly enriched pathways identified by 
GSAASeqSP in cisplatin-treated T2 and C4 samples, compared to control, which is in line with 
the functional work presented herein (Fig. 3.9 and Fig. 3.10). In cisplatin-treated T2 samples, 72 
genes from this ‘Apoptosis’ gene set were significantly enriched compared to control, and 58 in 
C4. Of these genes, 35 were common between both groups (Fig. 3.11), suggesting that many of 
the same apoptotic pathways were significantly affected in both samples. T2 had 37 uniquely 
differentially expressed genes while C4 had 23, suggesting that a wider range of apoptotic 
processes were significantly affected by cisplatin in T2. 
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Figure 3.11 Expression of apoptosis-related genes in cisplatin treated samples. 
Adapted GSAASeqSP blue-pink o’gram representing the expression changes of core 
enriched genes from the MSigDB Hallmark Apoptosis gene set in cisplatin treated control 
vs. T2 and control vs. C4. Blue indicates decreased expression compared to control, 
whereas red indicates increased expression compared to control. Genes listed in 
alphabetical order. 
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Interestingly, SMAD7 was the top enriched gene common to both T2 and C4 cisplatin-treated 
samples (third most enriched gene in both samples). Since SMAD7 has been shown to sensitize 
lung cells to cisplatin-mediated apoptosis (Jeon et al., 2012), it may be an important mediator of 
RBM5’s sensitizing effect regarding cisplatin-induced promotion of apoptosis. 
 
To further investigate which specific apoptotic processes were enriched in our cisplatin-treated 
samples, we analyzed the enriched genes from the ‘Hallmark Apoptosis’ gene set, as identified 
by GSAASeqSP, using the Reactome plug-in for Cytoscape (as described for RIP-Seq samples) 
(Fig. 3.12). These results confirmed that a wider range of apoptotic processes were influenced in 
the T2, compared to the C4, population; the ‘Intrinsic pathway for apoptosis’ and the ‘Apoptotic 
execution’ phase were significantly enriched in both cisplatin-treated T2 and C4 samples, 
however ‘Caspase-8 activation’ and the ‘Extrinsic pathway’ were only significantly enriched in 
T2 (Fig. 3.13 and Fig. 3.14). These T2-specific pathways are part of the early steps of apoptosis, 
suggesting that many cells in the cisplatin-treated T2 population were beginning the apoptotic 
process, but had not yet fully committed to programmed cell death. The cisplatin-treated C4 
population, however, had a significant enrichment of the ‘Intrinsic pathway for apoptosis’ 
subgroups ‘Activation of BH3-only proteins’ and ‘BH3-only proteins associate with and 
inactivate anti-apoptotic BCL-2 members’. These BH3-only proteins are essential for apoptosis 
(Shamas-Din et al., 2011). 
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Figure 3.12 Enriched 'Programmed cell death' pathways in cisplatin treated samples. Diagram 
illustrating the Reactome ‘Programmed cell death’ pathways enriched with an FDR below 10% in 
cisplatin-treated control vs. T2 (purple), control vs. C4 (blue) or control vs. T2 and C4 (orange). 
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Figure 3.13 Gene enrichment for apoptosis-related pathways in cisplatin-treated T2 samples. Reactome diagram for ‘Death 
receptor signaling’ (A) and ‘Caspase-8 activation by cleavage’ (B). Differentially expressed genes between cisplatin treated control vs. 
T2 are presented in purple. 
 
B 
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This in-depth pathway analysis shows that relatively low levels of RBM5 are able to sensitize 
SCLC cells to cisplatin-mediated apoptosis by influencing changes in the expression of genes 
Figure 3.14 'Apoptotic execution phase' gene enrichment in cisplatin-treated samples. Differentially 
expressed genes between cisplatin treated control vs. T2 (A) or control vs. C4 (B) are presented in purple 
in a portion of the Reactome ‘Apoptotic execution phase’ pathway. 
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involved in early apoptosis events. At relatively higher levels of RBM5 expression, this effect on 
cell death levels is detectable via fluorescent microscopy (Fig. 3.10C). These results suggest that 
the level of RBM5 expression in lung tumors could predict response to cisplatin. 
 
Taken together, our results show that RBM5 can functionally (a) influence cell cycle progression 
in untreated and cisplatin-treated SCLC cells (potentially via decreased DSG2 expression), and 
(b) sensitize cisplatin-treated SCLC cells to cisplatin-mediated apoptosis (potentially via 
decreased DSG2 and ATP11C expression, as well as increased SMAD7 expression). These 
findings reinforce the importance of RBM5 expression to SCLC cisplatin-sensitivity and 
highlight the potential of RBM5 as a response marker for this chemotherapy treatment in SCLC. 
In fact, a recent publication suggested that RBM5 gene therapy might be considered for NSCLC 
and that RBM5 might be a predictive marker to indicate the potential success of using cisplatin 
on a particular lung cancer (Li et al., 2012): our results support this suggestion and extend it to 
SCLC. 
 
It is important to note that RBM5 expression was recently shown to increase autophagy levels in 
a NSCLC cell line (Su et al., 2016), therefore, we also examined the expression of autophagy 
markers BCL2, NF-κB, LC-3, LAMP1 and BECLIN1 in the RNA-Seq data from our cisplatin-
treated C4 cells. Only NF-κB, however, was significantly differentially expressed compared to 
control; thus, autophagy does not seem to be a mechanism by which RBM5 expression influences 
membrane integrity in cisplatin-treated SCLC cells. 
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3.4.8 In patient samples, RNA-Seq shows that RBM5 expression is 
reduced by 50% in tumors and that similar pathways are disrupted 
 
 
To determine if the RBM5-influenced pathways that we identified in vitro were also influenced 
in vivo, we carried out RNA-Seq on primary tissue specimens. SCLC tumor resection is not 
routinely carried out in North America, but we did obtain two fresh frozen paired non-tumor and 
SCLC specimens. Transcriptome sequencing and analysis were performed on all four specimens. 
 
We identified 14,346 and 14,119 genes differentially expressed between both non-tumor and 
tumor pairs, respectively, thus slightly more than half of the genes studied. Interestingly 12,116 
(∼85%) of these differentially expressed genes were common to both paired groups, suggesting 
that, contrary to what one might expect in a tumor, a fairly conserved mechanism is involved in 
the evolution of SCLC, a favorable feature for treatment development. 
 
RBM5 expression was very similar in both non-tumor specimens, and decreased by half in the 
corresponding tumor specimens; from 40.43 FPKM to 18.55 FPKM in the first patient 
specimens, and from 39.00 FPKM to 22.30 FPKM in the second patient specimens. This 
significant decrease of approximately 50% suggests that loss of heterozygosity (LOH) may be 
the cause of decreased RBM5 expression in SCLC. In fact, LOH of a portion of 3p21.3 close to 
RBM5 has been observed in over 95% of SCLC and 70% of NSCLC (Ji et al., 2005; Kok et al., 
1997; Lerman and Minna, 2000; Sutherland et al., 2010; Wei et al., 1996; Wistuba et al., 2000). 
It is important to note that the RBM5 expression values in the non-tumor samples are very similar 
to that of T2 (58.26 FPKM), thus lending physiological relevance to our in vitro model. 
 
117 
 
 
 
Using FIDEA with the KEGG database, 34 pathways were shown to be significantly 
differentially regulated in both tumor specimens compared to their respective non-tumor control 
(Table 3.7). GSAASeqSP with MSigDB Hallmark gene set also showed that many gene sets 
were enriched; 18 in the first patient sample, and 26 in the second, with 15 gene sets being 
common between both sample pairs (Table 3.8). Differentially expressed pathways, as 
determined by both FIDEA and GSAASeqSP, included almost all of the RBM5-influenced 
pathways identified above, including many transformation-associated pathways, notably 
‘Pathways in cancer’, ‘Cell cycle’, ‘Small cell lung cancer’, ‘Axon guidance’, ‘p53 signaling’, 
‘TNFα signaling via NFĸB’ and ‘Apoptosis’. This high level of correlation between significantly 
differentially expressed pathways in our SCLC patient samples and the RBM5 expressing cell 
lines supports, once again, our conclusion that RBM5 plays a role influencing pathways that are 
very important to the transformed state of SCLC cells. 
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Table 3.7: Significantly altered pathways between both patient SCLC tumor/non-tumor pairs as 
determined by FIDEA analysis with KEGG database (using the samples’ RNA-Seq results). 
Pathways are listed based on significance of enrichment in the first patient sample. 
 
 Non-tumor/tumor pair 1 Non-tumor/tumor pair 2 
Pathway (Benjamini value) (Benjamini value) 
Pathways in cancer 1.23E-12 6.36E-14 
Cell cycle 9.75E-10 1.99E-10 
Regulation of actin cytoskeleton 3.03E-06 3.06E-07 
Focal adhesion 3.03E-06 5.50E-08 
Chronic myeloid leukemia 2.60E-05 7.09E-10 
p53 signaling pathway 2.60E-05 2.23E-06 
Fc gamma R-mediated phagocytosis 2.64E-05 3.95E-06 
Neurotrophin signaling pathway 1.11E-04 3.68E-10 
Colorectal cancer 1.64E-04 5.82E-08 
Bacterial invasion of epithelial cells 1.82E-04 1.22E-06 
Pancreatic cancer 1.82E-04 1.22E-06 
Phosphatidylinositol signaling system 2.81E-04 4.93E-04 
Prostate cancer 3.58E-04 1.58E-06 
Small cell lung cancer 6.00E-04 3.74E-04 
Axon guidance 1.04E-03 1.16E-06 
Leukocyte transendothelial migration 1.37E-03 3.74E-04 
Acute myeloid leukemia 1.73E-03 1.27E-05 
Renal cell carcinoma 1.79E-03 3.74E-04 
Inositol phosphate metabolism 2.29E-03 1.39E-02 
Ubiquitin mediated proteolysis 4.01E-03 6.36E-04 
Salmonella infection 4.20E-03 1.68E-02 
Adherens junction 4.20E-03 9.09E-06 
DNA replication 4.20E-03 1.39E-02 
T cell receptor signaling pathway 7.53E-03 2.78E-05 
mTOR signaling pathway 8.57E-03 4.60E-04 
Base excision repair 1.69E-02 1.26E-02 
Glioma 1.72E-02 1.31E-04 
Shigellosis 1.76E-02 2.25E-05 
B cell receptor signaling pathway 1.78E-02 8.53E-04 
MAPK signaling pathway 1.78E-02 4.77E-02 
ErbB signaling pathway 1.97E-02 1.57E-05 
Endometrial cancer 2.21E-02 1.57E-05 
N-Glycan biosynthesis 3.89E-02 1.23E-02 
Chemokine signaling pathway 4.69E-02 1.35E-04 
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Table 3.8: Altered gene sets with FDRs below 1% in both patient SCLC tumor/non-tumor pairs, 
as determined by GSAASeqSP analysis with the MSigDB Hallmark gene set (using the samples’ 
RNA-Seq results). Pathways are listed based on FDR in the first patient sample. 
 
 Non-tumor/tumor Non-tumor/tumor 
  pair 1  pair 2 
      
Gene set p-value FDR p-value FDR 
     
TNFα signaling via NFĸB
* 
0.0 0.0 0.0 0.0 
IL6 JK STAT3 signaling
* 
0.0 0.0 0.0 0.0 
G2M checkpoint 0.0 0.0 0.0 0.0 
Estrogen response late
* 
0.0 0.0 0.0 0.0 
Interferon γ response 0.0 0.0 0.0 0.0 
E2F targets 0.0 0.0 0.0 0.0 
EMT
* 
0.0 0.0 0.0 0.0 
Inflammatory response
* 
0.0 0.0 0.0 0.0 
KRAS signaling up
* 
0.0 0.0 0.0 0.0 
Pancreas β cells
* 
0.0 0.0 0.0 0.0 
UV response down
* 
0.0 0.01 0.0 0.0 
Interferon α response
* 
0.0 0.01 0.0 0.01 
IL2 STAT5 signaling
* 
0.0 0.01  0.0 0.0 
Apoptosis
* 
0.0 0.01  0.0 0.0 
Coagulation
* 
0.0 0.01 0.0 0.0 
*
 Beside a gene set name indicates it’s enrichment in untreated control vs. C4 samples, at an FDR < 10%. 
 
 
3.5 Conclusion 
 
Lung cancer is the leading cause of cancer-related deaths worldwide. The most aggressive form 
of lung cancer is SCLC, with a staggering 95% of diagnosed patients succumbing to the disease 
(Govindan et al., 2006). This high mortality rate clearly demonstrates the need for more effective 
screening techniques and treatment options. Our results show, for the first time, that RBM5 
expression is important to the maintenance of the non-transformed state of lung cells, and that 
this is accomplished via direct regulation of the cell cycle and apoptosis, and indirect regulation 
of overall cell death, angiogenesis, and cell adhesion. Functional studies confirmed that RBM5 
expression in SCLC (1) slowed the cell cycle, and (2) decreased membrane integrity, partially 
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via increased apoptosis when cells were treated with the chemotherapy agent cisplatin. 
Therefore, decreased RBM5 expression, as is observed in 95% of SCLC, may be a critical step in 
the establishment of this disease. In a clinical setting, downregulation of RBM5 expression could 
be a novel biomarker for the determination of SCLC risk. Therapeutic options involving RBM5 
and/or direct targets, or pathways altered by RBM5 expression, may also be very fruitful avenues 
to pursue. Furthermore, due to the significant sensitization RBM5 expression had on cisplatin-
treated samples, RBM5 expression could be a valuable predictive aid for assessing how a patient 
may respond to this chemotherapy. Ultimately, this work demonstrates, for the first time, the 
importance of RBM5 to SCLC. Our results present a stepping-off point for additional targeted 
functional work. 
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Chapter 4  
4 RBM10 promotes transformation-associated processes in small cell 
lung cancer and is directly regulated by RBM5 
 
Loiselle JJ, Roy JG and Sutherland LC. (2017) RBM10 promotes transformation-associated 
processes in small cell lung cancer and is directly regulated by RBM5. PLoS ONE. 
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4.1 Abstract 
Lung cancers are the leading cause of cancer-related deaths worldwide, with small cell lung 
cancer (SCLC) being the most aggressive type. At the time of diagnosis, SCLC has usually 
already metastasized, and an astonishing 95% of patients eventually succumb to the disease. This 
highlights the need for more effective SCLC screening and treatment options. Interestingly, the 
earliest and most frequent genetic alteration associated with lung cancers involves a lesion in the 
region to which the RNA binding protein RBM5 maps. We have recently shown that a decrease 
in RBM5 expression may be a key step in SCLC development, as RBM5 regulated many 
transformation-associated processes in SCLC cells. RBM5 is structurally and functionally 
similar to another RNA binding protein, RBM10. Both proteins have tumor-suppressor 
properties in a variety of cancer cell lines, and it has been suggested that RBM5 expression can 
influence RBM10. Due to their similarities, and the recent evidence that RBM10 is mutated in up 
to 21% of lung cancers, we hypothesized that RBM10 would share RBM5’s tumor-suppressor 
properties in SCLC. Using transcriptome analysis and functional assays, we show, however, that 
RBM10’s function was significantly altered by RBM5; in the endogenously RBM5-null GLC20 
SCLC cell line, RBM10 actually promoted cell proliferation and other transformation-associated 
processes. Using RNA immunoprecipitation followed by next generation sequencing (RIP-Seq) 
and Western blotting, we demonstrate that RBM5 post-transcriptionally regulated RBM10 
expression via direct interaction with specific RBM10 splice variants. We propose a working 
model describing the impact of this interaction on cellular processes. Our results provide 
evidence that RBM10 expression, in RBM5-null tumors, may contribute to tumor growth and 
metastasis. Measurement of both RBM10 and RBM5 expression in clinical samples may 
therefore hold prognostic and/or potentially predictive value.   
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4.2 Introduction 
According to the World Health Organization, cancer is one of the main causes of morbidity and 
mortality worldwide. Lung cancers are not only one of the most diagnosed cancers, but also the 
main cause of these cancer-related deaths, claiming over 1.6 million lives in 2012 [1]. The most 
aggressive form of lung cancer is small cell lung cancer (SCLC) [2]. In 90% of SCLC cases, the 
disease has already metastasized when the patient is diagnosed, which limits treatment options 
[3]. An astonishing 95% of SCLC patients eventually succumb to the disease, highlighting the 
need for more effective detection and treatment options [4]. Interestingly, the earliest and most 
frequent genetic alteration that occurs in lung cancer involves deletion within the 3p21.3 region 
[5-7]. The RNA binding protein, RBM5, resides within this region and is significantly 
downregulated [8], but not deleted [6], in the majority of lung cancers. Recently, our group 
demonstrated that this decline in RBM5 expression may be a key step in the establishment of the 
transformed state of lung cells; RBM5 is responsible for slowing the cell cycle, promoting 
apoptosis, and downregulating transformation-associated processes such as angiogenesis in 
SCLC cells [9]. RBM5 may therefore be an important marker for SCLC risk, and could guide the 
development of more effective screening and/or treatment options. 
 
RBM5 is structurally similar to another RNA binding protein, RBM10. RBM10 has two main 
alternative splice variants termed RBM10 variant 1 (RBM10v1) and RBM10 variant 2 (RBM10v2) 
[10-12]. Each main RBM10 splice variant also codes for alternative isoforms with or without the 
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addition of one valine residue (Fig 4.1) [13]. Structurally, RBM10v2 has 53% identity to RBM5 
[12].  
 
Figure 4.1 Schematic representation of RBM10v1/v2 exons. Exons are represented by grey boxes outlined in black.  Box sizes are not 
representative of actual exon size. Black ovals represent approximate location of the epitopes recognized by the antibodies used in this study. 
Solid black lines represent the approximate location of shRNA RBM10 targets, which were not variant specific. Corresponding names of 
antibodies and shRNA are listed next to their approximate location. Arrow indicates position of the GTG codon coding for the valine residue that 
can be differentially spliced from RBM10 transcripts (last amino acid coded by exon 10). 
 
RBM5 and RBM10 also share functional similarities, and both have tumor-suppressor properties 
in various cancer cell lines [10, 12, 14]. Functional data for RBM10 are limited, but in certain 
studies, RBM10 promoted apoptosis and/or decreased cell proliferation; (1) RBM10 expression 
correlated with decreased cell proliferation and increased apoptosis in primary chondrocytes 
induced to hypertrophy [15], (2) RBM10v1 expression in breast cancer specimens correlated with 
the expression of proapoptotic BAX and the tumor suppressor gene p53 [16], (3) stable RBM10 
knockdown (KD) in cervical cancer cells (HeLa) correlated with a significant increase in colony 
formation by clonogenic assays [17], (4) in lymphoblastic leukemia (Jurkat) and breast cancer 
(MCF-7) cells, transient RBM10 overexpression correlated with increased levels of apoptosis, 
whereas stable RBM10KD correlated with lower TNF-α protein levels, as well as decreased 
TNF-α mediated apoptosis [10], and (5) in a mouse xenograft tumor model with HeLa cells, 
RBM10KD enhanced tumor growth [14]. In contrast, other studies suggest an anti-apoptotic 
function for RBM10; (1) RBM10KD in SHSY5Y human neuronal cells augmented proapoptotic 
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caspase activity after staurosporine exposure [18], (2) expression of both RBM10 mRNA variants 
in breast cancer cells positively correlated with VEGF mRNA, a promoter of new blood vessel 
growth [16], and (3) in patients with metastatic melanoma, high RBM10 expression correlated 
with increased disease aggressiveness [19]. Considered as a whole, these results suggest that the 
regulation of cell growth is an important aspect of RBM10 function, but that the mechanism 
regulating this function requires elucidation. Limited evidence suggests that this regulation 
depends, at least in part, on the related RNA binding protein RBM5 [20].  
 
Considering the similarities between RBM5 and RBM10, and the recent finding that RBM10 is 
mutated in up to 21% of invasive lung adenocarcinomas [21], we hypothesized that RBM10 
shares RBM5’s tumor-suppressor properties in SCLC. Consequently, RBM10 may also hold 
prognostic potential for assessing SCLC risk and provide important information regarding the 
development and/or progression of this particularly aggressive form of lung cancer. To this end, 
we set out to determine RBM10’s role in SCLC, and compare it to that of RBM5.   
 
4.3 Materials and Methods 
4.3.1 Cell culture & subline establishment 
SCLC GLC20 cells were gifted by the late Dr. Charles Buys from the University of Groningen 
(Groningen, Netherlands) and cultured as previously described [9]. Stable RBM5-expressing T2 
and C4 GLC20 sublines were established as previously described [9].  
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SCLC GLC20 RBM10 stable KD sublines were generated from passage 7 GLC20 wild type 
cells. Several different dilutions of GLC20 cells were plated in 24-well flat-bottom plates 
(Sarstedt AG & Co., Nümbrecht, Germany) and incubated at 37°C with 5% CO2 in a humidified 
chamber for 24 hours. Half of the cells were transfected with a control shRNA vector “Hush 
300” (TR30003, Origene Technologies, Inc, Rockville, U.S.A) and the other half with a 50:50 
shRNA mix of “Hush 29” (TI308329, Origene, 5’-
GCCTTCGTCGAGTTTAGTCACTTGCAGGA) and “Hush 30” (TI308330, Origene, 5’-
AGTCACTTGCAGGACGCTACACGATGGAT). Hush 29 and 30 both target exon 6 of 
RBM10 and are not variant 1 or variant 2 specific (Fig 4.1). Cells were transfected using 
Lipofectamine 2000 (L2000) (Invitrogen, Life Technologies, Burlington, Canada). Transfected 
cells were selected using 0.1 μg/mL puromycin (Invitrogen) starting at 48 hours post-
transfection. After seven days of selection, cells were treated with a Histopaque solution (Sigma-
Aldrich) to separate live from dead cells. The stable negative control shRNA subline was named 
G300.3, and three surviving RBM10KD sublines were named G29/30.1, G29/30.3 and G29/30.4. 
 
4.3.2 RNA sequencing and analysis  
RNA samples were isolated using Tri-Reagent (BioCan Scientific, Mississauga, Canada). All 
sequencing was performed by the Donnelly Sequencing Centre (Toronto, Canada) on the 
Illumina HiSeq 2500 platform. RNA-Seq library preparation and sequencing specifications were 
as previously described [9]. All specimens, therefore, had (1) quality score distributions over all 
sequences above 37 (on a phred 33 quality scale), as determined by FastQC (Babraham 
Bioinformatics, http://bioinformatics.bbsrc.ac.uk/projects/fastqc/), and (2) low quality ends 
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trimmed during adapter trimming (quality cut-off of 26), as previously recommended [22]. 
Specifications for the GLC20 stable scramble control and RBM10KD (G29/30.4) were as 
follows; (1) RNA was not DNAse treated prior to sequencing, (2) reads were 125 bp long, and 
(3) both samples were multiplexed together and run in one lane. Sequencing data has been 
deposited to the NCBI Sequence Read Archive (SRA) database, under the submission ID 
SUB2649287. 
 
Sequencing results were analyzed and pathway analysis carried out as previously described [9].  
 
4.3.3 Western blotting 
Performed as previously described [9]. Two rabbit anti-human RBM10 primary antibodies were 
also used: Sigma-Aldrich, HPA034972 and Bethyl Laboratories, A301-006A-1. 
 
4.3.4 RNA immunoprecipitation followed by next generation sequencing 
(RIP-Seq) 
The basic RIP technique was carried out as previously described [23]. RNA was sequenced by 
the Donnelly Sequencing Centre on the Illumina HiSeq 2500 platform. Libraries were prepared 
using the Illumina TruSeq Stranded Total RNA library preparation kit with Ribozero Gold 
depletion and random priming. Associated samples were multiplexed together for sequencing, 
and each run was 125 bp and pair-ended. The RBM10 antibody used for RBM10 
immunoprecipitation was from Sigma-Aldrich (catalogue number: HPA034972), and the non-
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specific IgG Control was from Cell Signaling (catalogue number: 2729). Sequencing data has 
been deposited to the NCBI Sequence Read Archive (SRA) database, under the submission ID 
SUB2649287. 
 
The FPKM and log2-fold change expression values generated by Cuffdiff were used to 
determine protein targets. The potential target had to meet the following inclusion criteria in the 
RBM5 or RBM10 RIP sample, as previously described [9]:  (1) an FPKM value above one, and 
(2) a log2-fold change above one (and necessarily positive, indicating it was more highly 
expressed than in the Control RIP).  
 
4.3.5 Cell growth assay 
GLC20 cells and RBM10-knockdowns were plated, as previously described [9], and monitored 
every day for five days by MTT assays. At the indicated time intervals, cells were treated with 
10 μL of 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Reagent (Life Technologies) in PBS (Gibco) for 2 hours and 45 min at 37°C, as previously 
described [24].  Following incubation, cells were transferred to a 96-well Vee-bottom plate 
(Sarstedt) and subjected to centrifugation. Supernatant was discarded and the blue formazan 
precipitate was dissolved in DMSO (BDH Chemicals, VWR).  Dissolved crystals were then 
transferred to a 96-well flat-bottom plate and, after a ten minute incubation, absorbances were 
read at 540 nm using a BioTek Synergy S4 Spectrophotometer (BioTek Instruments, Inc).  Three 
biological replicates, using cells with different passage numbers, were performed.   
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Absorbances of each biological replicate were normalized to their respective day 0 absorbance 
value, and the averages of three or four biological replicates for each day are presented.  A Two-
way ANOVA statistical analysis was performed with the Bonferroni post-hoc test, comparing all 
growth to the pcDNA3 subline for the RBM5 sublines or G300.3 for the RBM10KD sublines, 
using Graphpad Prism 5 (Graphpad Software, Inc., San Diego, U.S.A).  
 
4.4 Results 
4.4.1 RBM10 RNA targets in GLC20 cells that express RBM5 cDNA 
We first set out to compare RBM5 and RBM10 targets in SCLC. As RBM10 is an RNA binding 
protein, and was previously shown to be a part of prespliceosomal complexes A and B [25, 26], 
we determined that RNA Immunoprecipitation followed by next generation sequencing (RIP-
Seq) was the most suitable method for identification of RBM10 targets. RIP-Seq involves 
antibody-driven immunoprecipitation of targeted endogenous protein without breakdown of 
protein-protein interactions, thus any RNA that is either directly bound to RBM10, and/or bound 
to RBM10 via another RBM10-bound protein would be captured. We anticipated that, having 
homology and similar functions, RBM10 targets would overlap with those of RBM5. Our group 
recently identified RBM5 targets using an endogenously RBM5-null SCLC cell line (4S1 Table), 
GLC20 [24], from which three stable sublines - an empty vector control and two RBM5 
expressing (T2 and C4) – had been generated [9]. The “T2” subline was derived from a pool of 
transfected cells, and had RBM5 expression levels comparable to non-tumor lung tissue, while 
the “C4” subline was derived from a single transfected cell, and had 6-fold higher levels of 
RBM5 than the T2 subline [9]. As RBM5 targets were previously identified in the C4 GLC20 
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subline, RBM10 RIP-Seq experiments were also performed in this subline in order to directly 
compare RBM5 and RBM10 targets. Specifically, RBM10 RIP-Seq was performed in biological 
duplicate in C4 cells using a non-specific IgG as a Control IP and an anti-RBM10 antibody for 
RBM10-specific IP. Following confirmation of successful IP (Fig 4.2A), the associated RNA 
was sequenced (4S1 Table).  
 
Figure 4.2 RBM10 RIP-Seq results and comparison to identified RBM5 targets. (A) Successful immunoprecipitation of RBM10 from C4 
cells, demonstrated by Western Blot of input and output protein samples. Blots probed for RBM10, using the same RBM10 antibody used in the 
immunoprecipitation experiment (Sigma-Aldrich). Control immunoprecipitation performed, using a non-specific rabbit IgG antibody. (B) 
Overlap between RBM5 and RBM10 targets in C4 GLC20 subline. (C) GO Molecular Function gene sets enriched in common RBM5 and 
RBM10 RIP-Seq targets, as determined by FIDEA. Values indicated are Benjamini values. 
 
Using moderate binding criteria, as previously described [9], we identified 5063 RBM10 targets. 
In our previous study, using the same RIP-Seq procedure and binding criteria, we had identified 
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773 RBM5 targets in this GLC20 subline [9]. RBM10, therefore, had many more targets than 
RBM5, suggesting the scope of RBM10’s influence in SCLC may be greater than that of RBM5. 
 
Interestingly, more than half of RBM5’s targets were shared by RBM10 (Fig 4.2B), confirming 
that they do have overlapping targets. Furthermore, this suggests that RBM10 plays a key role in 
RBM5 regulated processes but not vice versa. To determine the functional relevance of these 
common targets, we performed pathway analyses using the Functional Interpretation of 
Differential Expression Analysis (FIDEA) Program, a program that can be used to analyze 
various types of differential expression data [27]. Two different databases were used with the 
FIDEA Program; (1) the Kyoto Encyclopedia of Genes and Genomes (KEGG) Database, which 
groups genes based on established molecular interactions [28, 29], and (2) the Gene Ontology’s 
(GO) Molecular Function Database, which groups genes based on cellular functions [30, 31]. 
Using a Benjamini value cut off of 0.005, no KEGG pathways were found to be enriched, a not 
unexpected result since multiple targets within a single signaling pathway would not necessarily 
be required for an effect. Using the same Benjamini value parameter, ten GO Molecular Function 
gene sets were enriched (Fig 4.2C). Interestingly, all enriched gene sets involved binding, 
including to ATP, nucleotides, protein, RNA and small molecules. Thus RBM5 and RBM10’s 
common targets may regulate a plethora of cellular processes, which may also explain why no 
individual KEGG pathways were enriched.  
Since RBM10 had so many RNA targets that were not shared by RBM5 (Fig 4.2B), we went on 
to determine the functional importance of these RBM10-specific genes (will be referred to as 
RBM10-only targets). Using the FIDEA Program with the KEGG Database, we identified eight 
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significantly enriched pathways (Table 4.1). The most enriched pathway was ‘Metabolic 
pathways’, consistent with the top RBM10 targets, which are all involved in different aspects of 
cell metabolism: NDUFA6 (oxidoreductase activity), MDP1 (phosphatase activity) and ATP6VIF 
(ion transfer). We were particularly interested to see that the ‘Oxidative phosphorylation’ 
pathway was the second most-enriched pathway. Notably, changes in oxidative phosphorylation 
are not only linked to metabolism (the top enriched pathway identified), but also the three 
disease states enriched in RBM10-only targets: Parkinson’s [32, 33], Huntington’s [34] and 
Alzheimer’s [35, 36]. The fact that five of the eight enriched KEGG pathways are intimately 
linked to oxidative phosphorylation strongly suggests that RBM10 plays a particularly important 
role in this process.  
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Table 4.1: Pathways and gene sets enriched in RBM10-only RIP-Seq targets. 
Pathways & gene sets Benjamini value 
KEGG 
Metabolic pathways 1.78E-8 
Oxidative phosphorylation 9.34E-5 
Base excision pair 1.56E-4 
Huntington’s disease 4.37E-4 
Alzheimer’s disease 1.77E-3 
Neurotrophin signaling pathway 1.79E-3 
RNA transport 1.79E-3 
Parkinson’s disease 2.46E-3 
GO Molecular Function 
Protein binding 3.62E-34 
Binding 6.15E-21 
RNA binding 1.07E-13 
Structural constituent of ribosome  1.63E-7 
Catalytic activity  5.31E-7 
Transcription cofactor activity  2.07E-7 
Heterocycylic compound binding  2.07E-6 
Organic cyclic compound binding  2.07E-6 
Transcription factor binding 
transcription factor activity 
 4.98E-6 
Transferase activity  3.29E-6 
Protein binding transcription factor 
activity 
 4.34E-6 
Enzyme binding  2.30E-6 
Nucleic acid binding  2.30E-5 
Kinase binding  2.30E-5 
Transcription corepressor activity  3.61E-4 
Protein kinase binding  1.19E-4 
Mitogen-activated protein kinase 
binding 
 2.13E-3 
Significantly enriched gene sets with Benjamini values below 0.005 are listed. 
 
To determine if these RBM10-only targets shared similar functionality, we used the GO 
Molecular Function Database with the FIDEA Program. Enriched gene sets are listed in Table 
4.1. Many of the enriched gene sets are still showing RBM10 targets involved in a plethora of 
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binding activities, but a new functional activity involving transcription regulation emerged, 
suggesting that RBM10 has distinct RBM5-independent functions.  
 
Taken together our RIP-Seq results show that although RBM5 and RBM10 share many common 
targets, both have distinct targets, with RBM10 having over six times more than RBM5. RBM5 
and RBM10 targets, themselves, bind various cellular components, suggesting that RBM5 and 
RBM10 work together to regulate a variety of cellular processes in SCLC. On the other hand, 
targets bound by RBM10, but not RBM5, regulated oxidative phosphorylation and numerous 
aspects of gene expression and protein activity, suggesting RBM10 has distinct mechanisms of 
action that could be RBM5-independent.  
 
4.4.2 Effect of RBM10 inhibition on dehydrogenase activity in GLC20 
cells 
Our RIP-Seq results showed that RBM10 directly influenced metabolism, most specifically 
oxidative phosphorylation. Work in HeLa cells and primary chondrocytes had previously 
correlated RBM10 expression with decreased cell proliferation [15, 17]. Taken together, these 
observations suggested that RBM10 expression would result in decreased SCLC cell proliferation 
and/or metabolic activity. We therefore chose to use the MTT assay to examine the functional 
significance of RBM10 expression to SCLC. 
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As a first step, we generated stable RBM10 knockdowns (KDs) in the parental RBM5-null 
GLC20 cells. It is important to note that this GLC20 SCLC cell line is a particularly appropriate 
model for aggressive SCLC, as RBM5 is downregulated in the majority of lung cancers [8]. 
RBM10KD was not performed in the T2 or C4 sublines since all RBM5 expressed in these 
sublines results from exogenously introduced RBM5 cDNA. These sublines, therefore, do not 
express any of the various RBM5 splice variants that are present in endogenously RBM5-
expressing systems, rendering results from RBM10KD experiments in these sublines non-
physiological. As noted in Materials and Methods, GLC20 cells were subjected to transfection 
with two RBM10KD shRNA plasmids, together termed 29/30, that targeted an exon common to 
both RBM10v1 and RBM10v2. Thus, knockdown of RBM10v1 was not specifically targeted in 
this study, but due to the almost exclusive expression of RBM10v1 in the GLC20 cells at the 
protein level (Fig 4.3C), all decreases in RBM10 protein were reported as RBM10v1. Three 
stable sublines derived from three distinct pooled RBM10KD populations were produced, termed 
G29/30.1, G29/30.3 and G29/30.4, as well as one control subline, termed G300.3. Somewhat 
surprisingly, but in line with one of the known mechanisms of shRNA regulation [37, 38], RNA 
levels of RBM10 were not diminished in any of the KDs (Fig 4.3A and B). At the protein level, 
although the G29/30.1 subline demonstrated great variance in protein expression, with no 
significant decrease in RBM10v1 expression relative to Control (99% expression, p=0.9836), 
both G29/30.3 and G29/30.4 had significantly lower RBM10v1 protein levels relative to G300/3, 
with 55% (p=0.0026) and 16% (p=0.0033) the level of Control cells, respectively (Fig 4.3C and 
D). 
  
149 
 
 
 
 
Figure 4.3 RBM10 expression and dehydrogenase activity in control and stable RBM10KD GLC20 sublines. (A & B) RBM10 mRNA 
levels, determined by RNA-Seq, for all RBM10 variants combined (A) or for individual splice variants (B). ‘Control’ represents values from 
parental GLC20 cells and the control G300.3 GLC20 subline. RBM10KD sample used was the G29/30.4 subline, as it showed greatest decrease 
in RBM10 protein expression. (C & D) RBM10v1 protein levels were monitored in the G300.3, G29/30.1, G29/30.3 and G29/30.4 sublines using 
the Bethyl RBM10 antibody. (C) One representative Western blot result is presented for RBM10v1 and α-tubulin (loading control). (D) 
Densitometric results of the average RBM10v1 protein levels from three biological replicates performed in duplicate. Analysis was performed 
using the AlphaEaseFC, ‘1D-Multi’ analysis tool.  Values of RBM10v1 were normalized to the α-tubulin of each biological replicate, and then 
made relative to the G300.3 control subline. Standard error is presented.  Subline expression levels were compared using the Student’s unpaired t-
test, between sublines. (E) G300.3, G29/30.1, G29/30.3 and G29/30.4 were grown for five days and dehydrogenase activity was monitored daily 
using an MTT assay.  Absorbance was plotted relative to day 0. The average of three biological replicates performed in eight technical replicates 
with standard error is presented. A Two-way ANOVA was performed between the G300.3 and other sublines, with Bonferroni post-hoc analysis. 
* p < 0.05, ** p < 0.01, and **** p < 0.0001. 
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The effect of RBM10KD on dehydrogenase activity was analyzed by MTT assay over a five day 
period (Fig 4.3E). The G300.3 and G29/30.1 sublines had similar dehydrogenase activity, a 
result that was anticipated as both sublines had nearly identical levels of RBM10v1 protein 
expression (Fig 4.3D). The G29/30.3 and G29/30.4 sublines, however, both displayed 
significantly reduced activity, relative to the G300.3 control. G29/30.4 had the greatest reduction 
in dehydrogenase activity, with significant differences on day four and day five (p < 0.01 and p < 
0.0001, respectively), compared to G300.3.  
 
These results indicate that the effect of RBM10 was level-dependent. More importantly, 
however, is the observation that inhibition of RBM10 expression correlated with dehydrogenase 
activity that was decreased. Decreased activity could have resulted from either a decrease in cell 
number and/or a decrease in the metabolic rate of existing cells. Since this finding in an RBM5-
null background is in contradiction to the previous work in RBM5-retaining HeLa cells [14, 17], 
our results suggest that RBM10 function can not only be altered, but actually reversed by RBM5. 
 
4.4.3 Effect of RBM10 inhibition on signaling pathways in GLC20 cells 
To gain a more comprehensive understanding of the extent of RBM10’s influence in SCLC, we 
carried out RNA-Seq, because the MTT assay used above identifies only one functional 
consequence resulting from inhibition of RBM10. For these experiments, the stable RBM10KD 
G29/30.4 subline was used, as it had the greatest RBM10KD (referred to simply as RBM10KD 
in the following figures and the Discussion). As our Control, we sequenced and combined data 
for the stable pcDNA3 transfected GLC20 cells [9] and the stable scramble shRNA control 
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G300.3. Sequencing and analysis were performed as previously described [9]. Specific 
parameters are listed in Materials and Methods. Using the Cufflinks suite, we identified 1157 
significantly differentially expressed genes, representing approximately 4.45% of the 
transcriptome (4S2 Table).  
 
To determine the functional relevance of the differentially expressed genes, we performed 
pathway analyses. To ensure the validity of our results, as for the RIP-Seq data analyses, two 
different pathway analysis programs were used, each with their own database. We began with the 
FIDEA Program and the KEGG Database. With these tools, that group genes based on molecular 
interactions, we identified four enriched pathways (Fig 4.4A). The only upregulated pathway 
upon RBM10KD was ‘Axon guidance’. Genes involved in axon guidance are deleted or the 
subject of promoter hypermethylation in many cancers [39]. As RBM10 expression would 
correlate with decreased expression of these ‘Axon guidance’ factors, this may be one way by 
which RBM10 could promote the transformed state of lung cells. On the other hand, all three 
pathways that were significantly downregulated upon RBM10KD are positively linked with 
cancer; (1) ‘Alcoholism’-related pathways have been shown to promote the transformed state, in 
part via increased EMT [40], (2) ‘Glycolysis’ is upregulated in cancers and is the main pathway 
for ATP production, even in the presence of oxygen [41], and (3) ‘Systemic lupus 
erythematosus’, an autoimmune disease, is linked with an increased risk of cancer, especially 
cancers of hematologic origin, as well as lung and hepatobiliary cancers [42, 43]. These results 
suggest that RBM10 could promote the transformed state in a wide variety of ways, including 
modulation of the immune system and various aspects of cell metabolism.  
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Figure 4.4 Pathway analysis of genes differentially expressed upon RBM10KD in GLC20 cells. (A) KEGG pathways significantly enriched 
upon RBM10KD in GLC20 cells. Analysis performed using subline RNA-Seq expression data and the FIDEA pathways analysis program. (B) 
MSigDB Hallmark gene sets enriched at a false discovery rate of below 5% upon RBM10KD in GLC20 cells. Analysis performed using subline 
RNA-Seq expression data and the GSAASeqSP pathway analysis program. (C) Relationship between select RBM10-altered pathways in GLC20 
cells. Hypoxia is associated with decreased levels of mTORC1 signaling, and promotion of EMT and angiogenesis. In addition, hypoxia is 
associated with increased levels of glycolysis, and likewise, survival in hypoxic conditions is promoted by increased levels of glycolysis. The 
influence of RBM10KD on these pathways, as determined by RNA-Seq is indicated. 
 
To complement our FIDEA and KEGG pathway analysis, we used the Gene Set Association 
Analysis with Sequence Permutation (GSAASeqSP) Program, which is specific for RNA-Seq 
data [43], with the Broad Institute’s Molecular Signatures Hallmark Database (MSigDB), which 
groups genes based on known functions [45]. As shown in Fig 4.4B, six gene sets with false 
discovery rates (FDR) below 5% were enriched upon RBM10KD in GLC20 cells. The most 
enriched gene set was ‘Hypoxia’, which coordinates well with the KEGG pathway analysis 
results described above; hypoxic conditions increase rates of glycolysis, and likewise, increased 
glycolysis supports tumor growth in hypoxic conditions [46]. Interestingly, three of the other five 
gene sets significantly enriched upon RBM10KD are also influenced by hypoxia; ‘mTORC1 
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signaling’, ‘Epithelial to Mesenchymal Transition’ (EMT) and ‘Angiogenesis’. Of note, the 
‘mTORC1 signaling’ pathway, which regulates cell growth, is downregulated during hypoxia 
[47]. Conversely, EMT and angiogenesis can be promoted during hypoxia [48, 49] (Fig 4.4C). 
Although our GSAASeqSP analysis showed that these three hypoxia-related gene sets were 
enriched upon RBM10KD, we went on to determine if RBM10KD specifically promoted or 
inhibited these processes. 
 
Firstly, in hypoxic conditions, downregulation of mTORC1 signaling is accomplished, in part, by 
ATM protein kinase, REDD1 and BNIP3 [47, 50, 51]. Interestingly, in our system, RBM10KD 
correlated with decreased levels of all three of these genes: ATM levels decreased from 27.98 
fragments per kilobase of transcript per million mapped read (FPKM) (Control) to 20.188 FPKM 
(RBM10KD), REDD1 levels decreased from 71.65 FPKM (Control) to 30.96 FPKM 
(RBM10KD), and BNIP3 levels decreased from 58.02 FPKM (Control) to 19.70 FPKM 
(RBM10KD). These results suggest that mTORC1 signaling is promoted upon RBM10KD (Fig 
4.4C).  
 
Secondly, we examined the impact of RBM10KD on the expression of previously published 
EMT-associated genes [52]. Notably, all genes listed as downregulated during EMT in the 
referenced review were significantly upregulated upon RBM10KD in GLC20 cells, or showed 
no significant change in expression. The significantly upregulated genes included CDH1, TJP1, 
PATJ, JUP and DSC2. On the other hand, all genes listed as upregulated during EMT, except 
fibronectin, were either significantly downregulated upon RBM10KD in GLC20 cells or showed 
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no significant change expression. The significantly downregulated genes included VIM, ID1 and 
ZEB1. Our results therefore show that RBM10KD is associated with decreased EMT (Fig 4.4C). 
This is in line with our KEGG pathway analysis, which showed that RBM10KD decreased the 
EMT-promoting ‘Alcoholism’ pathway. 
 
Finally, we examined the expression of angiogenesis markers [49] in our RBM10KD samples: 
RBM10KD significantly decreased the expression of three by at least nine FPKM (VEGF from 
20 to 9 FPKM; FGF10 from 10 to 1 FPKM; PLGF from 75 to 33 FPKM), and increased the 
expression of two others, but only by 1-2 FPKM (THBS1 from 1.75 to 3.8 FPKM; ANGPT1 from 
0.89 to 1.8 FPKM). These results show that, in general, RBM10KD correlates with decreased 
angiogenic marker expression (Fig 4.4C).  
 
In summary, our GSAASeqSP pathway analysis showed that RBM10KD correlated with 
increased mTORC1 signaling, and decreased EMT and angiogenesis. Therefore, RBM10 
expression would be expected to downregulate mTORC1 signaling and promote EMT and 
angiogenesis, thereby influencing these processes in a similar way as hypoxia, and consequently 
promoting the transformed state. The large overlap in the results obtained using the two different 
pathway analysis programs (FIDEA and GSAASeqSP), each with their own database (KEGG 
and MSigDB), strongly supports our conclusion that RBM10 influences various hypoxia-related 
pathways to promote the transformed state. Together, our pathway analysis results suggest that, 
unlike RBM5, RBM10 promotes the transformed state. RBM10 does this specifically by (1) 
increasing glycolysis, (2) reducing mTORC1 signaling, which is associated with deregulated cell 
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growth and could contribute to the higher viable cell metabolism activity observed in RBM10 
expressing GLC20 cells by MTT (Fig 4.3E), (3) promoting EMT, thereby contributing to the 
establishment and progression of the transformed state, and (4) promoting angiogenesis. This 
wide scope of influence is supported by the large number of RBM10-only targets identified by 
RIP-Seq. 
 
4.4.4 Differential gene expression in GLC20 RBM10KD cells compared 
to RBM5 expressing GLC20 cells 
Having determined that RBM5 and RBM10 share similar targets in the C4 subline, and affect 
similar processes in SCLC, but with opposing functional consequences, we decided to identify 
and compare the genes influenced by both proteins. To this end, we examined differential gene 
expression following either RBM10KD or RBM5 expression in GLC20 cells. We anticipated that 
many of the same genes would be influenced, but in an opposite manner, by each protein. 
 
Comparing the RNA-Seq data from our G29/30.4 GLC20 RBM10KD subline with the RNA-Seq 
data from the stable RBM5-expressing GLC20 sublines T2 and C4, we determined that many of 
the same genes were in fact differentially expressed following either RBM10KD or RBM5 
expression; of the significantly differentially expressed genes in RBM10KD, 53.8% were also 
significantly differentially expressed between Control and T2, and 60.7% were also differentially 
expressed between Control and C4 (Fig 4.5). As expected, well over half of these common 
differentially expressed genes (428 genes) were the same whether RBM10KD was compared to 
T2 or C4. Therefore, RBM5 and RBM10 do affect the expression of many of the same genes. 
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Figure 4.5 Comparison of genes differentially expressed upon RBM10KD in GLC20 cells or RBM5 expression in GLC20 sublines. 
Differentially expressed genes, based on RNA-Seq results, in GLC20 cells upon RBM10KD, and moderate (A) or high (B) expression levels of 
RBM5 expression.  
 
We then went on to determine how RBM5 and RBM10 levels affected the expression of these 
commonly differentially expressed genes. Between RBM10KD and T2 RBM5 expression, 82% 
of the common significantly differentially expressed genes changed expression in the same 
direction (Fig 4.5A). As for RBM10KD and C4 RBM5 expression, 67% of the differentially 
expressed genes changed expression in the same direction (Fig 4.5B). Next, we wanted to 
determine if this similarity would extend to genes specifically associated with SCLC. In June 
2014, the National Cancer Institute compiled a list of ‘Genes of Interest in SCLC’, as part of 
their report entitled Scientific Framework for Small Cell Lung Cancer. We recently 
demonstrated that RBM5 expression in C4 significantly altered the expression of 11 of these 
SCLC-associated genes in a way which would suppress tumor growth [9]. Here we now show 
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that RBM10KD altered the expression of nine of these 11 genes in the same direction as RBM5 
expression; BLC2, CCNE1, CREBBP, EPHA7, MED12L, MYCL, SLIT2, SMO and SOX2 (Table 
4.2). This high level of similarity between the effect of RBM5 expression and RBM10KD on 
gene expression, especially SCLC-associated genes, suggests opposing roles for RBM5 and 
RBM10 in aggressive SCLC, and supports our MTT and RNA-Seq findings. 
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Table 4.2: Expression of select National Cancer Institute (NCI) ‘Genes of Interest in SCLC’ in 
Control and RBM10KD samples, as determined by RNA-Seq. 
† Genes significantly downregulated upon RBM10KD (p < 0.05). 
‡ Genes significantly upregulated upon RBM10KD (p < 0.05). 
 
  
Gene name Control RBM10KD p-value 
BCL2  1.81928 1.26218 0.29525 
CCNE1  18.6741 15.4965 0.2551 
COBL † 0.774161 1.82919 0.00095 
CREBBP  ‡ 5.54439 9.8752 0.0001 
EPHA7   16.5578 21.467 0.09965 
MED12L † 4.10916 2.75174 0.0181 
MYCL  11.3944 8.92857 0.17185 
RAB37  0.737284 0.803781 0.758 
SLIT2  ‡ 5.30312 10.1706 0.00005 
SMO † 5.8898 4.02038 0.04565 
SOX2 † 13.317 8.46985 0.0124 
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4.4.5 Effect of RBM5 on RBM10 expression 
Previous studies have shown tumor-suppressor properties for both RBM5 and RBM10. In the 
results presented herein, however, using an aggressive RBM5-null SCLC model, we show an 
opposite effect for RBM10, correlating its expression with promotion of various transformation-
associated processes. These results suggested to us that RBM5 may be a regulator of RBM10 
function, a relationship previously supported by our work in a rat myoblast system [20]. To 
investigate if and how RBM5 might influence RBM10, we examined RBM10 mRNA and protein 
expression in our stable RBM5-expressing GLC20 sublines T2 and C4.  
 
RBM10 mRNA levels in T2 and C4 were determined from RNA-Seq data [9]. Since RBM10 
splice variants differ, in some cases, by only one amino acid, this level of resolution was required 
to precisely quantify the expression of each variant (Fig 4.1). Differential expression analysis of 
RNA-Seq results showed no significant change in RBM10 mRNA expression levels following 
RBM5 expression in GLC20 cells (Fig 4.6A). There was also no significant change in the 
expression of any RBM10 splice variant when RBM5 levels were altered (Fig 4.6B). RBM5 did 
not, therefore, influence RBM10 transcription or alternative splicing. 
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Figure 4.6 RBM10 expression in the parental GLC20 cell line and stable RBM5-expressing sublines. (A) Expression of all RBM10 mRNA 
variants, as determined by RNA-Seq. (B) mRNA expression of specific RBM10 splice variants, as determined by RNA-Seq. ‘Control’ in A and B 
refers to the GLC20 parental cell line and stable pcDNA3-transfected GLC20 subline. (C) Representative Western blot for RBM5 and RBM10 
(Sigma antibody) protein expression levels. Alpha-tubulin was used as loading control. (D) Densitometric results of the average RBM10v1/v2 
expression of three biological replicates each performed in technical duplicate. Analysis was performed using AlphaEaseFC, ‘1D-Multi’ analysis 
tool.  Values of RBM10v1 and RBM10v2 were normalized to the α-tubulin of each biological technical duplicate, and then made relative to the 
pcDNA3 controls. Standard error is presented.  One-way ANOVA was performed with Tukey post-hoc analysis, between sublines. * p < 0.05 and 
** p < 0.01. 
 
To determine if RBM5 is capable of influencing RBM10 post-transcriptionally, RBM10 protein 
levels were investigated via Western blot. To note, only the two major isoforms of RBM10 (v1 
and v2) are distinguishable on Western blots. Interestingly, RBM10v1 levels were not altered 
between sublines, whereas RBM10v2 levels were significantly increased in C4 compared to 
either T2 or the Control (Fig 4.6C and D). These results demonstrated that RBM5 was capable of 
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influencing RBM10 expression, that this influence occurred post-transcriptionally, and that the 
effect was restricted to RBM10v2.  
 
This increase in RBM10v2 levels could potentially have resulted from a targeted increase of 
RBM10v2 translation, or from stabilization of the RBM10v2 isoform, by high levels of RBM5. 
Increased RBM10v2 translation would likely involve binding of RBM5 protein to RBM10v2 
transcript, whereas stabilization of the RBM10v2 isoform by RBM5 would involve a 
protein/protein interaction. As a next step in our investigations, we decided to examine the ability 
of RBM5 protein to interact with RBM10 transcripts. Towards this end, we re-examined our 
previous RBM5 RIP-Seq data (from C4 cells) [9]. As RIP-Seq provides a single nucleotide 
resolution of all RNA targets, we would be able to determine if RBM5 interacted with specific 
RBM10 splice variants. As shown in Fig 4.7A, RBM5 bound only the one specific RBM10 splice 
variant, RBM10v2(V277del). RBM5 bound 186.357 FPKM of RBM10v2(V277del), compared to 
2.62 FPKM of IgG bound RBM10v2(V277del) in the Control RIP. All other RBM10 splice 
variants had counts of 0.1 FPKM or below, in the RBM5 RIP sample, a result clearly unrelated 
to variant expression levels in C4 (Fig 4.6B). This level of specificity, in regards to RBM5’s 
binding of only one RBM10 splice variant, is likely due to structural differences between 
RBM10 alternative splice transcripts, which is supported by our preliminary RNA structure 
analysis (Fig 4.S1 – Thesis Fig 4.8) [53]. Interestingly, in an RBM5-null environment, we found 
that RBM10 was also capable of binding self; specifically, using our RIP-Seq data, we found that 
just like RBM5, RBM10 bound RBM10v2(V277del) mRNA. Unlike RBM5, which was only able 
to bind the one RBM10v2 variant, RBM10 was able to bind not only both variants of RBM10v2, 
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at high levels (Fig 4.7B), but also RBM10v1(V354del), to a lesser extent (28.1 FPKM). These 
results show that RBM10 protein can in fact bind RBM10 mRNA and thus it may, like RBM5, be 
involved in regulating RBM10 isoform expression.  
 
Figure 4.7 RBM5 and RBM10 RIP-Seq results for RBM10 splice variants. Graph representing the expression of the various RBM10 splice 
variants in RBM5 (A) and RBM10 (B) RIP-Seq experiments, which were carried out in C4 cells. 
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Figure 4.8 Predicted mRNA structure of RBM10 splice variants. Most probable RNA structure for (A) RBM10v1(V354), (B) 
RBM10v1(V354del), (C) RBM10v2(V277) and (D) RBM10v2(V277del), as determined by RNAstructure MaxExpect with standard settings. 
Structure generated is composed of highly probable base pairs. Black arrow indicates position of the ‘GTG’ codon alternatively spliced from both 
RBM10v1 and RBM10v2, which results in their respective +/- valine isoforms. *This figure is part of the supplementary materials of the 
published manuscript (Fig S1)* 
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4.5 Discussion 
Functional RBM10 is important for normal cellular processes. For instance, mutations in RBM10 
are the cause of TARP syndrome, which results in many developmental abnormalities and often 
lethality before or soon after birth [11, 54, 55]. Furthermore, RBM10 is mutated in pancreatic 
intraductal papillary mucinous neoplasms [56], 7% of lung adenocarcinomas [57], and 21% of 
invasive lung adenocarcinomas [21]. RBM10 has also been suggested to be important to rat 
myoblast differentiation [20]. Therefore, understanding the regulation of RBM10, as well as the 
range of its downstream effects, is of interest to various areas of cell, developmental and cancer 
biology.  
 
Previous studies relating to RBM10, which have been performed in RBM5-expressing systems, 
have primarily linked RBM10 expression with reduced cell proliferation and promotion of 
apoptosis [10, 14-17]. The study reported here explores, for the first time, the function of 
RBM10 in an RBM5-null system, and the regulation of RBM10 by RBM5. As RBM5 is 
downregulated in many cancers [8, 58-62], this work is particularly meaningful. Here we show 
that RBM10 actually promotes transformation-associated processes in an RBM5-null 
environment. Supporting our findings, RBM10 has been associated with increased expression of 
VEGF, a promoter of new blood vessel growth, in breast cancer samples [16]. In addition, in 
patients with metastatic melanoma, high RBM10 expression was correlated with increased 
disease aggression [19]. Of note, the RBM5 promoter was identified as a “Signature of 
accelerated somatic evolution” in melanomas, with mutations in this region correlating with 
significantly lower survival rates and a higher incidence of metastasis [63]. Therefore, altered 
165 
 
 
 
RBM5 levels in melanoma may result in decreased translational regulation of RBM10, and thus 
the pro-transformation characteristics associated with RBM10 in melanomas, and here in our 
RBM5-null system. In fact, in solid tumors in general, RBM5 is one of nine genes, within a 17 
gene signature associated with metastasis, that are downregulated in various humans [64] and 
mice [65]. Thus, the increased metastatic characteristics of tumors with decreased RBM5 levels 
could in part involve decreased translational regulation of RBM10 by RBM5. This is particularly 
relevant as we show that RBM10 upregulates processes such as EMT and angiogenesis in an 
RBM5-null system. 
 
The majority of functional studies relating to RBM10 have focused on its role in modulation of 
alternative splicing [14, 17, 66-69], likely due to the early findings that RBM10 is a core 
component of spliceosomal A and B complexes [25, 26, 70]. Our RNA-Seq results show, 
however, no significant shifts in alternative splicing upon RBM10KD in GLC20 cells (no genes 
had a significant increase in the expression of one alternative splice variant and a significant 
decrease in the expression of another) (4S2 Table), a finding we postulate may be dependent on 
RBM5 expression. Of note, upon RBM5 expression in GLC20 cells, using the same techniques 
and analysis parameters, we detected multiple alternative splicing changes. Our transcriptomic 
analyses, which show no effect of RBM10 downregulation on alternative splicing in GLC20 
cells, are supported by (1) our RBM10-only targets (Table 4.1), which are involved in various 
aspects of gene expression regulation, excluding alternative splicing, (2) RBM10’s mRNA 
stabilization effect on its only identified direct RNA target, the AT1 receptor  [71], and (3) 
RBM10’s interaction with the 2A-DUB deubiquitinase protein complex [72] and the Rac-
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specific GTPase-activitating protein FilGAP [73].  These findings are not unanticipated 
considering RNA binding proteins are known to participate in multiple aspects of RNA 
metabolism, including RNA editing, polyadenylation, export, localization, translation and 
stability [74]. Future studies regarding RBM10 should therefore attempt to capture its influence 
on these other aspects of RNA biology, and not be restricted to alternative splicing. Falling to do 
so would result in an incomplete view of the scope of RBM10’s influence on the cell.  
 
More important than the role of RBM10 in the regulation of alternative splicing might be the role 
of alternative splicing of RBM10 itself. The single valine residue that differentiates the two 
RBM10v1 variants, as well as the two RBM10v2 variants, occurs within the second RNA 
Recognition Motif (RRM) of RBM10. The presence or absence of this valine residue can 
influence the α-helical structure of this RRM domain, and could thus influence RBM10’s 
binding targets [13, 14]. Although the functional implications of this modification have yet to be 
tested, the level of binding specificity exhibited by RBM5 suggests that (1) the presence or 
absence of this valine residue modifies RBM10’s structure sufficiently for proteins (at least 
RBM5) to be able to distinguish between variants, and (2) RBM10 splice variants have specific, 
potentially opposing, roles in the cell, and thus require specific regulation. 
 
Based on our results and those of previous RBM10-related studies, we propose a working model 
describing RBM5’s influence on RBM10 and yet to be confirmed functional interactions between 
RBM5 and RBM10 (Fig 4.S2 – Thesis Fig 4.9). This is an extension of a previous model we 
developed in a non-transformed rat myoblast system, which described how RBM10 might 
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influence RBM5 [20]. We hypothesize that RBM10’s binding to RBM10v2 mRNA results in a 
downregulation of RBM10v2 protein expression levels. This would explain the much lower 
levels of RBM10v2 protein, compared to RBM10v1, that we observed in all GLC20 sublines 
(Fig 4.6C), even though mRNA levels for both variants were very similar (Fig 4.6A, B). 
Furthermore, we suggest that RBM5’s binding to RBM10v2(V277del) promotes this transcript’s 
translation or prevents its degradation, resulting in the higher levels of RBM10v2 protein seen in 
the C4 population. The lack of significantly higher RBM10v2 protein expression in T2 (Fig 
4.6C), compared to Control, is not unexpected since this subline has substantially less RBM5 
expressed than C4. We postulate that RBM10v2 is an essential component, or participates in the 
formation, of certain RBM5 protein complexes, which would explain why (1) RBM5 would 
upregulate RBM10v2 protein levels, (2) such a large proportion of RBM5 targets were also 
shared by RBM10 in our RIP-Seq experiments, and (3) RBM10 would have so many RBM10-
only targets; these targets would represent RBM10v1 targets, which would be independent from 
those targeted by the RBM5-RBM10v2 complex.  
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Figure 4.9 Working model representing RBM5 and RBM10 function and interactions in SCLC. Rectangles represent mRNA, whereas ovals 
represent protein. Blue ovals are unspecified proteins. *This figure is part of the supplementary materials of the published manuscript (Fig S2)* 
 
 
We propose that the RBM5-RBM10v2 complex regulates cell cycle progression and promotes 
apoptosis, functions with which RBM5 has been previously associated. We suggest that most, 
but not all, RBM5’s tumor-suppressor properties occur via this RBM5-RBM10v2 complex. The 
RBM5-RBM10v2 complex could also be responsible for the alternative splicing events 
previously associated with RBM10. This would explain why, in an RBM5-null system, these 
alternative splicing events do not appear to be influenced by RBM10 (e.g., there would be no 
RBM5-RBM10v2 complex). On the other hand, we suggest that RBM10v1 promotes 
transformation-associated processes, including glycolysis, EMT and angiogenesis. Some of the 
downstream RBM5-RBM10v2 and RBM10v1 targets overlap, with both complexes affecting the 
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expression of these genes in an opposing manner. This would explain the similarity of 
differentially expressed genes upon RBM5 expression and RBM10KD in GLC20 cells, but why 
RBM5 and RBM10 affected the expression of these genes in contrasting ways (Fig 4.5). We also 
propose that the RBM5-RBM10v2 complex has a more significant influence on transformation-
associated pathways than RBM10v1, explaining why cells expressing physiological levels of 
both RBM5 and RBM10 have regulated cell growth (as seen in the T2 subline) [9]. 
 
According to our working model, upon RBM5 expression, an RBM5-RBM10v2 complex would 
be formed, resulting in higher levels of apoptosis and cell cycle arrest (Fig 4.S3A – Thesis Fig 
4.10A). This is in line with what we have previously shown experimentally upon RBM5 
expression in GLC20 cells [9]. Inversely, upon RBM5KD, less RBM5-RBM10v2 complex 
would be formed, resulting in decreased apoptosis and deregulated cell growth, as well as less 
competition for RBM10v1 regarding their common targets (Fig 4.S3B – Thesis Fig 4.10B). This 
would all contribute to promotion of a transformation-like phenotype. Indeed, this is what we 
observed previously in parental GLC20 cells, compared to the RBM5-expressing sublines [9]. 
Upon RBM10KD in an RBM5-expressing system, we would expect almost no RBM5-RBM10v2 
complex to be formed, especially as RBM10v2 levels are already so much lower than RBM10v1 
in GLC20 cells (Fig 4.S3C – Thesis Fig 4.10C). This would result in a significant decrease in 
apoptosis, as well as reduced regulation of cell cycle progression. Although knockdown of 
RBM10 would also significantly decrease RBM10v1 levels, since RBM10 would not be 
completely knocked out in this situation, some RBM10v1 would remain in the cell. This small 
amount of RBM10v1 could still promote transformation-associated processes to a certain point, 
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especially with much less competition from the RBM5-RBM10v2 complex. In this case, we 
would expect a slight increase in cell growth upon RBM10KD in RBM5-expressing systems. 
This hypothesis is in line with previous functional work performed for RBM10 in endogenously 
RBM5-expressing HeLa cells [17]. Finally, upon RBM10KD in an RBM5-null system, since 
there would be no influence from the RBM5-RBM10v2 complex, RBM10KD would only 
significantly reduce levels of RBM10v1 (Fig 4.S3D – Thesis Fig 4.10D). This would result in 
diminished promotion of transformation-associated processes, and thus lower levels of cell 
growth and/or metabolism. This proposition is in line with the MTT and RNA-Seq results 
presented herein regarding RBM10KD in endogenously RBM5-null GLC20 cells (Figs 4.3E and 
4). 
 
 
171 
 
 
 
 
Figure 4.10 Prediction of the effects of modulating RBM5 and/or RBM10 levels. Using our working model, we predict the effects of (A) 
RBM5 overexpression, (B) RBM5KD, (C) RBM10KD in an RBM5-expressing system, and (D) RBM10KD in an RBM5-null system. Open green, 
blue and purple arrows indicate effect, and thickness of said arrows indicates activity levels (dotted arrows indicate least activity). Closed red 
arrows indicate direction of expression change only. For detailed description of model, refer to text. *This figure is part of the supplementary 
materials of the published manuscript (Fig S3)* 
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Interestingly, RBM10 mutations have recently been associated with lung adenocarcinoma 
pathogenesis [66]. Loss-of-function RBM10 mutations would result in no functional RBM10 in 
the cell and, based on our working model, no RBM5-RBM10v2 complex. This would have two 
opposing consequences; (1) loss of RBM10v1 would result in reduced promotion of 
transformation-associated processes, and (2) loss of RBM5-RBM10v2 complex would result in 
reduced regulation of the cell cycle and decreased apoptosis, and thus promotion of 
transformation. Since, as we proposed above, the influence of RBM5-RBM10v2 is greater than 
RBM10v1, we would expect the overall effect of loss-of-function RBM10 mutations to be pro-
transformatory, similar to the effects of RBM5KD. This is indeed the result seen in clinical 
samples; loss-of-function RBM10 mutations were associated with increased pathogenesis of lung 
adenocarcinomas [21]. These findings further support our working model. 
 
A very recent study in non-transformed mouse cells not only supports our working model, but 
extends its relevance beyond cancer-based systems [75]. In that study, Rodor et al. knocked out 
RBM10 in mouse cells and examined a number of processes, including cell proliferation. 
According to our working model, since RBM10 would be completely depleted in this scenario, 
RBM10v1 could no longer promote transformation-associated processes and RBM5-RBM10v2 
complexes would be completely eliminated. Since RBM10 would no longer influence cellular 
processes, RBM5 could exercise its RBM10v2-independent tumor-suppressor properties. We 
would thus predict that RBM10 knockout would result in a decrease in cell proliferation. This is 
indeed what the authors found. Although Rodor et al. strongly associated RBM10 with the 
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regulation of alternative splicing in that study [75], as mouse cells in general express RBM5 
[76], this could be an RBM5-dependent function of RBM10, as we propose above. 
 
 Considered together, our results suggest that the RBM10 reversal-of-function associated with 
downregulation of RBM5 is one means by which cells transition to a cancerous state, largely 
through processes that involve regulation of a hypoxic state. Our results shed light on the 
relationship between RBM5 and RBM10, a particularly important aspect to remember when 
studying either of these genes individually. We not only determine, for the first time, the role of 
RBM10 in an RBM5-null system, but also propose a working model to explain how RBM10 is 
influenced by RBM5 expression. We also identify all RBM10 targets and explore the extent of 
RBM10’s influence on cellular processes. In addition, we show that RBM5 directly binds 
RBM10 to regulate its expression post-transcriptionally, and that RBM5 and RBM10 share 
similar direct (RIP-Seq) and downstream (RNA-Seq) targets. These results lay the groundwork 
for additional studies to examine the role(s) of specific RBM10 isoforms, and the relationship 
between RBM5 and RBM10 in different systems and disease states.  
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4.7 Supporting information 
4S1 Table. RBM5 and RBM10 RIP-Seq results. RNA expression levels of all genes examined in 
RBM5 and RBM10 RIP-Seq experiments. Gene expression quantification was performed using 
Cuffdiff v2.2.1; however, targets were identified using the inclusion criteria elaborated in the 
Materials and Methods section. Genes listed based on log2(fold-change) in expression, and then 
their value in the experimental RIP sample. 
S1_Table.xlsx
 
4S2 Table. RNA-Seq gene expression data for Control and RBM10KD GLC20 cells. RNA 
expression levels for all genes examined, as well as their specific splice variants. Genes listed 
based on their q-value, and log2(fold-change) in expression. Ctrl refers to combined gene 
expression values for parental GLC20 cells and the stable pcDNA3 transfected GLC20 subline. 
Differential expression testing was performed using Cuffdiff v2.2.1. The third sheet contains the 
information required to identify a particular gene’s alternative splice variant(s) (based on their 
TCONS assigned number from Cufflinks). 
S2_Table.xlsx
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5.1 Abstract 
We previously examined the expression of Rbm5 during myoblast differentiation and found 
significantly more protein in the early stages of skeletal myoblast differentiation than during the 
later stages. We decided to determine if this elevated level was necessary for differentiation. Our 
hypothesis was that if high levels of Rbm5 protein expression were necessary for the initiation of 
skeletal myoblast differentiation, then inhibition of expression would prevent differentiation. Our 
long-term objective is to inhibit Rbm5 expression and examine the effect on H9c2 
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differentiation. Towards this end, stable knockdown clones and transient knockdown populations 
were generated. Expression analyses in H9c2 myoblasts demonstrated significant Rbm5 
messenger RNA (mRNA) inhibition but, surprisingly, no effect on RBM5 protein levels. 
Expression of the Rbm5 paralogue Rbm10 was examined in order to (a) ensure no off-target 
knockdown effect, and (b) investigate any possible compensatory effects. RBM10 protein levels 
were found to be elevated, in both the clonal and transiently transfected populations. These 
results suggest that myoblast RBM5 expression is regulated by a process that includes RNA 
sequestration and/or controlled translation, and that (a) RBM5 function is compensated for by 
RBM10, and/or (b) RBM5 regulates RBM10 expression. We have developed a model to describe 
our findings, and suggest further experiments for testing its validity. Since up-regulation of 
Rbm10 might compensate for downregulated Rbm5, and consequently might mask any potential 
knock-down effect, it could lead to incorrect conclusions regarding the importance of Rbm5 for 
differentiation. It is therefore imperative to determine how both RBM5 and RBM10 protein 
expression is regulated. 
 
 
5.2 Introduction 
In general, the expression of RNA-binding motif domain protein 5 (RBM5) is highest in cells 
that have reduced proliferation such as aging cells (Geigl et al. 2004), dormant seeds (Sugliani et 
al. 2010), and in adult thymus compared to fetal liver (Drabkin et al. 1999), and lowest in highly 
proliferating cells, e.g., most cancers such as non-small cell lung cancers (Oh et al. 2002), 
vestibular schwannomas (Welling et al. 2002), prostate cancers (Zhao et al. 2012), stage III 
serious ovarian carcinomas (Kim et al. 2010), pancreatic cancers (Peng et al. 2013), and biliary 
tract cancers (Miller et al. 2009). In fact, RBM5 was shown to be one of nine genes down 
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regulated in metastasis as part of the 17-gene signature associated with metastasis in various 
solid tumor types (Ramaswamy et al. 2003; Qiu et al. 2004). The triggers for these expression 
fluctuations are unknown; however, using cancer cell lines, some of the mechanisms by which 
RBM5 expression can be regulated have been identified. For instance, RBM5 can be 
downregulated at the transcriptional level by a process that involves the read-through of 
polymerase from the upstream RBM6 gene and the consequent generation of transcription-
induced chimeras (Wang et al. 2007). Changes in RBM5 expression also occur via the regulation 
of alternative splicing, a role played by human epidermal growth factor receptor 2 (Rintala-Maki 
et al. 2007) and potentially, the antisense non-coding RBM5-related factor, LUST (Rintala-Maki 
and Sutherland 2009). Post-transcriptionally, RBM5 can be differentially phosphorylated (Shu et 
al. 2007). 
 
Changes in RBM5 expression levels are associated with changes in both the expression level and 
the alternative splicing of downstream transcripts. For example, overexpression of RBM5 in the 
human leukemic cell line CEM-C7 was associated with altered expression of 35 genes, including 
cyclin-dependent kinase 2 (CDK2) and signal transducer and activator of transcription 5B 
(Stat5b), which are involved in processes such as G1/S transition and apoptosis, respectively 
(Mourtada-Maarabouni et al. 2006). Knockdown of RBM5 was associated with altered 
expression of many genes in a number of different cell lines (a normal lung epithelial cell line 
(BEAS-2B), a normal breast epithelial cell line (MCF-10A) and three different lung cancer cell 
lines with varying RBM5 expression levels (A549, Calu-6 and NCI-H1299), notably increasing 
the expression of genes involved in cell adhesion, migration, and motility, all processes 
important to metastasis (Oh et al. 2010). In addition, in the MCF-7 breast adenocarcinoma cell 
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line, RBM5 and tumor necrosis factor alpha (TNF-α) expression were shown to be positively 
correlated, TNF-α being an important apoptosis regulatory factor (Wang et al. 2012). RBM5 also 
regulates alternative splicing of pre-messenger RNAs (mRNAs) involved in apoptosis (exclusion 
of caspase-2 exon 9 (Fushimi et al. 2008) and FAS receptor exon 6 (Bonnal et al. 2008)), seed 
maturation (the inclusion of an ABIα/β exon (Sugliani et al. 2010), muscular dystrophy 
(exclusion of dystrophin exons 40 and 72 (O’Leary et al. 2009) and immunoglobulin 
diversification (exclusion of activation-induced cytidine deaminase exon 4 (Jin et al. 2012). 
 
Is it important to note that RBM5 shares highest homology with another RBM protein, RNA-
binding motif domain protein 10 (RBM10) (Sutherland et al. 2005). In fact, RBM5 and RBM10 
are approximately 50% homologous at the transcript level in both human and rat. Also, 
endogenous RBM5 and RBM10v1 protein expression levels have been shown to be significantly 
positively correlated in primary breast cancer samples (Rintala-Maki et al. 2007). 
 
Similar to RBM5, RBM10 has been shown to influence the alternative splicing of many genes 
(Behzadnia et al. 2007; Bechara et al. 2013; Wang et al. 2013; Zheng et al. 2013; Inoue et al. 
2014). RBM10 is also important for the regulation of apoptosis and proliferation (James et al. 
2007; Wang et al. 2012). Very little is known in regards to the importance of RBM5 and RBM10 
in muscle differentiation; however, (a) both Rbm5 and Rbm10 are downregulated in H9c2 
skeletal muscle differentiation (Loiselle and Sutherland 2014) and highly expressed in skeletal 
and cardiac muscle (Drabkin et al. 1999; Johnston et al. 2010), (b) RBM5 influences the 
alternative splicing of dystrophin, an important muscle protein (O’Leary et al. 2009), and (c) 
RBM10 is important to spermatid differentiation (O’Bryan et al. 2013). 
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In our previous study, we identified the rat H9c2 myoblast differentiation model as a suitable 
function-based muscle model in which to study Rbm5 and Rbm10 (Loiselle and Sutherland 
2014). Our long-term objective is to determine the importance of Rbm5 to myoblast 
differentiation. In the study described herein, we manipulated Rbm5 expression levels in 
undifferentiated myoblasts, in order to characterize expression prior to differentiation. The 
effects of knockdown and overexpression of Rbm5 on Rbm10 mRNA and protein expression 
levels were also examined, to rule out off-target knockdown effects and to determine if changes 
in Rbm5 ex-pression effected the expression of Rbm10, prior to differentiation. The interesting 
observations that were made have been incorporated into a model that will be tested in future 
experiments. 
 
 
5.3 Materials and Methods 
 
5.3.1 Cell culture 
 
Cells were grown as previously described (Loiselle and Sutherland 2014). 
 
5.3.2 Stable knockdown  
 
At 24 h prior to transfection, cells were passed in 100-mm plates (Sarstedt, Montreal, Canada) 
and as such that they would be approximately 35% confluent at the time of transfection. Twenty-
four hours following appropriate plating, 12 μl of Lipofectamine 2000 transfection re-agent (Life 
Technologies, Burlington, Canada) was mixed with 1.5 ml of Opti-MEM reduced serum media 
(Life Technologies) with GlutaMAX (Life Technologies), and incubated at room temperature for 
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5 min. The appropriate small hairpin RNA (shRNA) construct (12 μg) was also mixed with 1.5 
ml of Opti-MEM reduced serum media with GlutaMAX, and incubated at room temperature for 
five minutes. Control samples were transfected with CSHCTR001-nU6 shRNA scrambled 
control (GeneCopoeia, Rockville, MD). Rbm5 knockdown samples were transfected with both 
MSH039757-1 and MSH039757-6 Rbm5-specific shRNAs (6 μg of each) (GeneCopoeia) (Table 
5.1). The Rbm5-specific shRNAs were 100% homologous to both rat and mouse Rbm5 
sequence. Following, the Lipofectamine 2000 + Opti-MEM and shRNA + Opti-MEM solutions 
were mixed together and incubated at room temperature for 35 min. The transfection solution 
was then added to the normal, serum-containing media on the cells. Selection began 24 h post-
transfection by treating cells with 1 μg/ml of puromycin. Cells were then cultured in antibiotic-
containing media to select for successful transfectants for at least 28 days following transfection 
and until they filled a 100-mm plate (Sarstedt). 
 
5.3.3 Transient knockdown  
 
Twenty-four hours prior to transfection, cells were passed to 6-well plates (Sarstedt) so as to be 
40% confluent at the time of transfection. Twenty-four hours after appropriately plating cells, 5 
μl of Lipofectamine 2000 transfection reagent (Life Technologies) was added to 245 μl of Opti-
MEM reduced serum media (Life Technologies) with GlutaMAX (Life Technologies), and 
incubated at room temperature for 5 min. The appropriate small interfering RNA (siRNA) or 
shRNA was also added to 245 μl of Opti-MEM reduced serum media with GlutaMAX, and 
incubated at room temperature for 5 min. The first transient knockdown experiment was 
performed with siRNA. The siRNA used for the control sample was Trilencer-27mer universal 
scrambled negative control siRNA duplex (OriGene, Rockville, MD). For Rbm5 knockdown 
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samples, custom on-target RBM5 duplex siRNA (Dharmacon, Thermo Fisher Scientific, Ottawa, 
Canada) was used (Table 5.1). The second and third transient knockdown experiments were 
performed with shRNAs (same constructs used for stable knockdown experiments). Thus, 
control samples were transfected with the scramble control CSHCTR001-nU6, and Rbm5 
transient knockdown experiments two and three were transfected with MSH039757-1 and 
MSH039757-6 Rbm5-specific shRNAs, respectively (GeneCopoeia) (Table 5.1). siRNAs and 
shRNAs had a final concentration of 10 nM when administered to cells. Following a 5-min 
incubation, the Lipofectamine 2000 + Opti-MEM and siRNA + Opti-MEM solutions were mixed 
together and incubated at room temperature for 20 min. Next, the transfection solution was added 
to the normal, serum-containing media on the cells. Medium was not changed after addition of 
transfection solution, and cell pellets were collected at 72 h post-transfection. 
 
  
200 
 
 
 
Table 5.1: Small interfering RNA Rbm5 knockdown oligonucleotides. 
Type Name Sequence Location Homology to Rbm10 
     
shRNA CSHCTR001-nU6  Scrambled  
 MSH039757-1 5′ GTAGTGGAAGATATGGTTC 3′ Exon 3 (12/19) 63% 
 MSH039757-6 5′ GAGCGATATTCGAGAAATG 3′ Exon 4/5 (12/19) 63% 
siRNA Trilencer-27mer universal scrambled negative control  Scrambled  
 ON-TARGET RBM5 duplex siRNA 5′ GAGCGATATTCGAGAAATG 3′ Exon 4/5 (12/19) 63% 
     
 
5.3.4 Transient overexpression  
The plasmid used for the transient overexpression of RBM5 was pcDNA3.RBM5 (Rintala- Maki 
and Sutherland 2004), with pcDNA3 empty vector as the negative control. Note that RBM5 
sequence in the vector was human, which has approximately 80% homology with rat. Cells were 
passaged such that a confluency of 35% would be obtained on the day of the experiment. At that 
point, 12 μg of the respective pcDNA3 plasmid and 18 μl of Lipofectamine 2000 transfection 
reagent (Life Technologies) were each mixed separately with 1.5 ml of Opti-MEM reduced 
serum medium (Life Technologies) with GlutaMAX (Life Technologies). After a 5-min 
incubation at room temperature, the DNA + Opti-MEM and Lipofectamine 2000 + Opti-MEM 
mixtures were mixed together, and incubated at room temperature for 20 min. Following this, the 
transfection mixture was added to the cells. The medium was not changed after addition of the 
transfection mixture, and cell pellets were collected at 72 h post-transfection. 
 
5.3.5 RNA expression analysis 
RNA extraction, reverse transcription, and end-point semi-quantitative PCR were performed as 
previously described (Loiselle and Sutherland 2014), except in this case, 24 amplification cycles 
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were used for glyceraldehyde 3-phosphate dehydrogenase (Gapdh), and 38 cycles for Rbm5 and 
Rbm10 (Table 5.2). 
 
Table 5.2: Primers for end-point PCR. 
Gene name Accession no. Primer sequence (5′ to 3′) Amplicon length (bp) Annealing temp. (°C) 
     
Actb NM_031144 F: TGAGCGCAAGTACTCTGTGTGGAT 129 62 
  R: TAGAAGCATTTGCGGTGCACGATG   
Gapdh BC059110 F: ACCACAGTCCATGCCATCAC 452 58 
  R: TCCACCACCCTGTTGCTGTA   
Rbm5 BC166477 F: ATGGGTTCAGACAAAAGAG 520 55 
  R: GCATTGCAATGTGCTTTCCTTGA   
Rbm10 F1LWMO F: ATTGGCTCCCGTCGAACTAACAGT 916 (10v1) 63 
  R: ACTTCTCTCGGCGCTTGAAGTTCT 682 (10v2)  
 
F forward primer (5′ primer), R reverse primer (3′ primer) 
  
 
Densitometric analysis was performed using AlphaEase FC software (Alpha Innotec, Kasendorf, 
Germany). Rbm5 and Rbm10 mRNA expression values were first normalized to the 300-bp 
ladder band to account for gel exposure differences between replicates, then to Gapdh, the 
reference gene used. Next, the average of the normalized expression value obtained for all 
technical replicates of a biological replicate was determined. This average normalized expression 
value was then expressed as a fold-change from the control sample of that biological replicate, 
and averaged for the various biological replicates. This gave the final expression value that was 
graphed. 
 
5.3.6 Protein expression analysis 
Protein samples were prepared as previously described (Sutherland et al. 2000). Primary anti-
bodies used were mouse anti-α-tubulin (1:10,000, sc-8035, Santa Cruz Biotechnologies Inc., 
Santa Cruz, CA); rabbit anti-RBM10 (1:1000, A301-006A, Bethyl Laboratories Inc/ Cedarlane, 
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Burlington, Canada); rabbit anti-RBM5 (1:2500, ab85504, Abcam, Toronto, Canada); rabbit 
anti-RBM5 LUCA-15UK (1:2000, non-commercially available (Sutherland et al. 2000)); and 
rabbit anti-RBM5 SP1 and SP2 (1:1000, non-commercially available (Bonnal et al. 2008)). A 
goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (1:20,000, sc-
2005, Santa Cruz Biotechnologies Inc.) and a goat anti-rabbit HRP-conjugated secondary 
antibody (1:10,000, sc-2004, Santa Cruz Biotechnologies Inc.) were employed. The presence of 
anti-bodies on the membrane was detected using Amersham ECL Western Blotting Detection 
Reagents (GE Healthcare, Mississauga, Canada) and Amersham Hyperfilm ECL (GE 
Healthcare). 
 
 
 
The membranes were stripped between probing with different primary antibodies using the 
following mild stripping procedure: two 10-min washes in mild stripping buffer (1.5% glycine, 
0.1% SDS, 0.1% Tween 20, pH 2.2); two 10-min washes in phosphate-buffered saline (1× PBS, 
pH 7.4, Life Technologies); and finally, two 5-min washes with Tris-buffered saline with Tween 
20 (TBS-T). Densitometric analysis was performed on the resulting blots using AlphaEase FC 
software. The resulting RBM5 and RBM10 expression values were first normalized to α-tubulin, 
the reference gene used. Normalized expression values were then expressed as fold-change from 
the control sample for that biological replicate (control sample present on each gel), and the 
average of the technical replicates for each biological replicate determined. Following, the 
average across biological replicates was determined and graphed. 
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5.4 Results and Discussion 
 
5.4.1 Rbm5 mRNA knockdown has no effect on Rbm5 protein levels. 
 
One hundred seventeen Rbm5 shRNA transfected H9c2 clones were obtained following 28 or 29 
days of selection in puromycin. All 117 clones were screened for Rbm5 mRNA expression. 
Three clones (clones 87, 9, and 100) with significant inhibition of Rbm5 mRNA expression 
(>80%),compared to the scrambled control, were chosen for further analysis, along with two 
clones (clones 12 and 104) with no visible knockdown (Fig. 5.1A). Surprisingly, Rbm5 protein 
levels were not significantly inhibited in any of the Rbm5 knockdown clones (Fig. 5.1B, C). To 
rule out any possible clonal effect that could account for abnormal regulation of protein 
expression, three transient transfections were performed. The first transient transfection used 
siRNA-specific to Rbm5 sequence (but different from one of the shRNA sequences used) (KD1). 
The second and third transient transfections used the shRNA from the stable knock-down 
experiments, MSH039757-1 and MSH039757-6, respectively. mRNA knockdowns ranged 
between 55% and 70% (Fig. 5.2A), but, once again, there was no decrease in Rbm5 protein 
expression levels (Fig. 5.2B, C). To ensure that antibody affinity was not an issue, three different 
anti-RBM5 antibodies were used in the stable knockdown analysis, and two in the transient 
knock-down work (Figs. 5.1B and 5.2B).  
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Figure 5.1 Rbm5 and Rbm10 expression in Rbm5 shRNA stably transfected H9c2 clones. (A) RT-PCR results for Rbm5 and Rbm10 
expression in the various RBM5 knockdown (KD) clones, individually from technical duplicates (i) and pooled (ii). Gapdh was used as reference 
gene. (B) Representative raw Western blot protein expression data for RBM5 and RBM10 using one anti-RBM10 antibody and various anti-
RBM5 antibodies (antibody name or manufacturer indicated on the right of the blots). Precision Plus ladder (BioRad) was used, and ladder values 
refer to weight in kilodalton (kDa). (C) Densitometric analysis of protein expression in the various clones, individually (from technical duplicates 
for each clone except clone 87 and 104 in regards to RBM10 expression) (i) and pooled (ii). Results were normalized to alpha-tubulin. In the 
pooled figures (Aii, Cii), BNo KD Clones and Controls^ represents results from the scrambled control as well as clones which did not show at 
least 70% knockdown of Rbm5 at the RNA level (clones 12 and 104), whereas B5 KD Clones^ represent results from those clones that did show 
mRNA knockdown of Rbm5 (clones 87, 9, and 100). Values represent mean±standard error (SE). Asterisk placed directly above a bar indicates 
value is statistically different from control as determined by unpaired t test (**indicates p<0.01). 
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5.4.2 Rbm5 knockdown correlates with increased Rbm10 protein levels.  
Since rat Rbm10 has 57% homology with rat Rbm5, to ensure no off-target effect of the 
theoretically Rbm5-specific sh/siRNAs on Rbm10 expression, Rbm10 expression was also 
examined in the knockdowns. Both shRNA and siRNA sequences were chosen to limit the 
potential for off-target effects on Rbm10: Rbm5 shRNA and siRNA sequences were 19-mers 
with seven mismatches to rat Rbm10, meaning they had 63% homology. In the clones, at the 
RNA level (Fig. 5.1A), Rbm10 expression significantly decreased in of all the clones with the 
most significant Rbm5 RNA knockdown (clones 87, 9, and 100). At the protein level (Fig. 5.1C), 
Rbm10 expression was surprisingly increased, but only in the Rbm5 clones with the most 
significant Rbm5 RNA knockdown. Additionally, Rbm10 protein expression was unexpectedly 
decreased in clone 12, which had shown no change in Rbm5 mRNA expression levels as a result 
of knockdown. In the transient Rbm5 knockdown, RBM10 mRNA and protein expression were 
increased almost two-fold, compared to the scrambled control (Fig. 5.2A, C). 
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Figure 5.2 Rbm5 and Rbm10 expression in Rbm5 shRNA/siRNA transiently transfected H9c2 cells. (A) RT-PCR results for Rbm5 and 
Rbm10 expression in the various transient RBM5 knockdown (KD) experiments, individually (from technical duplicates, except KD3 (one 
technical replicate)) (i) and pooled (ii). Gapdh was used as reference gene. (B) Representative raw Western Blot protein expression data for 
RBM5 and RBM10 using one anti-RBM10 antibody and various anti-RBM5 antibodies (antibody name or manufacturer indicated on the right of 
the blots). Precision Plus ladder (BioRad) was used, and ladder values refer to weight in kDa. (C) Densitometric analysis of protein expression in 
the various KD experiments, individually from one technical replicate (two for KD1 expression of RBM5) (i) and pooled (ii). Results were 
normalized to alpha-tubulin. Values represent mean±SE. Asterisk placed directly above a bar indicates value is statistically different from control 
as determined by unpaired t test (** indicates p<0.01). 
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5.4.3 Rbm5 overexpression does not correlate with decreased Rbm10 
protein levels. 
Since inhibition of Rbm5 correlated with increased expression of RBM10 in both the stable and 
transient knockdowns, we sought to determine if the reverse were true, and overexpression of 
Rbm5 correlated with decreased Rbm10 expression. Transient overexpression of RBM5 protein 
from the human complementary DNA (cDNA) sequence (which has approximately 80% 
homology with rat) was confirmed with three different anti-RBM5 anti-bodies (Fig. 5.3B), but 
Rbm10 protein expression levels remained unchanged, compared to the scrambled control 
transfectants (Fig. 5.3B,C). 
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Figure 5.3 Rbm5 and Rbm10 expression in Rbm5 transiently overexpressed H9c2 cells. (A) RT-PCR results for Rbm5 and Rbm10 
expression in the various transient RBM5 overexpression (OE) experiments, individually from technical duplicates (i) and pooled (ii). Gapdh was 
used as reference gene. (B) Representative raw Western Blot protein expression data for RBM5 and RBM10 using one anti-RBM10 antibody and 
various anti-RBM5 antibodies (antibody name or manufacturer indicated on the right of the blots). Precision Plus ladder (BioRad) was used, and 
ladder values refer to weight in kDa. (C) Densitometric analysis of protein expression in the various OE experiments, individually from technical 
duplicates for RBM5 expression and one technical replicate for RBM10 expression (i) and pooled (ii). Results were normalized to alpha-tubulin. 
Values represent mean±SE. Statistical significance was evaluated using an unpaired t test for each sample compared to their respective control. 
 
Based on our findings, a number of conclusions can be drawn. Firstly, only a small quantity of 
Rbm5 mRNA is translated. Secondly, regulation of Rbm5 protein expression in H9c2 myoblasts 
has unique characteristics. Thirdly, decreased Rbm5 mRNA levels regulate Rbm10 protein 
expression. In the following sections, we discuss each of these conclusions, and present a model 
that depicts them. 
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5.4.4 Only a small quantity of Rbm5 mRNA is translated. 
 
Knockdown of Rbm5 mRNA in either stable or transient transfections is not reflected at the 
protein level. Lack of a positive correlation between Rbm5 mRNA and protein expression in the 
transient transfections could possibly relate to the fact that (a) Rbm5 protein is very stable or (b) 
the mRNA was not inhibited sufficiently to have an effect. When these transient data are 
combined with the lack of correlation between Rbm5 mRNA and protein expression in the stable 
clones, the data suggest that unchanged Rbm5 protein expression levels was not due to (a) any 
possible clonal effect in the stable clones or (b) Rbm5 protein stability. A precedented 
explanation for the lack of correlation between Rbm5 mRNA and protein expression levels in the 
knockdown experiments is that only a fraction of endogenous Rbm5 mRNA is actually translated 
into protein. The shRNA was able to degrade up to 90% of the Rbm5 mRNA in the stable clones, 
but the ∼10% that was left might be all that is normally translated in the wild-type myoblasts. 
 
One possible reason to account for the fact that only a small portion of Rbm5 mRNA may be 
translated is that messenger ribonucleoproteins (mRNPs) may be involved in sequestering the 
majority of Rbm5 mRNA in H9c2 cells. Precedent for this occurs in Xenopus oogenesis, where 
80% of maternal mRNAs are sequestered in mRNP storage particles, and translation is inhibited 
until specific time-points during early embryogenesis when the mRNAs are recruited to 
ribosomes and finally translated (Spirin 1966; Tafuri and Wolffe 1993). A second precedent 
occurs in P19 murine embryonic carcinoma cell differentiation, where the composition of 
mRNP-sequestered mRNAs changes following exposure to differentiation-inducing stimuli 
(Tenenbaum et al. 2000). Furthermore, in satellite cells, transcripts of Myf5, an important 
regulator of myogenesis, have been shown to be sequestered in mRNP granules. Upon activation 
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of the satellite cell, these granules dissociate, leading to liberation of myogenic factor 5(Myf5) 
transcripts and consequently higher levels of Myf5 (Crist et al. 2012). This regulatory 
mechanism thus allows quiescent satellite cells to transcribe Myf5 without activating 
differentiation. A similar mechanism could be occurring in the H9c2 cells, which would explain 
not only why a 90% knockdown of Rbm5 mRNA is not reflected at the protein level, and why 
the changes in Rbm5 protein levels during cardiac differentiation were not positively correlated 
with changes in Rbm5 mRNA levels (i.e., during differentiation, it is not the total amount of 
Rbm5 mRNA in the cell that is important but the amount that is not sequestered, and thus 
available for translation) (Loiselle and Sutherland 2014). 
 
In the overexpression experiments, exogenous Rbm5 mRNA was translated. If our sequestering 
hypothesis is correct, this result suggests that either (a) the cell could distinguish between 
exogenously and endogenously transcribed Rbm5 transcript, or (b) there was a finite quantity of 
Rbm5 message that could be sequestered, a quantity that might be regulated by levels of 
endogenous Rbm5 protein or Rbm10 mRNA/protein levels. 
 
5.4.5 Regulation of Rbm5 protein expression in H9c2/myoblasts has 
unique characteristics. 
 Correlations between RBM5 expression at both the mRNA and protein levels have been 
examined in breast (Oh et al. 2002; Rintala-Maki et al. 2007), lung (Liang et al. 2012), and 
pancreatic (Peng et al. 2013) non-tumor and tumor tissue, and various cell lines including A549 
(lung adenocarcinoma) (Oh et al. 2010; Li et al. 2012), Calu-6 (possibly lung carcinoma) (Oh et 
al. 2010), NCI-H1299 (non-small cell lung carcinoma) (Oh et al. 2010), U2OS (osteosarcoma) 
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(Kobayashi et al. 2011), PC-3 (prostate adenocarcinoma) (Zhao et al. 2012), BEAS-2B 
(immortalized human bronchial epithelial cells) (Oh et al. 2010), HEK293 (human embryonic 
kidney cells) (Fushimi et al. 2008), MCF-10A (immortalized epithelial cells derived from human 
fibrocystic mammary tissue) (Oh et al. 2010), and those of various mantle cell and follicular 
lymphomas (Weinkauf et al. 2007): a positive correlation between mRNA and protein expression 
levels was consistently observed. Only in non-tumor breast tissue was a positive correlation 
between RBM5 mRNA and protein expression not observed (Rintala-Maki et al. 2007). 
Therefore, the mechanism suggested earlier in which only a percentage of Rbm5 mRNA is 
translated, and the rest is sequestered (perhaps in mRNPs) may be a restricted phenomenon that 
occurs in, for example, particular cell types or in cells with certain growth characteristics, 
including rat myoblasts. 
 
5.4.6 Decreased Rbm5 mRNA levels regulate Rbm10 protein 
expression. 
It was interesting to note that, despite unchanged levels of Rbm5 protein, Rbm10 protein levels 
went up. This observation was particularly interesting in view of the fact that Rbm10 mRNA 
levels significantly decreased in the stable knockdowns. Any potential off-target effect of Rbm5 
shRNA on Rbm10 was considered highly unlikely once the elevated levels of Rbm10 protein 
were observed. The results suggest a complex regulatory mechanism linking degradation of 
Rbm5 mRNA with Rbm10 protein expression. It is important to note that another group has also 
recently reported that decreased expression of Rbm5 correlated with increased levels of Rbm10. 
Their study was performed in injured mouse brain homogenates (Jackson et al. 2015). 
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5.4.7 Model 
Based on the results of the Rbm5 knockdown and overexpression experiments, we hypothesize 
that the majority of Rbm5 transcripts are sequestered, possibly in mRNPs, and unavailable for 
translation. Release of sequestered Rbm5 transcripts would occur at certain points during 
differentiation, as required. Therefore, this could be the post-transcriptional mechanism 
regulating Rbm5 expression throughout H9c2 skeletal and cardiac differentiation suggested by 
our group previously (Loiselle and Sutherland 2014). 
 
 
We postulate that two things are occurring in H9c2 cells regarding RBM10. Firstly, that RBM10 
is a component of the mRNP complexes sequestering Rbm5 mRNA in H9c2 cells (Fig. 5.4A), as 
RBM proteins have been shown to play important roles in these structures, as previously 
reviewed (Hieronymus and Silver 2004). Secondly, that RBM10 can bind the 3′ UTR of its own 
mRNA transcript and thereby increase its own stability. The rat homologue of RBM10, S1-1, has 
already been shown to bind the 3′ UTR of angiotensin II receptor type 1 (AT1), stabilizing the 
message, and ultimately decreasing transcription (Mueller et al . 2009). Furthermore, previously 
identified RBM10 binding sequences are located within the Rbm10 3′ UTR (Fig. 5.5) (Bechara 
et al. 2013). It is important to note that Bechara et al. demonstrated that even 2/7 mismatches 
from the top selected motifs still enabled good RBM10 binding.  
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Figure 5.4 Model representing the effects of varying levels of Rbm5 mRNA on the expression of RBM5 and RBM10. Rbm5 and Rbm10 
expression in H9c2 wild-type cells (A), upon transient Rbm5 knockdown (B), upon stable Rbm5 knockdown (C), and upon transient Rbm5 
overexpression (D). RBM5 protein is represented by blue clouds, with lighter blue representing overexpressed protein, and RBM10 protein is 
represented by purple ovals. Orange mRNP ovals represent complex mRNP particles with various components. For in-depth model description, 
refer to text. 
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Figure 5.5 RBM10 binding sites in the Rbm10 3'UTR. Segments of the top consensus motifs for RBM10 binding sites, as determined by 
Bechara et al. (2013), underlined at their respective locations in the Rbm10 3′ UTR. Double underlined sequences are part of the motifs on each 
side. All sequences have two mismatches compared to the top previously identified motif, except the most 3′- motif which is a complete match. 
 
In our model, when Rbm5 mRNA is decreased and its associated mRNP complexes 
disassembled, RBM10protein would be released into the cell. This RBM10 would be free to bind 
the 3′ UTR of Rbm10 mRNA, stabilizing the transcript (Fig. 5.4B). Initially, this may lead to 
increased levels of Rbm10 mRNA and protein, which is what we observed in our transient Rbm5 
knockdown experiments (Fig. 5.2). Ultimately, however, this stabilization may lead to decreased 
transcription of Rbm10, as has been shown upon rat RBM10 stabilization of AT-1 transcript 
(Mueller et al. 2009) (Fig. 5.4C). As a result, lower levels of Rbm10 mRNA would be expected. 
This is, in fact what we observed in our Rbm5 stable knockdown clones (Fig. 5.1). 
 
  
On the other hand, upon overexpression of Rbm5, we would expect these non-physiological 
levels to be too high to all be sequestered in mRNP complexes, resulting in their transcription, 
translation, and, as a result, higher levels RBM5 (Fig. 5.4D). Furthermore, since the mRNP 
complexes sequestering Rbm5 would not be disrupted by this overexpression, we would expect 
Rbm10 mRNA and protein levels to remain constant. As shown in Fig. 5.3, this is what we 
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observed experimentally; higher levels of RBM5 upon Rbm5 overexpression, but no change in 
Rbm10 mRNA or protein levels. 
 
 
 
To test the validity of this model, immunoprecipitation of Rck/p54 (p-body protein and mRNP 
complex component) could be performed, followed by next generation sequencing of its 
associated RNA (RIP-Seq). This would determine if Rbm5 is among the mRNP-sequestered 
transcripts in H9c2 myoblasts. Furthermore, RNA-binding protein purification and identification 
(RaPID) could be used to determine if Rbm10 is a component of the mRNP/Rbm5 mRNA 
complexes. This would involve tagging Rbm5 mRNA, transfecting it into H9c2 cells, purifying 
the tagged transcripts, then detecting associated proteins via mass-spectrometry (Slobodin and 
Gerst 2010). Direct binding of Rbm10 to its own transcript could be analyzed via electromobility 
shift assays (EMSAs), using tagged Rbm10 3′ UTR probes. Knockdown and overexpression of 
Rbm10 would not be useful to test this model since it would involve directly manipulating levels 
of Rbm10, which may mask any effect that protein levels have on transcript expression. 
 
 
 
5.4.8 Conclusion 
 
The results from this work suggest that Rbm5 is post-transcriptionally regulated in rat myoblasts. 
More specifically, our results suggest that only a small portion of Rbm5 mRNA may be 
translated in myoblasts, while the rest is sequestered in the cell. Results from Rbm10 mRNA and 
protein expression in Rbm5 knockdown and overexpression samples also suggest that Rbm10 
expression is influenced by Rbm5 and by its own protein levels. This co-regulation has already 
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been shown in neuronal cells (Jackson et al. 2015), and suggests that, as in transformed cells 
(Sutherland et al. 2000; Bonnal et al. 2008; Fushimi et al. 2008; Wang et al. 2012; Inoue et al. 
2014), Rbm5 and Rbm10 may influence similar cellular processes in myoblasts. Finally, the 
intricate regulation of Rbm5 protein levels in H9c2 cells suggest a function of the utmost 
importance to myoblast differentiation, and perhaps, muscle development in general. 
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Chapter 6 
6 Discussion 
The objectives of this study were (1) identify all cellular processes and events enriched by 
changes in RBM5 and/or RBM10 expression in a particular cultured cell line, and (2) to 
determine the extent of functional overlap for RBM5 and RBM10 in these cells. Entering into 
this study, I hypothesized that processes influenced by changes in RBM5 and RBM10 
expression are not limited to apoptosis and cell cycle regulation. I also hypothesized that RBM5 
and RBM10 influence many events in addition to differentiation. Finally, based on their 
structural similarities, I hypothesized some overlap in functional roles for RBM5 and RBM10. 
 
My results suggest that RBM5 and RBM10 influence many events, in addition to differentiation. 
RBM5-altered events typically involved apoptosis and cell cycle regulation, whereas RBM10-
altered events involved additional processes. These results suggest that even though RBM5 and 
RBM10’s consensus functional motifs are very homologous, the sequence variations between 
RBM5 and RBM10 do have functional implications. Furthermore, I demonstrated that while both 
proteins have overlapping roles, sharing similar targets and influencing similar processes and 
events, the functional implications of their expression were quite different. In fact, the putative 
tumor suppressor RBM10, in an RBM5-null environment, actually promoted transformation 
associated processes. This suggests that RBM5 expression levels can significantly alter the 
function of RBM10. The complex relationship demonstrated in this body of work between 
RBM5 and RBM10, in both transformed and non-transformed cells, also underscores the 
importance of their regulated expression. 
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Since the beginning of this project, many studies, in addition to those presented herein, have 
continued to confirm RBM5’s tumor suppressive properties. There has been an overall growing 
interest in regards to RBM10 – a greater than 50% increase in RBM10-related Pubmed-indexed 
publications (i.e. 27 manuscripts) since the beginning of this study. These studies, together with 
my doctoral research work, have provided a much more comprehensive understanding of the 
roles of, and relationship between, these two RBPs. Specific aspects of RBM5’s and RBM10’s 
functions that are now much better understood, compared to the beginning of this study, will be 
briefly discussed to truly highlight the range of processes altered by these proteins, and the 
impact and novelty of the findings presented in this thesis. 
 
6.1. RBM5 and RBM10 are not only modulators of alternative 
splicing 
Prior to the beginning of this study, mechanistic information regarding RBM5 had been solely 
focused on its role as a modulator of alternative splicing. As for RBM10, although a role in 
alternative splicing had been suggested, no mechanism of action had been demonstrated. Since 
then, a number of studies have confirmed RBM5’s role as a modulator of alternative splicing 
(Sebestyen et al., 2016; Zhang et al., 2014). Of note, RNA splicing by RBM5 was shown to be 
dependent on its OCRE and RRM domains (Mourao et al., 2016; Zhang et al., 2014). A role for 
RBM10 in the modulation of alternative splicing was also established by many groups 
(Hernandez et al., 2016; Inoue et al., 2014; Rodor et al., 2017; Wang et al., 2013; Zhao et al., 
2017; Zheng et al., 2013). In addition, some studies have identified RNA consensus binding 
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sequences for RBM5 and RBM10 (Bechara et al., 2013; Maaskola and Rajewsky, 2014; Ray et 
al., 2013; Rodor et al., 2017; Wang et al., 2013). The similarity between the identified sequences 
between studies, however, is quite low. This may be due to the difference in techniques used in 
each study, or could indicate that secondary RNA structure is important to consider when 
predicting RBM5 and RBM10 targets, rather than simply a short consensus binding sequence in 
the target RNA. 
 
The target identification and gene expression data presented herein support a role for RBM5 in 
the modulation of alternative splicing. We suggest, however, that RBM10’s ability to influence 
alternative splicing is largely dependent on RBM5 expression since (a) RBM10 knockdown in an 
RBM5-null system resulted in no significant changes in alternative splicing, and (b) no RBM10 
mRNA targets are involved in any aspect of alternative splicing. In addition, we determined that, 
mechanistically, RBM5 and RBM10 are much more than modulators of apoptosis, and influence 
RNA metabolism in various ways. In fact, although RBM5 influenced the expression of 
thousands of genes, only 47 genes underwent significant changes in alternative splicing upon 
modulating RBM5 expression levels. The fact that only 47 of thousands of differentially 
expressed genes experienced alternative splicing suggests that RBM5 influences not only 
alternative splicing but other aspects of RNA metabolism. This is in line with a recent study 
showing that RBM5 knockdown in HeLa cells altered only 30 alternative splicing events 
(Bechara et al., 2013). Alternate methods of regulation of gene expression by RBM5 and 
RBM10 suggested by our results include nonsense-mediated decay (NMD), transcriptional and 
post-translational control (elaborated in Chapters 3 and 4). Actually, we showed that RBM5 
directly interacted with RBM10v2(V277del) and influenced its expression post-transcriptionally. 
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Furthermore, we demonstrated that RBM10 interacted with both RBM10v2(V277) and 
RBM10v2(V277del), and suggested that this interaction ultimately influenced RBM10v2 protein 
expression levels. Supporting our suggestion that these RBPs function in ways other than 
modulating alternative splicing are the reports that; (a) RBM10 interacted with the FilGAP 
protein independently of RNA to control FilGAP localization and function  (Yamada et al., 
2016), (b) RBM10’s rat homologue, S1-1, bound mRNA’s 3-UTR and influenced transcript 
stability (Inoue et al., 1996), (c) RBM10 interacted with 2A-DUB deubiquitinase protein 
complex, which influences histone modifications and thus gene transcription (Zhu et al., 2007), 
(d) RBM5 co-localized with p53 and caspase 3 in the cytoplasm upon spinal cord injury in rat, 
and correlated with increased levels of apoptosis (Zhang et al., 2015), (e) RBM5 was associated 
with decreased phosphorylation of β-catenin and GSK-3B (Hao et al., 2015), and (f) in mouse 
spermatid differentiation, RBM5 had putative protein partners involved in various aspects of 
RNA metabolism (O'Bryan et al., 2013). In all, our work suggests that RBM5 and RBM10 have 
multiple functions, independent of their role in alternative splicing. Future studies involving 
RBM5 and/or RBM10 should, therefore, recognize the limitations of alternative splicing focused 
assays.  
 
6.2. RBM5 regulates many cellular events, in addition to 
differentiation 
RBM5 is an established tumor suppressor gene and its inhibition of cell division (Jiang et al., 
2017; Lv et al., 2016; Zhang et al., 2014) and promotion of apoptosis (Bechara et al., 2013; Jiang 
et al., 2017; Lv et al., 2016; Zhang et al., 2015; Zhang et al., 2014) have been recently confirmed 
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in a number of cell lines. In addition, RBM5’s regulation of differentiation, an event involving 
control of both the cell cycle and apoptosis, has been further explored (Di Cecilia et al., 2016; 
Loiselle and Sutherland, 2014).  
 
The work presented herein supports a role for RBM5 in the control of the cell cycle and 
apoptosis, as well as differentiation. RBM5’s importance to development is particularly 
highlighted by our identification and description of its complex post-transcriptional regulation in 
H9c2 myoblasts (Chapter 5). Our data also suggests that RBM5 expression influences two 
transformation-associated events: angiogenesis and EMT. In fact, RBM5 expression correlated 
with downregulation of angiogenesis and EMT markers; two events which, like differentiation, 
involve cell cycle control and apoptosis. Supporting our suggestion that RBM5 influences 
angiogenesis is the correlation previously established between RBM5 overexpression and lower 
levels of epidermal growth factor receptor (EGFR), an angiogenesis promoter (Ellis, 2004), in an 
in vitro model and a xenograft mouse model (Su et al., 2014). Supporting our suggestion that 
RBM5 influences EMT is RBM5’s association with inhibition of cell migration and invasion 
(Jiang et al., 2017; Lv et al., 2016), and inhibition of the Wnt/β-catenin pathway (positive 
regulator of EMT) (Hao et al., 2015; Lamouille et al., 2014). Importantly, the Wnt/β-catenin 
signaling is also critical to development and is associated with a number of diseases (MacDonald 
et al., 2009; Morin, 1999), suggesting a link between RBM5’s regulation of both EMT and 
development. In sum, RBM5 likely influences many cellular events, and may prevent many 
facets of the transformed state. 
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6.3. Decreased RBM5 expression may be a key step in SCLC 
development 
The earliest and most frequent genetic alteration observed in lung cancer occurs at a 
chromosomal location very close to RBM5, within region 3p21.3 (Hung et al., 1995; Lerman and 
Minna, 2000; Wei et al., 1996; Wistuba et al., 2000). In addition, RBM5 was found to be 
downregulated in 70-95% of lung cancers (Travis W.D., 2004). Our findings provide insight into 
the impact of RBM5 downregulation to SCLC development and progression: (a) modification of 
only RBM5 expression levels influenced many SCLC transformation-associated processes and 
events, and (b) RBM5 regulated the expression of many SCLC-associated genes. Of note, SCLC 
occurs almost exclusively in tobacco smokers (Toyooka et al., 2003), which has in turn been 
associated with decreased RBM5 expression in two different in vitro systems (Hao et al., 2015; 
Lv et al., 2016). Taken together, these findings suggest that downregulation of RBM5, by smoke 
exposure, is important to SCLC risk. Furthermore, RBM5 is required for aryl hydrocarbon 
receptor (AHR) expression and consequent CYP1A1 induction in mouse Hepa-1 cells 
(Solaimani et al., 2013). The role of CYP1A1 is two-pronged; it can detoxify environmental 
toxins, but also bioactivate procarcinogens (Stejskalova and Pavek, 2011). Such procarcinogens 
include polycyclic aromatic hydrocarbons (PAH), which are found in cigarette smoke. Therefore, 
as CYP1A1 can have beneficial, as well as cancer-promoting functions, its strict regulation of 
function is extremely necessary (Androutsopoulos et al., 2009). Taken together, these results not 
only support our suggestion that RBM5 downregulation is an early and important step in SCLC 
development and progression, but suggest a mechanism by which this may occur.  
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6.4. RBM10 influences many processes and events, ultimately 
promoting transformation in a number of ways  
RBM10’s role as a promoter of apoptosis (Inoue et al 2014) and inhibitor of proliferation (Zhao 
et al 2017, Hernandez et al 2016) have, like RBM5, been recently confirmed in a number of 
studies. My results, however, extend the influence of RBM10 past cell cycle arrest and apoptosis, 
and suggest its ability to alter many transformation- and hypoxia-associated processes and 
events. Unexpectedly, in an RBM5-null environment, RBM10 may influence these processes and 
events in a way that would promote transformation. Specifically, knockdown of RBM10 
expression induced changes in gene expression predicted to reduce glycolysis, EMT, 
angiogenesis, and inhibition of mTORC1 pathways – potentially by direct regulation of cell 
metabolism, particularly oxidative phosphorylation.  
 
Interestingly, RBM10 has been previously shown to influence the expression of genes associated 
with various neurodegenerative disorders (Bechara et al., 2013).  As elaborated in Chapter 4, 
such diseases usually involve impairments in oxidative phosphorylation and, therefore, these 
findings support a potential role for RBM10 in the regulation of oxidative phosphorylation. In 
addition, RBM10’s association with FilGAP, a regulator of cell spreading (Yamada et al., 2016), 
supports a role for RBM10 in the regulation of EMT. Finally, RBM10’s potential role in the 
promotion of angiogenesis is supported by its phosphorylation by c-SRC, and consequent 
involvement in the PDGF signaling pathway (Amanchy et al., 2008), which controls motility, 
and angiogenesis (Heldin et al., 1998; Sato et al., 1993). Our comprehensive study suggests 
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compelling links between these disparate findings regarding RBM10, and suggests processes by 
which RBM10 may influence these transformation-associated events.  
 
In fact, this overall pro-transformatory role for RBM10 has been previously demonstrated in 
embryonic stem cells and mouse mandibular cells, where knockdown of RBM10 was associated 
with decreased cell growth (Rodor et al., 2017). Furthermore, RBM10 knockdown in neuronal 
cells increased caspase activation induced by staurosporine, an apoptosis inducer (Jackson et al., 
2015). Despite one brief recognition of a functional RBM10 dichotomy (Rodor et al., 2017), no 
previous study had ever investigated it. Chapter 4 directly tackled the opposing functional 
findings regarding RBM10, even proposing a working model which described the regulatory 
measures that determine the functional outcome of RBM10 expression, whether tumor 
suppressive or transformation-promoting. 
 
6.5. RBM10’s pro-transformatory role may be RBM5-dependent 
One important factor we identified that influenced RBM10 expression and function was RBM5. 
In fact, my work suggests that the pro-transformatory characteristics of RBM10 are largely 
regulated by RBM5, with RBM10 exercising this ability in RBM5-deficient systems. The 
working model presented in Chapter 4, which describes this association, is very comprehensive, 
and takes into account even the most recent published findings regarding RBM10 (the Chapter 4 
manuscript is very recent – currently under review).  
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Three recent gene expression studies involving various tumors types provide in vivo evidence 
supporting our suggestion that RBM10 promotes transformation in systems where RBM5 is 
downregulated. Firstly, gene expression analysis of Cancer Genome Atlas (TCGA) samples from 
various tumor types showed that RBM10 was significantly upregulated in many cancer types, 
while RBM5 expression was significantly downregulated (Sebestyen et al., 2016). Secondly, 
RBM10 mutations in pancreactic ductal cancer correlated with better 5-year survival probability 
(Witkiewicz et al., 2015) and RBM5 mRNA and protein expression was significantly reduced in 
pancreatic cancers (Peng et al., 2013). Thirdly, RBM10 expression correlated with increased 
disease aggressiveness in metastatic melanomas (Garrisi et al., 2014) and RBM5’s promoter 
region was found to be significantly mutated in metastatic melanomas (Smith et al., 2015), 
meaning that RBM5 expression is likely compromised in this type of cancer. Taken together, 
these studies suggest, like our in vitro work, that RBM10 expression promotes transformation in 
RBM5-reduced environments. We have, therefore, begun to elucidate how RBM10 expression 
and function are regulated, a better understanding of which is key to predicting the functional 
consequences of its expression. 
 
6.6. A relationship between RBM5 and RBM10 is present in 
many systems 
The body of work presented herein demonstrates an association between RBM5 and RBM10 in 
human SCLC and rat myoblast cell lines. Additional studies have also shown a relationship 
between RBM5 and RBM10: (1) in SHSY5Y human neuronal cells, RBM10 knockdown 
correlated with increased levels of RBM5 (Jackson et al., 2015), and (2) in HEK293 cells, 
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RBM10 overexpression correlated with increased RBM5 exon 6 exclusion, whereas RBM10 
knockdown correlated with a slight decrease in RBM5 exon 6 exclusion (Wang et al., 2013). It is, 
therefore, evident that a relationship exists between RBM5 and RBM10 in many systems, 
highlighting their potential fundamental importance to the cell. The nature of this relationship 
between RBM5 and RBM10 has begun to be elucidated; however, many more studies are 
required to completely understand this association, and its consistencies/differences between cell 
types. 
 
6.7. Significance and conclusions  
This body of work represents the first comprehensive analysis of the many potential roles of 
RBM5 and RBM10 in cells. We determined that RBM5 and RBM10 influenced a number of 
cellular events, and that although they had significantly overlapping targets and altered 
processes/events, the functional consequences of their expression were antagonistic. 
Furthermore, we took preliminary steps in evaluating the impact of RBM5 downregulation and 
RBM10 mutation to SCLC development, progression and treatment. Frighteningly, 70% of 
patients already have extensive stage SCLC at the time of diagnosis, characterized by the 
presence of at least one distant metastasis (Lekic et al., 2012; Micke et al., 2002). Due to the late 
stage diagnosis, treatment options are usually limited, and the 5-year survival rate has not 
improved over the past two decades, remaining at a dismal 2% (Gaspar et al., 2012; Lekic et al., 
2012; Micke et al., 2002). The development of novel treatment options, with better success rates, 
is thus of utmost importance. Our work suggests that restoring RBM5 expression levels, or 
processes and events regulated by RBM5, may significantly slow SCLC progression. 
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Furthermore, downregulation of RBM10 or RBM10-associated processes and events in RBM5-
null SCLC tumors may also be a fruitful avenue to pursue in terms of new SCLC therapeutic 
options.  
 
The alarming SCLC survival statistics make it evident that earlier detection of SCLC could also 
significantly improve outcomes. Since, at the molecular level, the earliest and most frequent 
genetic alteration observed in lung cancer is very close to RBM5, within region 3p21.3, RBM5 
may not only hold therapeutic value, but also predictive value for SCLC risk  (Hung et al., 1995; 
Lerman and Minna, 2000; Wei et al., 1996; Wistuba et al., 2000). Such predictive tests could 
include evaluating RBM5 expression levels of lung tissues of at-risk patients (e.g. smokers). 
Furthermore, screening for RBM10 mutations in lung cancers with RBM5-downregulation may 
provide important insight as to the metastatic potential of the tumor, and thus suggest a more 
intensive treatment plan for the patient. Taken together, the work presented herein is an 
important step towards better understanding SCLC at a molecular level, and thus presents an 
important base for future screening and therapeutic options.  
 
An important part of this study is the demonstration and description of a complex relationship 
between RBM5 and RBM10, in both transformed and non-transformed cells. This work thus 
greatly expands the knowledge of RBM5 and RBM10 function and regulation, which is 
particularly important to better understand and treat disease states, such as TARP, in which one 
or both of these RBPs are altered. This work also increases the general knowledge regarding the 
functioning of, and relationship between, similar RBPs. As RBPs control all aspects of RNA 
metabolism, and their aberrant expression and/or function can have devastating consequences, 
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strengthening the basic understanding of how this class of proteins work is important to all 
aspects of biology, including molecular, cellular, and developmental. 
 
6.8. Future directions  
Our study takes important preliminary steps towards understanding the roles of RBM5 and 
RBM10 in the cell, and the complex relationship between these two RBPs. More studies, 
however, are required to fully understand the nature of this relationship, how their interactions 
are regulated, and how these may vary between cell types and disease states. Given the 
significant functional consequences of altered RBM5 or RBM10 expression, as elaborated in the 
Introduction, future work in this area could have important clinical relevance. 
 
In addition, our work particularly highlights how very similar alternative splice variants, 
differing in fact by only one triplet, can differentially interact with proteins, and may have 
varying downstream functions. Future studies should, therefore, consider the RBM10 splice 
variant expression profile in the cell types used prior to undertaking functional assays related to 
RBM10. Furthermore, it’s essential to specify which particular variants are being overexpressed 
or knocked down, and which are able to be detected by each experimental assay. This aspect of 
variant identification is often completely overlooked in RBM10-related studies. Future studies 
examining how each RBM10 isoform functions would also be an extremely important avenue. 
Particularly since we propose that different isoforms have opposing functions, the ratio of the 
various RBM10 isoforms, along with RBM5 expression levels, in a patient could be of predictive 
significance for cancer incidence and/or progression. 
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In all, our results really highlight the complexity of RBP function, and how an RBP’s interaction 
with specific proteins, or even RNA molecules, can influence the downstream effects of the 
RBP’s expression. Future work should, therefore, not only focus on determining RBPs function, 
but also consider the regulatory mechanisms which may be modulating their function under 
specific circumstances. These types of studies would help to give a more rounded picture of 
RBPs, and a much better understanding of the many ways by which RNA function and 
metabolism are regulated. 
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